{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:44:30Z","timestamp":1794462270239,"version":"4.9.1"},"reference-count":826,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073311"],"award-info":[{"award-number":["82073311"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2022JDTD0025"],"award-info":[{"award-number":["2022JDTD0025"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Traditional Chinese Medicine Administration"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.<\/jats:p>","DOI":"10.1038\/s41392-024-02107-5","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:02:30Z","timestamp":1741114950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":460,"title":["Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines"],"prefix":"10.1038","volume":"10","author":[{"given":"Wenjing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1555-7594","authenticated-orcid":false,"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-0282","authenticated-orcid":false,"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2107_CR1","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/MJT.0000000000001069","volume":"27","author":"A de Leiva-Hidalgo","year":"2020","unstructured":"de Leiva-Hidalgo, A. & de Leiva-P\u00e9rez, A. Experiences of First Insulin-Treated Patients (1922\u20131923). Am. J. Ther. 27, e13\u2013e23 (2020).","journal-title":"Am. J. Ther."},{"key":"2107_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Tar. 7, 48 (2022).","journal-title":"Signal Transduct. Tar."},{"key":"2107_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122\u2013128 (2015).","journal-title":"Drug Discov. Today"},{"key":"2107_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1586\/14787210.2014.976613","volume":"12","author":"SJ Kang","year":"2014","unstructured":"Kang, S. J., Park, S. J., Mishig-Ochir, T. & Lee, B. J. Antimicrobial peptides: therapeutic potentials. Expert Rev. Anti Infect. Ther. 12, 1477\u20131486 (2014).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"2107_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s10989-023-10543-0","volume":"29","author":"AN de Oliveira","year":"2023","unstructured":"de Oliveira, A. N., Soares, A. M. & Da Silva, S. L. Why to Study Peptides from Venomous and Poisonous Animals? Int. J. Pept. Res. Ther. 29, 76 (2023).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"2107_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrd1828","volume":"4","author":"MB Davidson","year":"2005","unstructured":"Davidson, M. B., Bate, G. & Kirkpatrick, P. Exenatide. Nat. Rev. Drug Discov. 4, 713\u2013714 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","volume":"3","author":"JG McGivern","year":"2007","unstructured":"McGivern, J. G. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr. Dis. Treat. 3, 69\u201385 (2007).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"2107_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00228-019-02817-8","volume":"76","author":"J Gong","year":"2020","unstructured":"Gong, J. et al. Tirofiban for acute ischemic stroke: systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 76, 475\u2013481 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2107_CR9","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.3390\/ijms24065446","volume":"24","author":"G Tonin","year":"2023","unstructured":"Tonin, G. & Klen, J. Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice. Int. J. Mol. Sci. 24, 5446 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR10","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau, J. L. & Dunn, M. K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Biorg. Med. Chem. 26, 2700\u20132707 (2018).","journal-title":"Biorg. Med. Chem."},{"key":"2107_CR11","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1021\/ja01115a553","volume":"75","author":"VD Vigneaud","year":"1953","unstructured":"Vigneaud, V. D. et al. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc. 75, 4879\u20134880 (1953).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR12","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1021\/ja01546a040","volume":"80","author":"V Du Vigneaud","year":"1958","unstructured":"Du Vigneaud, V., Gish, D. T., Katsoyannis, P. G. & Hess, G. P. Synthesis of the Pressor-Antidiuretic Hormone, Arginine-Vasopressin. J. Am. Chem. Soc. 80, 3355\u20133358 (1958).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","volume":"61","author":"A Henninot","year":"2018","unstructured":"Henninot, A., Collins, J. C. & Nuss, J. M. The Current State of Peptide Drug Discovery: Back to the Future? J. Med. Chem. 61, 1382\u20131414 (2018).","journal-title":"J. Med. Chem."},{"key":"2107_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199707313370502","volume":"337","author":"M Bolla","year":"1997","unstructured":"Bolla, M. et al. Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin. N. Engl. J. Med. 337, 295\u2013300 (1997).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"M Muttenthaler","year":"2021","unstructured":"Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309\u2013325 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/dom.15393","volume":"26","author":"S Furusawa","year":"2024","unstructured":"Furusawa, S. et al. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study). Diabetes Obes. Metab. 26, 961\u2013970 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"2107_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","volume":"26","author":"W Qin","year":"2024","unstructured":"Qin, W. et al. Efficacy and safety of semaglutide 2.4\u2009mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diabetes Obes. Metab. 26, 911\u2013923 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"2107_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","volume":"84","author":"NL France","year":"2024","unstructured":"France, N. L. & Syed, Y. Y. Tirzepatide: A Review in Type 2 Diabetes. Drugs 84, 227\u2013238 (2024).","journal-title":"Drugs"},{"key":"2107_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-024-03646-0","volume":"80","author":"M Kaur","year":"2024","unstructured":"Kaur, M. & Misra, S. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669\u2013676 (2024).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2107_CR20","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3390\/cancers14081914","volume":"14","author":"N Vahidfar","year":"2022","unstructured":"Vahidfar, N. et al. Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC. Cancers (Basel) 14, 1914 (2022).","journal-title":"Cancers (Basel)"},{"key":"2107_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jcis.2020.09.081","volume":"583","author":"M Gontsarik","year":"2021","unstructured":"Gontsarik, M., Yaghmur, A. & Salentinig, S. Dispersed liquid crystals as pH-adjustable antimicrobial peptide nanocarriers. J. Colloid Interface Sci. 583, 672\u2013682 (2021).","journal-title":"J. Colloid Interface Sci."},{"key":"2107_CR22","doi-asserted-by":"publisher","first-page":"701504","DOI":"10.3389\/fbioe.2021.701504","volume":"9","author":"M Liu","year":"2021","unstructured":"Liu, M., Fang, X., Yang, Y. & Wang, C. Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications. Front Bioeng. Biotechnol. 9, 701504 (2021).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2107_CR23","first-page":"54","volume":"2","author":"K McNamara","year":"2017","unstructured":"McNamara, K. & Tofail, S. A. M. Nanoparticles in biomedical applications. Adv. Phys.: X. 2, 54\u201388 (2017).","journal-title":"Adv. Phys.: X."},{"key":"2107_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1039\/C8NR07769J","volume":"11","author":"X Han","year":"2019","unstructured":"Han, X., Xu, K., Taratula, O. & Farsad, K. Applications of nanoparticles in biomedical imaging. Nanoscale 11, 799\u2013819 (2019).","journal-title":"Nanoscale"},{"key":"2107_CR25","doi-asserted-by":"publisher","first-page":"113050","DOI":"10.1016\/j.ejmech.2020.113050","volume":"213","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment. Eur. J. Med. Chem. 213, 113050 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR26","doi-asserted-by":"publisher","first-page":"174512","DOI":"10.1016\/j.ejphar.2021.174512","volume":"915","author":"D Vyas","year":"2022","unstructured":"Vyas, D., Patel, M. & Wairkar, S. Strategies for active tumor targeting-an update. Eur. J. Pharmacol. 915, 174512 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"2107_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/D0CS00556H","volume":"50","author":"BM Cooper","year":"2021","unstructured":"Cooper, B. M. et al. Peptides as a platform for targeted therapeutics for cancer: Peptide\u2013drug conjugates (PDCs). Chem. Soc. Rev. 50, 1480\u20131494 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"2107_CR28","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1016\/j.apsb.2023.01.006","volume":"13","author":"Y Hou","year":"2023","unstructured":"Hou, Y. et al. Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies. Acta Pharm. Sin. B. 13, 3321\u20133338 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2023.0438","volume":"26","author":"C Mathieu","year":"2024","unstructured":"Mathieu, C. et al. The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review. Diabetes Technol. Ther. 26, 66\u201375 (2024).","journal-title":"Diabetes Technol. Ther."},{"key":"2107_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40265-023-01982-6","volume":"84","author":"C Allard","year":"2023","unstructured":"Allard, C., Cota, D. & Quarta, C. Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges. Drugs 84, 127\u2013148 (2023).","journal-title":"Drugs"},{"key":"2107_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.it.2019.06.005","volume":"40","author":"C Westwell-Roper","year":"2019","unstructured":"Westwell-Roper, C. & Verchere, C. B. Modulation of Innate Immunity by Amyloidogenic Peptides. Trends Immunol. 40, 762\u2013780 (2019).","journal-title":"Trends Immunol."},{"key":"2107_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cub.2020.10.076","volume":"31","author":"MP Sinner","year":"2021","unstructured":"Sinner, M. P. et al. Innate Immunity Promotes Sleep through Epidermal Antimicrobial Peptides. Curr. Biol. 31, 564\u2013577 (2021).","journal-title":"Curr. Biol."},{"key":"2107_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/neu.2023.57","volume":"36","author":"FG Graeff","year":"2024","unstructured":"Graeff, F. G., Joca, S. & Zangrossi, H. Jr Bradykinin actions in the central nervous system: historical overview and psychiatric implications. Acta Neuropsychiatr. 36, 129\u2013138 (2024).","journal-title":"Acta Neuropsychiatr."},{"key":"2107_CR34","doi-asserted-by":"publisher","first-page":"2062982","DOI":"10.1080\/21645515.2022.2062982","volume":"18","author":"M Tang","year":"2022","unstructured":"Tang, M. et al. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum. Vaccin. Immunother. 18, 2062982 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2107_CR35","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.3390\/cells10112908","volume":"10","author":"CM Li","year":"2021","unstructured":"Li, C. M. et al. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells 10, 2908 (2021).","journal-title":"Cells"},{"key":"2107_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12272-019-01125-0","volume":"42","author":"SMP Vadevoo","year":"2019","unstructured":"Vadevoo, S. M. P. et al. Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. Arch. Pharm. Res. 42, 150\u2013158 (2019).","journal-title":"Arch. Pharm. Res."},{"key":"2107_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","volume":"8","author":"DP McGregor","year":"2008","unstructured":"McGregor, D. P. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8, 616\u2013619 (2008).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2107_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/psc.2836","volume":"22","author":"R Behrendt","year":"2016","unstructured":"Behrendt, R., White, P. & Offer, J. Advances in Fmoc solid-phase peptide synthesis. J. Pept. Sci. 22, 4\u201327 (2016).","journal-title":"J. Pept. Sci."},{"key":"2107_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1385\/MB:33:3:239","volume":"33","author":"M Amblard","year":"2006","unstructured":"Amblard, M., Fehrentz, J. A., Martinez, J. & Subra, G. Methods and protocols of modern solid phase Peptide synthesis. Mol. Biotechnol. 33, 239\u2013254 (2006).","journal-title":"Mol. Biotechnol."},{"key":"2107_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/bios12030153","volume":"12","author":"H Kim","year":"2022","unstructured":"Kim, H., Jang, J. H., Jung, I. Y. & Cho, J. H. A Novel Peptide as a Specific and Selective Probe for Klebsiella pneumoniae Detection. Biosens. (Basel) 12, 153 (2022).","journal-title":"Biosens. (Basel)"},{"key":"2107_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1359-6446(04)03104-6","volume":"9","author":"RC Ladner","year":"2004","unstructured":"Ladner, R. C., Sato, A. K., Gorzelany, J. & de Souza, M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov. Today 9, 525\u2013529 (2004).","journal-title":"Drug Discov. Today"},{"key":"2107_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/v13040649","volume":"13","author":"A Aloisio","year":"2021","unstructured":"Aloisio, A. et al. Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy. Viruses 13, 649 (2021).","journal-title":"Viruses"},{"key":"2107_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00604-023-05907-8","volume":"190","author":"J Xia","year":"2023","unstructured":"Xia, J. et al. Perspectives and trends in advanced optical and electrochemical biosensors based on engineered peptides. Mikrochim. Acta 190, 327 (2023).","journal-title":"Mikrochim. Acta"},{"key":"2107_CR44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1039\/b611791k","volume":"2","author":"G Hummel","year":"2006","unstructured":"Hummel, G., Reineke, U. & Reimer, U. Translating peptides into small molecules. Mol. Biosyst. 2, 499\u2013508 (2006).","journal-title":"Mol. Biosyst."},{"key":"2107_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/psc.366","volume":"8","author":"A Loffet","year":"2002","unstructured":"Loffet, A. Peptides as drugs: is there a market? J. Pept. Sci. 8, 1\u20137 (2002).","journal-title":"J. Pept. Sci."},{"key":"2107_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.apsb.2019.11.002","volume":"10","author":"D Kwon","year":"2020","unstructured":"Kwon, D., Kim, S. M. & Correia, M. A. Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications. Acta Pharm. Sin. B 10, 42\u201360 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"2107_CR47","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/biof.1913","volume":"49","author":"U Anand","year":"2023","unstructured":"Anand, U. et al. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate. Biofactors 49, 251\u2013269 (2023).","journal-title":"Biofactors"},{"key":"2107_CR48","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1017\/erm.2012.10","volume":"14","author":"MC Smith","year":"2012","unstructured":"Smith, M. C. & Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16 (2012).","journal-title":"Expert Rev. Mol. Med."},{"key":"2107_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","volume":"5","author":"H Lu","year":"2020","unstructured":"Lu, H. et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct. Target Ther. 5, 213 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2107_CR50","doi-asserted-by":"publisher","first-page":"114097","DOI":"10.1016\/j.addr.2021.114097","volume":"182","author":"S Haddadzadegan","year":"2022","unstructured":"Haddadzadegan, S., Dorkoosh, F. & Bernkop-Schn\u00fcrch, A. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. Adv. Drug Deliv. Rev. 182, 114097 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2107_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1208\/s12249-019-1325-z","volume":"20","author":"SJ Cao","year":"2019","unstructured":"Cao, S. J. et al. Nanoparticles: Oral Delivery for Protein and Peptide Drugs. AAPS PharmSciTech 20, 190 (2019).","journal-title":"AAPS PharmSciTech"},{"key":"2107_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0378-5173(91)90185-Q","volume":"75","author":"X Zhou","year":"1991","unstructured":"Zhou, X. & Po, A. L. W. Peptide and protein drugs: II. Non-parenteral routes of delivery. Int. J. Pharm. 75, 117\u2013130 (1991).","journal-title":"Int. J. Pharm."},{"key":"2107_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","volume":"20","author":"RI Mahato","year":"2003","unstructured":"Mahato, R. I., Narang, A. S., Thoma, L. & Miller, D. D. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carr. Syst. 20, 153\u2013214 (2003).","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"2107_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/ijms25020815","volume":"25","author":"M Nicze","year":"2024","unstructured":"Nicze, M. et al. The Current and Promising Oral Delivery Methods for Protein-and Peptide-Based Drugs. Int. J. Mol. Sci. 25, 815 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.addr.2020.12.016","volume":"170","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation. Adv. Drug Del. Rev. 170, 261\u2013280 (2021).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","volume":"20","author":"GA Christou","year":"2019","unstructured":"Christou, G. A. et al. Semaglutide as a promising antiobesity drug. Obes. Rev. 20, 805\u2013815 (2019).","journal-title":"Obes. Rev."},{"key":"2107_CR57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ecoleng.2016.11.028","volume":"99","author":"C Xiang","year":"2017","unstructured":"Xiang, C., Wang, Y. & Liu, H. A scientometrics review on nonpoint source pollution research. Ecol. Eng. 99, 400\u2013408 (2017).","journal-title":"Ecol. Eng."},{"key":"2107_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.addr.2021.03.011","volume":"173","author":"JP Gleeson","year":"2021","unstructured":"Gleeson, J. P., Fein, K. C. & Whitehead, K. A. Oral delivery of peptide therapeutics in infants: Challenges and opportunities. Adv. Drug Del. Rev. 173, 112\u2013124 (2021).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"2107_CR60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ajhp\/zxae105","volume":"81","author":"EM Tichy","year":"2024","unstructured":"Tichy, E. M. et al. National trends in prescription drug expenditures and projections for 2024. Am. J. Health Syst. Pharm. 81, 583\u2013598 (2024).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2107_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11892-024-01533-7","volume":"24","author":"G Yu","year":"2024","unstructured":"Yu, G. et al. Lessons and Applications of Omics Research in Diabetes Epidemiology. Curr. Diab. Rep. 24, 27\u201344 (2024).","journal-title":"Curr. Diab. Rep."},{"key":"2107_CR62","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.1039\/D3TB01202F","volume":"11","author":"C Lim","year":"2023","unstructured":"Lim, C. et al. Development and application of novel peptide-formulated nanoparticles for treatment of atopic dermatitis. J. Mater. Chem. B 11, 10131\u201310146 (2023).","journal-title":"J. Mater. Chem. B"},{"key":"2107_CR63","doi-asserted-by":"publisher","first-page":"116119","DOI":"10.1016\/j.ejmech.2023.116119","volume":"265","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Peptide-drug conjugates: A new paradigm for targeted cancer therapy. Eur. J. Med. Chem. 265, 116119 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2024.01.006","volume":"221","author":"V Vysochinskaya","year":"2024","unstructured":"Vysochinskaya, V. et al. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro. Biochimie 221, 1\u201312 (2024).","journal-title":"Biochimie"},{"key":"2107_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z. et al. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Tar. 7, 93 (2022).","journal-title":"Signal Transduct. Tar."},{"key":"2107_CR66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody\u2013drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2107_CR67","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","volume":"13","author":"C Fu","year":"2023","unstructured":"Fu, C. et al. Peptide\u2013drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm. Sin. B. 13, 498\u2013516 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR68","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1021\/acsptsci.3c00269","volume":"7","author":"SFA Rizvi","year":"2024","unstructured":"Rizvi, S. F. A., Zhang, L., Zhang, H. & Fang, Q. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic. ACS Pharmacol. Transl. Sci. 7, 309\u2013334 (2024).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2107_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17425247.2022.2034784","volume":"19","author":"CP Cerrato","year":"2022","unstructured":"Cerrato, C. P. & Langel, \u00dc. An update on cell-penetrating peptides with intracellular organelle targeting. Expert Opin. Drug Deliv. 19, 133\u2013146 (2022).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2107_CR70","doi-asserted-by":"publisher","first-page":"e202308251","DOI":"10.1002\/anie.202308251","volume":"63","author":"X Ji","year":"2024","unstructured":"Ji, X., Nielsen, A. L. & Heinis, C. Cyclic Peptides for Drug Development. Angew. Chem. Int. Ed. 63, e202308251 (2024).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2107_CR71","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/0113892037268777231013154850","volume":"25","author":"T Bisht","year":"2024","unstructured":"Bisht, T., Adhikari, A., Patil, S. & Dhoundiyal, S. Bioconjugation Techniques for Enhancing Stability and Targeting Efficiency of Protein and Peptide Therapeutics. Curr. Protein Pept. Sci. 25, 226\u2013243 (2024).","journal-title":"Curr. Protein Pept. Sci."},{"key":"2107_CR72","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s00253-023-12512-5","volume":"107","author":"H Rohira","year":"2023","unstructured":"Rohira, H., Arora, A., Kaur, P. & Chugh, A. Peptide cargo administration: current state and applications. Appl. Microbiol. Biotechnol. 107, 3153\u20133181 (2023).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"2107_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2019.07.020","volume":"309","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Cell-penetrating peptide: a means of breaking through the physiological barriers of different tissues and organs. J. Control. Release 309, 106\u2013124 (2019).","journal-title":"J. Control. Release"},{"key":"2107_CR74","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","volume":"64","author":"M Alas","year":"2021","unstructured":"Alas, M., Saghaeidehkordi, A. & Kaur, K. Peptide\u2013Drug Conjugates with Different Linkers for Cancer Therapy. J. Med. Chem. 64, 216\u2013232 (2021).","journal-title":"J. Med. Chem."},{"key":"2107_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6800","volume":"13","author":"H Javid","year":"2024","unstructured":"Javid, H. et al. RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin\u2013RGD interactions. Cancer Med. 13, e6800 (2024).","journal-title":"Cancer Med."},{"key":"2107_CR76","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s12253-019-00773-3","volume":"26","author":"AAP Tripodi","year":"2020","unstructured":"Tripodi, A. A. P. et al. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery. Pathol. Oncol. Res. 26, 1879\u20131892 (2020).","journal-title":"Pathol. Oncol. Res."},{"key":"2107_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/092986733101230723022504","volume":"31","author":"S Sakshi","year":"2024","unstructured":"Sakshi, S. et al. Cell-Penetrating Peptides as Keys to Endosomal Escape and Intracellular Trafficking in Nanomedicine Delivery. Curr. Med. Chem. 31, 1\u201325 (2024).","journal-title":"Curr. Med. Chem."},{"key":"2107_CR78","doi-asserted-by":"publisher","first-page":"11159","DOI":"10.1021\/acsami.3c14908","volume":"16","author":"B Ghaemi","year":"2024","unstructured":"Ghaemi, B. et al. Cell-Penetrating and Enzyme-Responsive Peptides for Targeted Cancer Therapy: Role of Arginine Residue Length on Cell Penetration and In Vivo Systemic Toxicity. ACS Appl. Mater. Interfaces 16, 11159\u201311171 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2107_CR79","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1039\/D3MO00124E","volume":"20","author":"J Straubhaar","year":"2024","unstructured":"Straubhaar, J., D\u2019Souza, A., Niziolek, Z. & Budnik, B. Single cell proteomics analysis of drug response shows its potential as a drug discovery platform. Mol. Omics 20, 6\u201318 (2024).","journal-title":"Mol. Omics"},{"key":"2107_CR80","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1021\/acsomega.3c06527","volume":"9","author":"L Xu","year":"2024","unstructured":"Xu, L. et al. Phage Display Screening of Anchor Peptides for Red Blood Cell-Derived Extracellular Vesicles. ACS Omega 9, 6492\u20136504 (2024).","journal-title":"ACS Omega"},{"key":"2107_CR81","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","volume":"13","author":"L Gong","year":"2023","unstructured":"Gong, L. et al. Research advances in peptide\u2012drug conjugates. Acta Pharm. Sin. B. 13, 3659\u20133677 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR82","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.2174\/1568026618666180118153502","volume":"17","author":"M Walles","year":"2017","unstructured":"Walles, M., Connor, A. & Hainzl, D. ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development. Curr. Top. Med. Chem. 17, 3463\u20133475 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"2107_CR83","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody\u2013drug conjugates. Chem. Soc. Rev. 48, 4361\u20134374 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"2107_CR84","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3390\/ijms25031864","volume":"25","author":"G Mez\u0151","year":"2024","unstructured":"Mez\u0151, G. et al. Oxime-Linked Peptide\u2013Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview. Int. J. Mol. Sci. 25, 1864 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR85","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1039\/D3TB02610H","volume":"12","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. Stimuli-responsive peptide hydrogels for biomedical applications. J. Mater. Chem. B 12, 1748\u20131774 (2024).","journal-title":"J. Mater. Chem. B"},{"key":"2107_CR86","doi-asserted-by":"publisher","first-page":"215969","DOI":"10.1016\/j.canlet.2022.215969","volume":"552","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Drug conjugate-based anticancer therapy - Current status and perspectives. Cancer Lett. 552, 215969 (2023).","journal-title":"Cancer Lett."},{"key":"2107_CR87","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3762\/bjoc.14.80","volume":"14","author":"EI Vrettos","year":"2018","unstructured":"Vrettos, E. I., Mez\u0151, G. & Tzakos, A. G. On the design principles of peptide\u2013drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J. Org. Chem. 14, 930\u2013954 (2018).","journal-title":"Beilstein J. Org. Chem."},{"key":"2107_CR88","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/molecules27175429","volume":"27","author":"C Stokke","year":"2022","unstructured":"Stokke, C., Kvassheim, M. & Blakkisrud, J. Radionuclides for Targeted Therapy: Physical Properties. Molecules 27, 5429 (2022).","journal-title":"Molecules"},{"key":"2107_CR89","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.nucmedbio.2020.07.003","volume":"92","author":"HH Coenen","year":"2021","unstructured":"Coenen, H. H. & Ermert, J. Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. Nucl. Med. Biol. 92, 241\u2013269 (2021).","journal-title":"Nucl. Med. Biol."},{"key":"2107_CR90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cpet.2023.08.003","volume":"19","author":"T Yamaya","year":"2024","unstructured":"Yamaya, T., Tashima, H., Takyu, S. & Takahashi, M. Whole Gamma Imaging: Challenges and Opportunities. PET Clin. 19, 83\u201393 (2024).","journal-title":"PET Clin."},{"key":"2107_CR91","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fchem.2020.00571","volume":"8","author":"P Hoppenz","year":"2020","unstructured":"Hoppenz, P., Els-Heindl, S. & Beck-Sickinger, A. G. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front. Chem. 8, 571 (2020).","journal-title":"Front. Chem."},{"key":"2107_CR92","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","volume":"26","author":"SJ Keam","year":"2022","unstructured":"Keam, S. J. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. Mol. Diagn. Ther. 26, 467\u2013475 (2022).","journal-title":"Mol. Diagn. Ther."},{"key":"2107_CR93","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/10600280211058388","volume":"56","author":"JK Jessee","year":"2021","unstructured":"Jessee, J. K. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Ann. Pharmacother. 56, 951\u2013957 (2021).","journal-title":"Ann. Pharmacother."},{"key":"2107_CR94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","volume":"11","author":"M Wu","year":"2022","unstructured":"Wu, M., Huang, W., Yang, N. & Liu, Y. Learn from antibody\u2013drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Exp. Hematol. Oncol. 11, 93 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2107_CR95","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11899-022-00682-4","volume":"17","author":"A McCurdy","year":"2022","unstructured":"McCurdy, A. & Visram, A. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma. Curr. Hematol. Malig. Rep. 17, 306\u2013318 (2022).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2107_CR96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/pharmaceutics16020240","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Peptide-Mediated Nanocarriers for Targeted Drug Delivery: Developments and Strategies. Pharmaceutics 16, 240 (2024).","journal-title":"Pharmaceutics"},{"key":"2107_CR97","doi-asserted-by":"publisher","first-page":"175","DOI":"10.18632\/oncotarget.27431","volume":"11","author":"K Fodor","year":"2020","unstructured":"Fodor, K. et al. The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma. Oncotarget 11, 175 (2020).","journal-title":"Oncotarget"},{"key":"2107_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3561","volume":"30","author":"J Paulus","year":"2024","unstructured":"Paulus, J. & Sewald, N. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment. J. Pept. Sci. 30, e3561 (2024).","journal-title":"J. Pept. Sci."},{"key":"2107_CR99","doi-asserted-by":"publisher","first-page":"108458","DOI":"10.1016\/j.pharmthera.2023.108458","volume":"247","author":"F Liu","year":"2023","unstructured":"Liu, F., Wu, Q., Dong, Z. & Liu, K. Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacol. Ther. 247, 108458 (2023).","journal-title":"Pharmacol. Ther."},{"key":"2107_CR100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejps.2018.11.023","volume":"128","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y. & Ji, Y. RGD-modified polymer and liposome nanovehicles: Recent research progress for drug delivery in cancer therapeutics. Eur. J. Pharm. Sci. 128, 8\u201317 (2019).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2107_CR101","doi-asserted-by":"publisher","first-page":"121783","DOI":"10.1016\/j.biomaterials.2022.121783","volume":"289","author":"YS Cho","year":"2022","unstructured":"Cho, Y. S. et al. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. Biomaterials 289, 121783 (2022).","journal-title":"Biomaterials"},{"key":"2107_CR102","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/path.5320","volume":"249","author":"CS Reader","year":"2019","unstructured":"Reader, C. S. et al. The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J. Pathol. 249, 332\u2013342 (2019).","journal-title":"J. Pathol."},{"key":"2107_CR103","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.7150\/thno.38702","volume":"10","author":"KM Moore","year":"2020","unstructured":"Moore, K. M. et al. Integrin \u03b1v\u03b26-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics 10, 2930 (2020).","journal-title":"Theranostics"},{"key":"2107_CR104","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah, D. A., Hajjo, R. & Sweidan, K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr. Top. Med. Chem. 20, 815\u2013834 (2020).","journal-title":"Curr. Top. Med. Chem."},{"key":"2107_CR105","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.dyepig.2018.11.055","volume":"163","author":"L Yu","year":"2019","unstructured":"Yu, L. et al. Synthesis and biological evaluation of phthalocyanine-peptide conjugate for EGFR-targeted photodynamic therapy and bioimaging. Dyes Pigment 163, 197\u2013203 (2019).","journal-title":"Dyes Pigment"},{"key":"2107_CR106","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1021\/acs.jmedchem.0c01677","volume":"64","author":"JCH Chu","year":"2021","unstructured":"Chu, J. C. H., Fong, W.-P., Wong, C. T. T. & Ng, D. K. P. Facile Synthesis of Cyclic Peptide\u2013Phthalocyanine Conjugates for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy. J. Med. Chem. 64, 2064\u20132076 (2021).","journal-title":"J. Med. Chem."},{"key":"2107_CR107","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1021\/acs.jmedchem.3c01682","volume":"67","author":"GJ-B Philippe","year":"2024","unstructured":"Philippe, G. J.-B. et al. Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide. J. Med. Chem. 67, 1197\u20131208 (2024).","journal-title":"J. Med. Chem."},{"key":"2107_CR108","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","volume":"186","author":"M Galogre","year":"2023","unstructured":"Galogre, M. et al. A review of HER2 overexpression and somatic mutations in cancers. Crit. Rev. Oncol. \/Hematol. 186, 103997 (2023).","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"2107_CR109","doi-asserted-by":"crossref","unstructured":"Liu, S., Tian, Y., Jiang, S. & Wang, Z. A Novel Homodimer Peptide\u2013Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms24054590"},{"key":"2107_CR110","doi-asserted-by":"publisher","first-page":"116032","DOI":"10.1016\/j.ejmech.2023.116032","volume":"264","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors. Eur. J. Med. Chem. 264, 116032 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR111","doi-asserted-by":"crossref","unstructured":"Candelaria, P. V., Leoh, L. S., Penichet, M. L. & Daniels-Wells, T. R. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents. Front. Immunol. 12 (2021).","DOI":"10.3389\/fimmu.2021.607692"},{"key":"2107_CR112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cbdd.13613","volume":"95","author":"S Li","year":"2020","unstructured":"Li, S. et al. Design, synthesis, and in vitro antitumor activity of a transferrin receptor-targeted peptide\u2013doxorubicin conjugate. Chem. Biol. Drug Des. 95, 58\u201365 (2020).","journal-title":"Chem. Biol. Drug Des."},{"key":"2107_CR113","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/acsomega.3c07486","volume":"9","author":"P Bataille Backer","year":"2024","unstructured":"Bataille Backer, P. et al. Development of a Targeted SN-38-Conjugate for the Treatment of Glioblastoma. ACS Omega 9, 2615\u20132628 (2024).","journal-title":"ACS Omega"},{"key":"2107_CR114","first-page":"91","volume":"10","author":"RG Castillo-Avila","year":"2023","unstructured":"Castillo-Avila, R. G. et al. Association between Genetic Variants of CELSR2-PSRC1-SORT1 and Cardiovascular Diseases: A Systematic Review and Meta-Analysis. J. Cardiovasc. Dev. Dis. 10, 91 (2023).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"2107_CR115","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1111\/cas.15086","volume":"112","author":"M Demeule","year":"2021","unstructured":"Demeule, M. et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 112, 4317\u20134334 (2021).","journal-title":"Cancer Sci."},{"key":"2107_CR116","doi-asserted-by":"publisher","first-page":"15585","DOI":"10.3390\/ijms232415585","volume":"23","author":"P Mabeta","year":"2022","unstructured":"Mabeta, P. & Steenkamp, V. The VEGF\/VEGFR Axis Revisited: Implications for Cancer Therapy. Int. J. Mol. Sci. 23, 15585 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR117","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41420-022-01198-9","volume":"8","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy. Cell Death Discov. 8, 411 (2022).","journal-title":"Cell Death Discov."},{"key":"2107_CR118","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","volume":"21","author":"M Rigby","year":"2022","unstructured":"Rigby, M. et al. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Mol. Cancer Ther. 21, 1747\u20131756 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2107_CR119","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gilli\u00e9ron","year":"2015","unstructured":"Gerster-Gilli\u00e9ron, K. et al. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J. Nucl. Med. 56, 1748\u20131751 (2015).","journal-title":"J. Nucl. Med."},{"key":"2107_CR120","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","volume":"21","author":"U Jo","year":"2022","unstructured":"Jo, U. et al. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol. Cancer Ther. 21, 1090\u20131102 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2107_CR121","doi-asserted-by":"publisher","first-page":"116047","DOI":"10.1016\/j.ejmech.2023.116047","volume":"264","author":"Y Fang","year":"2024","unstructured":"Fang, Y. et al. Smart glypican-3-targeting peptide\u2013chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma. Eur. J. Med. Chem. 264, 116047 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR122","doi-asserted-by":"publisher","first-page":"102182","DOI":"10.1016\/j.nantod.2024.102182","volume":"55","author":"M R\u00fctter","year":"2024","unstructured":"R\u00fctter, M. et al. E-selectin-targeted polymer-doxorubicin conjugate induces regression of established colorectal liver metastases and improves mice survival. Nano Today 55, 102182 (2024).","journal-title":"Nano Today"},{"key":"2107_CR123","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/ijms25021095","volume":"25","author":"I Szab\u00f3","year":"2024","unstructured":"Szab\u00f3, I. et al. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of \u03b1-MSH\u2013Peptide Conjugates. Int. J. Mol. Sci. 25, 1095 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR124","doi-asserted-by":"publisher","first-page":"129589","DOI":"10.1016\/j.bmcl.2023.129589","volume":"98","author":"JX Qiao","year":"2024","unstructured":"Qiao, J. X. et al. Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1). Bioorg. Med. Chem. Lett. 98, 129589 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2107_CR125","doi-asserted-by":"publisher","first-page":"114617","DOI":"10.1016\/j.ejmech.2022.114617","volume":"241","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer. Eur. J. Med. Chem. 241, 114617 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR126","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-022-01274-8","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang, Y. et al. DTX-P7, a peptide\u2013drug conjugate, is highly effective for non-small cell lung cancer. J. Hematol. Oncol. 15, 73 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2107_CR127","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1021\/acs.nanolett.3c04371","volume":"24","author":"Q Dai","year":"2024","unstructured":"Dai, Q., Xie, L., Ren, E. & Liu, G. Cathepsin B Responsive Peptide\u2013Purpurin Conjugates Assembly-Initiated in Situ Self-Aggregation for Cancer Sonotheranostics. Nano Lett. 24, 950\u2013957 (2024).","journal-title":"Nano Lett."},{"key":"2107_CR128","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/17460441.2021.1851187","volume":"16","author":"L Porosk","year":"2021","unstructured":"Porosk, L., Gaidut\u0161ik, I. & Langel, \u00dc. Approaches for the discovery of new cell-penetrating peptides. Expert Opin. Drug Dis. 16, 553\u2013565 (2021).","journal-title":"Expert Opin. Drug Dis."},{"key":"2107_CR129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41551-023-01168-1","volume":"8","author":"AM Hummer","year":"2024","unstructured":"Hummer, A. M. & Deane, C. M. Designing stable humanized antibodies. Nat. Biomed. Eng. 8, 3\u20134 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2107_CR130","doi-asserted-by":"publisher","first-page":"114773","DOI":"10.1016\/j.addr.2023.114773","volume":"196","author":"T Sun","year":"2023","unstructured":"Sun, T. & Jiang, C. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Adv. Drug Del. Rev. 196, 114773 (2023).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR131","first-page":"3","volume":"15","author":"M Yadav","year":"2023","unstructured":"Yadav, M. & Eswari, J. S. Opportunistic Challenges of Computer-aided Drug Discovery of Lipopeptides: New Insights for Large Molecule Therapeutics. Avicenna J. Med. Biotechnol. 15, 3 (2023).","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"2107_CR132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/nyas.14100","volume":"1455","author":"TW Moody","year":"2019","unstructured":"Moody, T. W. Peptide receptors as cancer drug targets. Ann. N. Y. Acad. Sci. 1455, 141\u2013148 (2019).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2107_CR133","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1007\/s12274-022-5236-z","volume":"16","author":"M Li","year":"2023","unstructured":"Li, M. et al. A composite peptide-supramolecular microneedle system for melanoma immunotherapy. Nano Res. 16, 5335\u20135345 (2023).","journal-title":"Nano Res."},{"key":"2107_CR134","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","volume":"30","author":"DB Kohn","year":"2023","unstructured":"Kohn, D. B., Chen, Y. Y. & Spencer, M. J. Successes and challenges in clinical gene therapy. Gene Ther. 30, 738\u2013746 (2023).","journal-title":"Gene Ther."},{"key":"2107_CR135","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/ijms23031445","volume":"23","author":"M Akbarian","year":"2022","unstructured":"Akbarian, M., Khani, A., Eghbalpour, S. & Uversky, V. N. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int. J. Mol. Sci. 23, 1445 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR136","doi-asserted-by":"publisher","first-page":"104475","DOI":"10.1016\/j.jddst.2023.104475","volume":"84","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Penetrating peptides: Applications in drug delivery. J. Drug Deliv. Sci. Technol. 84, 104475 (2023).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"2107_CR137","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/1567201820666230407092924","volume":"21","author":"DD Kotadiya","year":"2024","unstructured":"Kotadiya, D. D., Patel, P. & Patel, H. D. Cell-Penetrating Peptides: A Powerful Tool for Targeted Drug Delivery. Curr. Drug Deliv. 21, 368\u2013388 (2024).","journal-title":"Curr. Drug Deliv."},{"key":"2107_CR138","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2016.03.020","volume":"229","author":"D Zhang","year":"2016","unstructured":"Zhang, D., Wang, J. & Xu, D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J. Control. Release 229, 130\u2013139 (2016).","journal-title":"J. Control. Release"},{"key":"2107_CR139","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","volume":"55","author":"AD Frankel","year":"1988","unstructured":"Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189\u20131193 (1988).","journal-title":"Cell"},{"key":"2107_CR140","doi-asserted-by":"publisher","first-page":"130162","DOI":"10.1016\/j.ijbiomac.2024.130162","volume":"263","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan. Int. J. Biol. Macromol. 263, 130162 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"2107_CR141","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/life11090924","volume":"11","author":"M Lichtenstein","year":"2021","unstructured":"Lichtenstein, M. et al. TAT for Enzyme\/Protein Delivery to Restore or Destroy Cell Activity in Human Diseases. Life 11, 924 (2021).","journal-title":"Life"},{"key":"2107_CR142","doi-asserted-by":"publisher","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","volume":"17","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Engineered Extracellular Vesicle-Delivered CRISPR\/Cas9 for Radiotherapy Sensitization of Glioblastoma. ACS Nano 17, 16432\u201316447 (2023).","journal-title":"ACS Nano"},{"key":"2107_CR143","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.3390\/pharmaceutics15122789","volume":"15","author":"Y Wan","year":"2023","unstructured":"Wan, Y. et al. Fluorinated Cell-Penetrating Peptide for Co-Delivering siHIF-1\u03b1 and Sorafenib to Enhance In Vitro Anti-Tumor Efficacy. Pharmaceutics 15, 2789 (2023).","journal-title":"Pharmaceutics"},{"key":"2107_CR144","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","volume":"16","author":"K Kardani","year":"2019","unstructured":"Kardani, K., Milani, A., H. Shabani, S. & Bolhassani, A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin. Drug Deliv. 16, 1227\u20131258 (2019).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2107_CR145","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/pharmaceutics13091391","volume":"13","author":"A Shoari","year":"2021","unstructured":"Shoari, A., Tooyserkani, R., Tahmasebi, M. & L\u00f6wik, D. W. P. M. Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 13, 1391 (2021).","journal-title":"Pharmaceutics"},{"key":"2107_CR146","first-page":"523","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Zhao, Z. & Li, M. Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers. Asian J. Pharm. Sci. 17, 523\u2013543 (2022).","journal-title":"Asian J. Pharm. Sci."},{"key":"2107_CR147","doi-asserted-by":"publisher","first-page":"11768","DOI":"10.3390\/ijms241411768","volume":"24","author":"K Tsuchiya","year":"2023","unstructured":"Tsuchiya, K. et al. Development of Hydrophobic Cell-Penetrating Stapled Peptides as Drug Carriers. Int. J. Mol. Sci. 24, 11768 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR148","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3762\/bjnano.11.10","volume":"11","author":"I Ruseska","year":"2020","unstructured":"Ruseska, I. & Zimmer, A. Internalization mechanisms of cell-penetrating peptides. Beilstein J. Nanotechnol. 11, 101\u2013123 (2020).","journal-title":"Beilstein J. Nanotechnol."},{"key":"2107_CR149","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/IDR.S396566","volume":"16","author":"X Huang","year":"2023","unstructured":"Huang, X. & Li, G. Antimicrobial Peptides and Cell-Penetrating Peptides: Non-Antibiotic Membrane-Targeting Strategies Against Bacterial Infections. Infect. Drug Resistance. 16, 1203\u20131219 (2023).","journal-title":"Infect. Drug Resistance."},{"key":"2107_CR150","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1007\/s00253-018-8889-5","volume":"102","author":"MZ Islam","year":"2018","unstructured":"Islam, M. Z., Sharmin, S., Moniruzzaman, M. & Yamazaki, M. Elementary processes for the entry of cell-penetrating peptides into lipid bilayer vesicles and bacterial cells. Appl. Microbiol. Biotechnol. 102, 3879\u20133892 (2018).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"2107_CR151","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5603\/FHC.a2014.0034","volume":"52","author":"J Ruczynski","year":"2014","unstructured":"Ruczynski, J. et al. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells. Folia Histochem. Cytobiol. 52, 257\u2013269 (2014).","journal-title":"Folia Histochem. Cytobiol."},{"key":"2107_CR152","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.3390\/ijms23169038","volume":"23","author":"M Hao","year":"2022","unstructured":"Hao, M., Zhang, L. & Chen, P. Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides. Int. J. Mol. Sci. 23, 9038 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR153","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2004.10.018","volume":"102","author":"IM Kaplan","year":"2005","unstructured":"Kaplan, I. M., Wadia, J. S. & Dowdy, S. F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 102, 247\u2013253 (2005).","journal-title":"J. Control. Release"},{"key":"2107_CR154","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215815120","volume":"120","author":"S Gollapudi","year":"2023","unstructured":"Gollapudi, S. et al. Steric pressure between glycosylated transmembrane proteins inhibits internalization by endocytosis. Proc. Natl Acad. Sci. 120, e2215815120 (2023).","journal-title":"Proc. Natl Acad. Sci."},{"key":"2107_CR155","doi-asserted-by":"publisher","first-page":"118892","DOI":"10.1016\/j.carbpol.2021.118892","volume":"277","author":"T Wei","year":"2022","unstructured":"Wei, T. et al. Development of oral curcumin based on pH-responsive transmembrane peptide-cyclodextrin derivative nanoparticles for hepatoma. Carbohydr. Polym. 277, 118892 (2022).","journal-title":"Carbohydr. Polym."},{"key":"2107_CR156","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ph5111177","volume":"5","author":"A Erazo-Oliveras","year":"2012","unstructured":"Erazo-Oliveras, A. et al. Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges. Pharmaceuticals 5, 1177\u20131209 (2012).","journal-title":"Pharmaceuticals"},{"key":"2107_CR157","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms21175994","volume":"21","author":"TA Davidson","year":"2020","unstructured":"Davidson, T. A., McGoldrick, S. J. & Kohn, D. H. Phage Display to Augment Biomaterial Function. Int. J. Mol. Sci. 21, 5994 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR158","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1093\/nar\/gkaa1279","volume":"49","author":"K Pleiko","year":"2021","unstructured":"Pleiko, K. et al. In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues. Nucleic Acids Res 49, e38\u2013e38 (2021).","journal-title":"Nucleic Acids Res"},{"key":"2107_CR159","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s13346-021-01035-z","volume":"12","author":"R Goyal","year":"2022","unstructured":"Goyal, R. et al. Molecular hybridization combining tumor homing and penetrating peptide domains for cellular targeting. Drug Deliv. Transl. Res. 12, 1285\u20131292 (2022).","journal-title":"Drug Deliv. Transl. Res."},{"key":"2107_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00776-9","volume":"11","author":"D Tonnelet","year":"2021","unstructured":"Tonnelet, D. et al. Angiogenesis imaging study using interim [18 F] RGD-K5 PET\/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence. EJNMMI Res. 11, 1\u20139 (2021).","journal-title":"EJNMMI Res."},{"key":"2107_CR161","doi-asserted-by":"publisher","first-page":"105386","DOI":"10.1016\/j.compbiomed.2022.105386","volume":"144","author":"M Dahri","year":"2022","unstructured":"Dahri, M. et al. Nanoscale aggregation of doxorubicin-short peptide conjugates for enzyme-responsive delivery with various MOF carriers: In-silico steps towards smart cancer chemotherapy. Comput. Biol. Med. 144, 105386 (2022).","journal-title":"Comput. Biol. Med."},{"key":"2107_CR162","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12951-020-00654-x","volume":"18","author":"Y Haddad","year":"2020","unstructured":"Haddad, Y. et al. Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells. J. Nanobiotechnol. 18, 95 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"2107_CR163","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.2147\/IJN.S325891","volume":"21","author":"H Li","year":"2021","unstructured":"Li, H. et al. iRGD peptide-mediated liposomal nanoparticles with photoacoustic\/ultrasound dual-modality imaging for precision theranostics against hepatocellular carcinoma. Int. J. Nanomed. 21, 6455\u20136475 (2021).","journal-title":"Int. J. Nanomed."},{"key":"2107_CR164","doi-asserted-by":"publisher","first-page":"46721","DOI":"10.1021\/acsami.3c11561","volume":"15","author":"S Pal","year":"2023","unstructured":"Pal, S. et al. Albumin Nanoparticles Surface Decorated with a Tumor-Homing Peptide Help in Selective Killing of Triple-Negative Breast Cancer Cells. ACS Appl. Mater. Interfaces 15, 46721\u201346737 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2107_CR165","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jconrel.2021.08.044","volume":"338","author":"E Seyyednia","year":"2021","unstructured":"Seyyednia, E. et al. Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging. J. Control. Release 338, 367\u2013393 (2021).","journal-title":"J. Control. Release"},{"key":"2107_CR166","doi-asserted-by":"publisher","first-page":"116050","DOI":"10.1016\/j.ejmech.2023.116050","volume":"265","author":"T Singh","year":"2024","unstructured":"Singh, T. et al. Tumor\u2013homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy. Eur. J. Med. Chem. 265, 116050 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR167","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/pharmaceutics10010002","volume":"10","author":"I Genta","year":"2018","unstructured":"Genta, I. et al. GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. Pharmaceutics 10, 2 (2018).","journal-title":"Pharmaceutics"},{"key":"2107_CR168","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/abr.abr_18_19","volume":"8","author":"G Fotoohi-Ardakani","year":"2019","unstructured":"Fotoohi-Ardakani, G. et al. Targeting MCF-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion with AHNP Targeted Peptide. Adv. Biomed. Res. 8, 33 (2019).","journal-title":"Adv. Biomed. Res."},{"key":"2107_CR169","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/polym12091906","volume":"12","author":"S Kang","year":"2020","unstructured":"Kang, S., Lee, S. & Park, S. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers 12, 1906 (2020).","journal-title":"Polymers"},{"key":"2107_CR170","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/cbdd.14333","volume":"102","author":"Y-J Wu","year":"2023","unstructured":"Wu, Y.-J. et al. Design and characterization of a novel tumor-homing cell-penetrating peptide for drug delivery in TGFBR3 high-expressing tumors. Chem. Biol. Drug Des. 102, 1421\u20131434 (2023).","journal-title":"Chem. Biol. Drug Des."},{"key":"2107_CR171","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/cas.14909","volume":"112","author":"E Kondo","year":"2021","unstructured":"Kondo, E., Iioka, H. & Saito, K. Tumor-homing peptide and its utility for advanced cancer medicine. Cancer Sci. 112, 2118\u20132125 (2021).","journal-title":"Cancer Sci."},{"key":"2107_CR172","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1039\/D2BM00826B","volume":"10","author":"S Tarvirdipour","year":"2022","unstructured":"Tarvirdipour, S. et al. A self-assembling peptidic platform to boost the cellular uptake and nuclear delivery of oligonucleotides. Biomater. Sci. 10, 4309\u20134323 (2022).","journal-title":"Biomater. Sci."},{"key":"2107_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012252","volume":"5","author":"M Zahid","year":"2010","unstructured":"Zahid, M. et al. Identification of a Cardiac Specific Protein Transduction Domain by In Vivo Biopanning Using a M13 Phage Peptide Display Library in Mice. PLoS One 5, e12252 (2010).","journal-title":"PLoS One"},{"key":"2107_CR174","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.bbrc.2020.09.087","volume":"533","author":"T Iwasaki","year":"2020","unstructured":"Iwasaki, T., Murakami, N. & Kawano, T. A polylysine\u2013polyhistidine fusion peptide for lysosome-targeted protein delivery. Biochem. Biophys. Res. Commun. 533, 905\u2013912 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2107_CR175","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1016\/j.apsb.2021.06.010","volume":"11","author":"X Li","year":"2021","unstructured":"Li, X. et al. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression. Acta Pharm. Sin. B. 11, 2655\u20132669 (2021).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR176","doi-asserted-by":"publisher","first-page":"106125","DOI":"10.1016\/j.ejps.2022.106125","volume":"171","author":"B Panigrahi","year":"2022","unstructured":"Panigrahi, B. et al. Cyclic peptides nanospheres: A \u20182-in-1\u2032 self-assembled delivery system for targeting nucleus and cytoplasm. Eur. J. Pharm. Sci. 171, 106125 (2022).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2107_CR177","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/ijms24076292","volume":"24","author":"E Hijov\u00e1","year":"2023","unstructured":"Hijov\u00e1, E. Benefits of Biotics for Cardiovascular Diseases. Int. J. Mol. Sci. 24, 6292 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR178","doi-asserted-by":"publisher","first-page":"10825","DOI":"10.1039\/D0TB01106A","volume":"8","author":"CP Cerrato","year":"2020","unstructured":"Cerrato, C. P. et al. Intracellular delivery of therapeutic antisense oligonucleotides targeting mRNA coding mitochondrial proteins by cell-penetrating peptides. J. Mater. Chem. B 8, 10825\u201310836 (2020).","journal-title":"J. Mater. Chem. B"},{"key":"2107_CR179","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/biom13121690","volume":"13","author":"D Sahagun","year":"2023","unstructured":"Sahagun, D. & Zahid, M. Cardiac-Targeting Peptide: From Discovery to Applications. Biomolecules 13, 1690 (2023).","journal-title":"Biomolecules"},{"key":"2107_CR180","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/jphp.13317","volume":"72","author":"B von Mentzer","year":"2020","unstructured":"von Mentzer, B. et al. A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine. J. Pharm. Pharmacol. 72, 1352\u20131360 (2020).","journal-title":"J. Pharm. Pharmacol."},{"key":"2107_CR181","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.bioeng.8.061505.095735","volume":"8","author":"VP Torchilin","year":"2006","unstructured":"Torchilin, V. P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8, 343\u2013375 (2006).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"2107_CR182","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nano.2018.09.010","volume":"16","author":"KM Ahlschwede","year":"2019","unstructured":"Ahlschwede, K. M. et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer\u2019s disease brain. Nanomed. Nanotechnol. Biol. Med. 16, 258\u2013266 (2019).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"2107_CR183","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3390\/pharmaceutics14102223","volume":"14","author":"AAP Mansur","year":"2022","unstructured":"Mansur, A. A. P. et al. Bioengineered Carboxymethylcellulose\u2013Peptide Hybrid Nanozyme Cascade for Targeted Intracellular Biocatalytic\u2013Magnetothermal Therapy of Brain Cancer Cells. Pharmaceutics 14, 2223 (2022).","journal-title":"Pharmaceutics"},{"key":"2107_CR184","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s11095-023-03486-0","volume":"40","author":"MF Lee","year":"2023","unstructured":"Lee, M. F. & Poh, C. L. Strategies to improve the physicochemical properties of peptide-based drugs. Pharm. Res. 40, 617\u2013632 (2023).","journal-title":"Pharm. Res."},{"key":"2107_CR185","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1021\/acs.accounts.1c00560","volume":"55","author":"D Pei","year":"2022","unstructured":"Pei, D. How Do Biomolecules Cross the Cell Membrane? Acc. Chem. Res. 55, 309\u2013318 (2022).","journal-title":"Acc. Chem. Res."},{"key":"2107_CR186","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jconrel.2021.01.015","volume":"331","author":"M Sylvestre","year":"2021","unstructured":"Sylvestre, M. et al. Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice. J. Control. Release 331, 142\u2013153 (2021).","journal-title":"J. Control. Release"},{"key":"2107_CR187","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cbic.201500312","volume":"17","author":"HM Werner","year":"2016","unstructured":"Werner, H. M., Cabalteja, C. C. & Horne, W. S. Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution. ChemBioChem 17, 712\u2013718 (2016).","journal-title":"ChemBioChem"},{"key":"2107_CR188","doi-asserted-by":"publisher","first-page":"106892","DOI":"10.1016\/j.bioorg.2023.106892","volume":"141","author":"X Li","year":"2023","unstructured":"Li, X. et al. Backbone N-methylation of peptides: Advances in synthesis and applications in pharmaceutical drug development. Bioorg. Chem. 141, 106892 (2023).","journal-title":"Bioorg. Chem."},{"key":"2107_CR189","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3225","volume":"26","author":"A Asano","year":"2020","unstructured":"Asano, A., Yamada, T. & Doi, M. Incorporation of \u03b2-amino acids into ascidiacyclamides: Effects on conformation, cytotoxicity and interaction with copper (II) ion. J. Pept. Sci. 26, e3225 (2020).","journal-title":"J. Pept. Sci."},{"key":"2107_CR190","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1021\/acschembio.6b00404","volume":"11","author":"RW Cheloha","year":"2016","unstructured":"Cheloha, R. W. et al. Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist\/Inverse Agonist. ACS Chem. Biol. 11, 2752\u20132762 (2016).","journal-title":"ACS Chem. Biol."},{"key":"2107_CR191","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/molecules28073189","volume":"28","author":"TJ Tyler","year":"2023","unstructured":"Tyler, T. J., Durek, T. & Craik, D. J. Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads. Molecules 28, 3189 (2023).","journal-title":"Molecules"},{"key":"2107_CR192","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/bs.mie.2021.04.012","volume":"656","author":"RS Ayikpoe","year":"2021","unstructured":"Ayikpoe, R. S. & van der Donk, W. A. Peptide backbone modifications in lanthipeptides. Methods Enzymol. 656, 573\u2013621 (2021).","journal-title":"Methods Enzymol."},{"key":"2107_CR193","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.2174\/0929867329666220510214402","volume":"29","author":"K Fan Cheng","year":"2022","unstructured":"Fan Cheng, K., VanPatten, S., He, M. & Al-Abed, Y. Azapeptides -A History of Synthetic Milestones and Key Examples. Curr. Med. Chem. 29, 6336\u20136358 (2022).","journal-title":"Curr. Med. Chem."},{"key":"2107_CR194","doi-asserted-by":"publisher","first-page":"e3384","DOI":"10.1002\/psc.3384","volume":"28","author":"GW Preston","year":"2022","unstructured":"Preston, G. W. Different directions for retro-inverso peptides. J. Pept. Sci. 28, e3384 (2022).","journal-title":"J. Pept. Sci."},{"key":"2107_CR195","doi-asserted-by":"publisher","first-page":"106686","DOI":"10.1016\/j.bioorg.2023.106686","volume":"139","author":"J Zhu","year":"2023","unstructured":"Zhu, J. et al. Recent advances in anticancer peptoids. Bioorg. Chem. 139, 106686 (2023).","journal-title":"Bioorg. Chem."},{"key":"2107_CR196","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1039\/D2SC04147B","volume":"14","author":"R Vanhoutte","year":"2023","unstructured":"Vanhoutte, R. et al. Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells. Chem. Sci. 14, 1666\u20131672 (2023).","journal-title":"Chem. Sci."},{"key":"2107_CR197","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.jaut.2020.102543","volume":"115","author":"A Lombardi","year":"2020","unstructured":"Lombardi, A. et al. Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes. J. Autoimmun. 115, 102543 (2020).","journal-title":"J. Autoimmun."},{"key":"2107_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28437-y","volume":"13","author":"J Sun","year":"2023","unstructured":"Sun, J. et al. Protective effect of urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity. Sci. Rep. 13, 1279 (2023).","journal-title":"Sci. Rep."},{"key":"2107_CR199","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.pupt.2022.102185","volume":"78","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells. Pulm. Pharmacol. Ther. 78, 102185 (2023).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2107_CR200","doi-asserted-by":"publisher","first-page":"16333","DOI":"10.3390\/ijms242216333","volume":"24","author":"A Giorgio","year":"2023","unstructured":"Giorgio, A. et al. Peptoids: Smart and Emerging Candidates for the Diagnosis of Cancer, Neurological and Autoimmune Disorders. Int. J. Mol. Sci. 24, 16333 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR201","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1021\/acs.orglett.0c00713","volume":"22","author":"E Masri","year":"2020","unstructured":"Masri, E., Ahsanullah, Accorsi, M. & Rademann, J. Side-Chain Modification of Peptides Using a Phosphoranylidene Amino Acid. Org. Lett. 22, 2976\u20132980 (2020).","journal-title":"Org. Lett."},{"key":"2107_CR202","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/acs.jnatprod.7b00337","volume":"81","author":"S Fotso","year":"2018","unstructured":"Fotso, S. et al. Alveolarides: Antifungal Peptides from Microascus alveolaris Active against Phytopathogenic Fungi. J. Nat. Prod. 81, 10\u201315 (2018).","journal-title":"J. Nat. Prod."},{"key":"2107_CR203","doi-asserted-by":"publisher","first-page":"127925","DOI":"10.1016\/j.bmcl.2021.127925","volume":"40","author":"K Sakamoto","year":"2021","unstructured":"Sakamoto, K. et al. Use of homoarginine to obtain attenuated cationic membrane lytic peptides. Bioorg. Med. Chem. Lett. 40, 127925 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2107_CR204","doi-asserted-by":"publisher","first-page":"113624","DOI":"10.1016\/j.jphotochem.2021.113624","volume":"424","author":"MS Michie","year":"2022","unstructured":"Michie, M. S. et al. Side-chain modification of collagen-targeting peptide prevents dye aggregation for improved molecular imaging of arthritic joints. J. Photochem. Photobiol. A: Chem. 424, 113624 (2022).","journal-title":"J. Photochem. Photobiol. A: Chem."},{"key":"2107_CR205","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson III","year":"2023","unstructured":"Thompson, G. R. III et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 401, 49\u201359 (2023).","journal-title":"Lancet"},{"key":"2107_CR206","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","volume":"29","author":"ZD Crees","year":"2023","unstructured":"Crees, Z. D. et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat. Med. 29, 869\u2013879 (2023).","journal-title":"Nat. Med."},{"key":"2107_CR207","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr.","year":"2023","unstructured":"Howard, J. F. Jr. et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 22, 395\u2013406 (2023).","journal-title":"Lancet Neurol."},{"key":"2107_CR208","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1021\/acs.jmedchem.0c00686","volume":"63","author":"CBF Mour\u00e3o","year":"2020","unstructured":"Mour\u00e3o, C. B. F. et al. Head-to-Tail Cyclization after Interaction with Trypsin: A Scorpion Venom Peptide that Resembles Plant Cyclotides. J. Med. Chem. 63, 9500\u20139511 (2020).","journal-title":"J. Med. Chem."},{"key":"2107_CR209","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1021\/acs.jmedchem.7b00768","volume":"61","author":"P-Y Yang","year":"2018","unstructured":"Yang, P.-Y. et al. Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models. J. Med. Chem. 61, 3218\u20133223 (2018).","journal-title":"J. Med. Chem."},{"key":"2107_CR210","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1002\/anie.201916257","volume":"59","author":"MG Ricardo","year":"2020","unstructured":"Ricardo, M. G. et al. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein\u2013Protein Interactions. Angew. Chem. Int. Ed. 59, 5235\u20135241 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2107_CR211","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1021\/acs.jmedchem.9b01811","volume":"63","author":"CY Li","year":"2020","unstructured":"Li, C. Y. et al. Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors. J. Med. Chem. 63, 816\u2013826 (2020).","journal-title":"J. Med. Chem."},{"key":"2107_CR212","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1021\/acs.chemrev.0c01087","volume":"121","author":"J Damjanovic","year":"2021","unstructured":"Damjanovic, J., Miao, J., Huang, H. & Lin, Y.-S. Elucidating solution structures of cyclic peptides using molecular dynamics simulations. Chem. Rev. 121, 2292\u20132324 (2021).","journal-title":"Chem. Rev."},{"key":"2107_CR213","doi-asserted-by":"publisher","first-page":"7206","DOI":"10.1021\/acsomega.3c09377","volume":"9","author":"G V\u00e1radi","year":"2024","unstructured":"V\u00e1radi, G. et al. Rational Design of Antifungal Peptides Based on the \u03b3-Core Motif of a Neosartorya (Aspergillus) fischeri Antifungal Protein to Improve Structural Integrity, Efficacy, and Spectrum. ACS Omega 9, 7206\u20137214 (2024).","journal-title":"ACS Omega"},{"key":"2107_CR214","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1021\/acs.jmedchem.2c01837","volume":"66","author":"SM Linker","year":"2023","unstructured":"Linker, S. M. et al. Lessons for oral bioavailability: how conformationally flexible cyclic peptides enter and cross lipid membranes. J. Med. Chem. 66, 2773\u20132788 (2023).","journal-title":"J. Med. Chem."},{"key":"2107_CR215","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","volume":"28","author":"J Patocka","year":"2021","unstructured":"Patocka, J., Nepovimova, E., Kuca, K. & Wu, W. Cyclosporine A: Chemistry and Toxicity - A Review. Curr. Med. Chem. 28, 3925\u20133934 (2021).","journal-title":"Curr. Med. Chem."},{"key":"2107_CR216","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","volume":"81","author":"Y-A Heo","year":"2021","unstructured":"Heo, Y.-A. Voclosporin: First Approval. Drugs 81, 605\u2013610 (2021).","journal-title":"Drugs"},{"key":"2107_CR217","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4037\/aacnacc2020815","volume":"31","author":"N Goad","year":"2020","unstructured":"Goad, N. & Levesque, M. Role of desmopressin in the critical care setting. AACN Adv. Crit. Care. 31, 5\u201311 (2020).","journal-title":"AACN Adv. Crit. Care."},{"key":"2107_CR218","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/13543784.2023.2267972","volume":"32","author":"JR Burnett","year":"2023","unstructured":"Burnett, J. R. & Hooper, A. J. MK-0616: An oral PCSK9 inhibitor for hypercholesterolemia treatment. Expert Opin. Investig. Drugs 32, 873\u2013878 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2107_CR219","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1021\/acs.chemrev.0c00532","volume":"120","author":"X Li","year":"2020","unstructured":"Li, X., Chen, S., Zhang, W.-D. & Hu, H.-G. Stapled Helical Peptides Bearing Different Anchoring Residues. Chem. Rev. 120, 10079\u201310144 (2020).","journal-title":"Chem. Rev."},{"key":"2107_CR220","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3409","volume":"28","author":"S Tzotzos","year":"2022","unstructured":"Tzotzos, S. Stapled peptides as potential inhibitors of SARS-CoV-2 binding to the hACE2 receptor. J. Pept. Sci. 28, e3409 (2022).","journal-title":"J. Pept. Sci."},{"key":"2107_CR221","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1039\/D3CC06345C","volume":"60","author":"M Kijewska","year":"2024","unstructured":"Kijewska, M. et al. Stapling of leu-enkephalin analogs with bifunctional reagents for prolonged analgesic activity. Chem. Commun. (Camb.). 60, 3023\u20133026 (2024).","journal-title":"Chem. Commun. (Camb.)."},{"key":"2107_CR222","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202318893","volume":"63","author":"P Guo","year":"2024","unstructured":"Guo, P. et al. Peptide Stapling by Crosslinking Two Amines with \u03b1-Ketoaldehydes through Diverse Modified Glyoxal-Lysine Dimer Linkers. Angew. Chem. Int Ed. Engl. 63, e202318893 (2024).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2107_CR223","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1021\/acs.orglett.9b02592","volume":"21","author":"MG Ricardo","year":"2019","unstructured":"Ricardo, M. G., Vasco, A. V., Rivera, D. G. & Wessjohann, L. A. Stabilization of Cyclic \u03b2-Hairpins by Ugi-Reaction-Derived N-Alkylated Peptides: The Quest for Functionalized \u03b2-Turns. Org. Lett. 21, 7307\u20137310 (2019).","journal-title":"Org. Lett."},{"key":"2107_CR224","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1021\/jm200839a","volume":"54","author":"KK Khoo","year":"2011","unstructured":"Khoo, K. K. et al. Lactam-Stabilized Helical Analogues of the Analgesic \u03bc-Conotoxin KIIIA. J. Med. Chem. 54, 7558\u20137566 (2011).","journal-title":"J. Med. Chem."},{"key":"2107_CR225","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.bioconjchem.2c00592","volume":"34","author":"H Irie","year":"2023","unstructured":"Irie, H. et al. Tyrosinase-Related Protein2 Peptide with Replacement of N-Terminus Residue by Cysteine Binds to H-2Kb and Induces Antigen-Specific Cytotoxic T Lymphocytes after Conjugation with CpG-DNA. Bioconjugate Chem. 34, 433\u2013442 (2023).","journal-title":"Bioconjugate Chem."},{"key":"2107_CR226","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.bmcl.2014.02.038","volume":"24","author":"A Muppidi","year":"2014","unstructured":"Muppidi, A. et al. Design of antiviral stapled peptides containing a biphenyl cross-linker. Bioorg. Med. Chem. Lett. 24, 1748\u20131751 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2107_CR227","doi-asserted-by":"publisher","DOI":"10.1002\/pep2.24310","volume":"116","author":"MD Nolan","year":"2024","unstructured":"Nolan, M. D., Sch\u00fcttel, M., Scanlan, E. M. & Nielsen, A. L. Nanomole-scale photochemical thiol-ene chemistry for high-throughput late-stage diversification of peptide macrocycles. Pept. Sci. 116, e24310 (2024).","journal-title":"Pept. Sci."},{"key":"2107_CR228","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1002\/cpz1.957","volume":"4","author":"M Malhis","year":"2024","unstructured":"Malhis, M. & Funke, S. A. Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics. Curr. Protoc. 4, e957 (2024).","journal-title":"Curr. Protoc."},{"key":"2107_CR229","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202303943","volume":"62","author":"A Nazzaro","year":"2023","unstructured":"Nazzaro, A. et al. Macrocyclic \u03b2-Sheets Stabilized by Hydrogen Bond Surrogates. Angew. Chem. Int. Ed. 62, e202303943 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2107_CR230","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1021\/acscentsci.3c00230","volume":"9","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Experimental Insights into Conformational Ensembles of Assembled \u03b2-Sheet Peptides. ACS Cent. Sci. 9, 1480\u20131487 (2023).","journal-title":"ACS Cent. Sci."},{"key":"2107_CR231","doi-asserted-by":"publisher","first-page":"2284685","DOI":"10.1080\/10717544.2023.2284685","volume":"30","author":"A My\u0161kov\u00e1","year":"2023","unstructured":"My\u0161kov\u00e1, A., S\u00fdkora, D., Kune\u0161, J. & Malet\u00ednsk\u00e1, L. Lipidization as a tool toward peptide therapeutics. Drug Deliv. 30, 2284685 (2023).","journal-title":"Drug Deliv."},{"key":"2107_CR232","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2174\/0929867325666181026100849","volume":"27","author":"S Bartlett","year":"2020","unstructured":"Bartlett, S., Skwarczynski, M. & Toth, I. Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery. Curr. Med. Chem. 27, 2887\u20132901 (2020).","journal-title":"Curr. Med. Chem."},{"key":"2107_CR233","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","volume":"22","author":"P Kurtzhals","year":"2023","unstructured":"Kurtzhals, P., \u00d8stergaard, S., Nishimura, E. & Kjeldsen, T. Derivatization with fatty acids in peptide and protein drug discovery. Nat. Rev. Drug Discov. 22, 59\u201380 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR234","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","volume":"14","author":"D Irby","year":"2017","unstructured":"Irby, D., Du, C. & Li, F. Lipid\u2013Drug Conjugate for Enhancing Drug Delivery. Mol. Pharm. 14, 1325\u20131338 (2017).","journal-title":"Mol. Pharm."},{"key":"2107_CR235","doi-asserted-by":"publisher","first-page":"105053","DOI":"10.1016\/j.chemphyslip.2021.105053","volume":"236","author":"M Bhat","year":"2021","unstructured":"Bhat, M. et al. Opportunities and challenges of fatty acid conjugated therapeutics. Chem. Phys. Lipids 236, 105053 (2021).","journal-title":"Chem. Phys. Lipids"},{"key":"2107_CR236","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1021\/acsami.0c20607","volume":"13","author":"D Van Lysebetten","year":"2021","unstructured":"Van Lysebetten, D. et al. Lipid-Polyglutamate Nanoparticle Vaccine Platform. ACS Appl. Mater. Interfaces 13, 6011\u20136022 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2107_CR237","doi-asserted-by":"publisher","first-page":"105197","DOI":"10.1016\/j.ejps.2019.105197","volume":"144","author":"R Manteghi","year":"2020","unstructured":"Manteghi, R., Pallagi, E., Olajos, G. & Cs\u00f3ka, I. Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach. Eur. J. Pharm. Sci. 144, 105197 (2020).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2107_CR238","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd3349","volume":"10","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger, N., Yasothan, U. & Kirkpatrick, P. Pegloticase. Nat. Rev. Drug Discov. 10, 17\u201318 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR239","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/pharmaceutics13122065","volume":"13","author":"MC Lucana","year":"2021","unstructured":"Lucana, M. C. et al. Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics 13, 2065 (2021).","journal-title":"Pharmaceutics"},{"key":"2107_CR240","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/21691401.2017.1414823","volume":"46","author":"M Soleymani-Goloujeh","year":"2018","unstructured":"Soleymani-Goloujeh, M. et al. Effects of N-terminal and C-terminal modification on cytotoxicity and cellular uptake of amphiphilic cell penetrating peptides. Artif. Cell. Nanomed. Biotechnol. 46, 91\u2013103 (2018).","journal-title":"Artif. Cell. Nanomed. Biotechnol."},{"key":"2107_CR241","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijbiomac.2021.07.080","volume":"187","author":"H-y Tao","year":"2021","unstructured":"Tao, H.-y, Wang, R.-q, Sheng, W.-j & Zhen, Y.-s The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. Int. J. Biol. Macromol. 187, 24\u201334 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"2107_CR242","first-page":"188486","volume":"1875","author":"N Furukawa","year":"2021","unstructured":"Furukawa, N. & Popel, A. S. Peptides that immunoactivate the tumor microenvironment. Biochim. Biophys. Acta 1875, 188486 (2021).","journal-title":"Biochim. Biophys. Acta"},{"key":"2107_CR243","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/pharmaceutics12040364","volume":"12","author":"M Bak","year":"2020","unstructured":"Bak, M. et al. Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide. Pharmaceutics 12, 364 (2020).","journal-title":"Pharmaceutics"},{"key":"2107_CR244","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2174\/0929866525666181120090857","volume":"25","author":"A Singh","year":"2018","unstructured":"Singh, A. & Srivastava, V. Multi-functional Chimeric Peptides: The More the Merrier. Protein Pept. Lett. 25, 1090\u20131100 (2018).","journal-title":"Protein Pept. Lett."},{"key":"2107_CR245","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10020-022-00577-3","volume":"28","author":"MM Gomari","year":"2022","unstructured":"Gomari, M. M. et al. Peptidomimetics in cancer targeting. Mol. Med. 28, 146 (2022).","journal-title":"Mol. Med."},{"key":"2107_CR246","doi-asserted-by":"publisher","first-page":"103468","DOI":"10.1016\/j.drudis.2022.103468","volume":"28","author":"D Ding","year":"2023","unstructured":"Ding, D. et al. Medicinal chemistry insights into antiviral peptidomimetics. Drug Discov. Today 28, 103468 (2023).","journal-title":"Drug Discov. Today"},{"key":"2107_CR247","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.drudis.2021.01.020","volume":"26","author":"AT Zizzari","year":"2021","unstructured":"Zizzari, A. T. et al. New perspectives in oral peptide delivery. Drug Discov. Today 26, 1097\u20131105 (2021).","journal-title":"Drug Discov. Today"},{"key":"2107_CR248","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/13543784.2020.1825680","volume":"29","author":"A Fern\u00e1ndez-Carvajal","year":"2020","unstructured":"Fern\u00e1ndez-Carvajal, A., Gonz\u00e1lez-Mu\u00f1iz, R., Fern\u00e1ndez-Ballester, G. & Ferrer-Montiel, A. Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels. Expert Opin. Investig. Drugs 29, 1209\u20131222 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2107_CR249","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1039\/D1GC04387K","volume":"24","author":"L Ferrazzano","year":"2022","unstructured":"Ferrazzano, L. et al. Sustainability in peptide chemistry: current synthesis and purification technologies and future challenges. Green. Chem. 24, 975\u20131020 (2022).","journal-title":"Green. Chem."},{"key":"2107_CR250","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/cbdd.14180","volume":"101","author":"MP Khalily","year":"2023","unstructured":"Khalily, M. P. & Soydan, M. Peptide-based diagnostic and therapeutic agents: Where we are and where we are heading? Chem. Biol. Drug Des. 101, 772\u2013793 (2023).","journal-title":"Chem. Biol. Drug Des."},{"key":"2107_CR251","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/oby.2008.231","volume":"16","author":"DB Allison","year":"2008","unstructured":"Allison, D. B. et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obes. (Silver Spring) 16, 1161\u20131177 (2008).","journal-title":"Obes. (Silver Spring)"},{"key":"2107_CR252","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol. (Lausanne) 12, 721135 (2021).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2107_CR253","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan, D. H. & Yockey, S. R. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr. Obes. Rep. 6, 187\u2013194 (2017).","journal-title":"Curr. Obes. Rep."},{"key":"2107_CR254","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/cob.12203","volume":"7","author":"RL Kolotkin","year":"2017","unstructured":"Kolotkin, R. L. & Andersen, J. R. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin. Obes. 7, 273\u2013289 (2017).","journal-title":"Clin. Obes."},{"key":"2107_CR255","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481\u20131486 (2011).","journal-title":"Diabetes Care"},{"key":"2107_CR256","first-page":"93","volume":"16","author":"M Bliss","year":"1997","unstructured":"Bliss, M. The discovery of insulin: the inside story. Publ. Am. Inst. Hist. Pharm. 16, 93\u201399 (1997).","journal-title":"Publ. Am. Inst. Hist. Pharm."},{"key":"2107_CR257","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/biot.200700214","volume":"3","author":"T Dingermann","year":"2008","unstructured":"Dingermann, T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol. J. 3, 90\u201397 (2008).","journal-title":"Biotechnol. J."},{"key":"2107_CR258","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1073\/pnas.76.1.106","volume":"76","author":"DV Goeddel","year":"1979","unstructured":"Goeddel, D. V. et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106\u2013110 (1979).Visualization of important events in the development of peptide drugs. In this figure, important peptide drugs are classified according to the disease to which they correspond. In addition, the progress of optimization strategy of peptide drugs and Cell-penetrating peptides are also listed in this figure","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2107_CR259","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijpharm.2018.06.023","volume":"547","author":"M Akbarian","year":"2018","unstructured":"Akbarian, M., Ghasemi, Y., Uversky, V. N. & Yousefi, R. Chemical modifications of insulin: Finding a compromise between stability and pharmaceutical performance. Int J. Pharm. 547, 450\u2013468 (2018).Visualization of important events in the development of peptide drugs. In this figure, important peptide drugs are classified according to the disease to which they correspond. In addition, the progress of optimization strategy of peptide drugs and Cell-penetrating peptides are also listed in this figureVisualization of important events in the development of peptide drugs. In this figure, important peptide drugs are classified according to the disease to which they correspond. In addition, the progress of optimization strategy of peptide drugs and Cell-penetrating peptides are also listed in this figure","journal-title":"Int J. Pharm."},{"key":"2107_CR260","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.diabet.2014.10.001","volume":"40","author":"L Monnier","year":"2014","unstructured":"Monnier, L., Colette, C. & Owens, D. Acylated-based long-acting insulin analogues: is \u201cmisfolding\u201d the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes. Diabetes Metab. 40, 483\u2013484 (2014).Visualization of important events in the development of peptide drugs. In this figure, important peptide drugs are classified according to the disease to which they correspond. In addition, the progress of optimization strategy of peptide drugs and Cell-penetrating peptides are also listed in this figureVisualization of important events in the development of peptide drugs. In this figure, important peptide drugs are classified according to the disease to which they correspond. In addition, the progress of optimization strategy of peptide drugs and Cell-penetrating peptides are also listed in this figure","journal-title":"Diabetes Metab."},{"key":"2107_CR261","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1039\/D0CC05171C","volume":"56","author":"M Akbarian","year":"2020","unstructured":"Akbarian, M., Yousefi, R., Farjadian, F. & Uversky, V. N. Insulin fibrillation: toward strategies for attenuating the process. Chem. Commun. (Camb.). 56, 11354\u201311373 (2020).","journal-title":"Chem. Commun. (Camb.)."},{"key":"2107_CR262","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","volume":"58","author":"CP Kimball","year":"1923","unstructured":"Kimball, C. P. & Murlin, J. R. Aqueous Extracts of Pancreas:III. Some Precipitation Reactions of Insulin. J. Biol. Chem. 58, 337\u2013346 (1923).","journal-title":"J. Biol. Chem."},{"key":"2107_CR263","doi-asserted-by":"publisher","first-page":"678055","DOI":"10.3389\/fendo.2021.678055","volume":"12","author":"A Marzook","year":"2021","unstructured":"Marzook, A., Tomas, A. & Jones, B. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Front Endocrinol. (Lausanne) 12, 678055 (2021).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2107_CR264","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits, M. M. & Van Raalte, D. H. Safety of Semaglutide. Front Endocrinol. (Lausanne) 12, 645563 (2021).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2107_CR265","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2016.00394","volume":"7","author":"JH Ha","year":"2016","unstructured":"Ha, J. H., Kim, J. E. & Kim, Y. S. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front. Immunol. 7, 394 (2016).","journal-title":"Front. Immunol."},{"key":"2107_CR266","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131\u20132157 (2007).","journal-title":"Gastroenterology"},{"key":"2107_CR267","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392, 2180\u20132193 (2018).","journal-title":"Lancet"},{"key":"2107_CR268","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med"},{"key":"2107_CR269","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/oby.23612","volume":"31","author":"CW le Roux","year":"2023","unstructured":"le Roux, C. W. et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obes. (Silver Spring) 31, 96\u2013110 (2023).","journal-title":"Obes. (Silver Spring)"},{"key":"2107_CR270","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/DDDT.S358989","volume":"16","author":"L Wang","year":"2022","unstructured":"Wang, L. Designing a dual GLP-1R\/GIPR Agonist from Tirzepatide: comparing residues between Tirzepatide, GLP-1, and GIP. Drug Des. Devel. Ther. 16, 1547\u20131559 (2022).","journal-title":"Drug Des. Devel. Ther."},{"key":"2107_CR271","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun, T. et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 34, 1234\u20131247.e1239 (2022).","journal-title":"Cell Metab."},{"key":"2107_CR272","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/13543784.2023.2283020","volume":"32","author":"SA Doggrell","year":"2023","unstructured":"Doggrell, S. A. Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin. Investig. Drugs 32, 997\u20131001 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2107_CR273","doi-asserted-by":"publisher","first-page":"1256093","DOI":"10.3389\/fendo.2023.1256093","volume":"14","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. The role of C-peptide in diabetes and its complications: an updated review. Front Endocrinol. (Lausanne) 14, 1256093 (2023).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2107_CR274","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.molmet.2022.101665","volume":"68","author":"S Wagner","year":"2023","unstructured":"Wagner, S. et al. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression. Mol. Metab. 68, 101665 (2023).","journal-title":"Mol. Metab."},{"key":"2107_CR275","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.molmet.2021.101180","volume":"47","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease. Mol. Metab. 47, 101180 (2021).","journal-title":"Mol. Metab."},{"key":"2107_CR276","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2107_CR277","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.suronc.2018.07.011","volume":"27","author":"Z Cai","year":"2018","unstructured":"Cai, Z. et al. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years. Surg. Oncol. 27, 563\u2013574 (2018).","journal-title":"Surg. Oncol."},{"key":"2107_CR278","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"W-D Yu","year":"2019","unstructured":"Yu, W.-D. et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 452, 66\u201370 (2019).","journal-title":"Cancer Lett."},{"key":"2107_CR279","doi-asserted-by":"publisher","first-page":"530.e537","DOI":"10.1016\/j.urolonc.2018.05.025","volume":"36","author":"F Aljabery","year":"2018","unstructured":"Aljabery, F. et al. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer. Urol. Oncol. 36, 530.e537\u2013530.e518 (2018).","journal-title":"Urol. Oncol."},{"key":"2107_CR280","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2019.04.017","volume":"454","author":"Q Luo","year":"2019","unstructured":"Luo, Q., Zhang, L., Luo, C. & Jiang, M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 454, 191\u2013203 (2019).","journal-title":"Cancer Lett."},{"key":"2107_CR281","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/bfgp\/ely022","volume":"18","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Cancer immunotherapy for metastasis: past, present and future. Brief. Funct. Genomics 18, 140\u2013146 (2019).","journal-title":"Brief. Funct. Genomics"},{"key":"2107_CR282","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prp.2018.10.021","volume":"215","author":"K Yang","year":"2019","unstructured":"Yang, K. et al. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma\/leukemia. Pathol. - Res. Pract. 215, 265\u2013271 (2019).","journal-title":"Pathol. - Res. Pract."},{"key":"2107_CR283","first-page":"79","volume":"67","author":"PJ Hayden","year":"2019","unstructured":"Hayden, P. J. et al. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Curr. Res. Transl. Med. 67, 79\u201388 (2019).","journal-title":"Curr. Res. Transl. Med."},{"key":"2107_CR284","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CMAR.S232708","volume":"12","author":"X Pan","year":"2020","unstructured":"Pan, X., Xu, J. & Jia, X. Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides. Cancer Manag. Res. 12, 397\u2013409 (2020).","journal-title":"Cancer Manag. Res."},{"key":"2107_CR285","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s11658-022-00332-w","volume":"27","author":"M Karami Fath","year":"2022","unstructured":"Karami Fath, M. et al. Anti-cancer peptide-based therapeutic strategies in solid tumors. Cell. Mol. Biol. Lett. 27, 33 (2022).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"2107_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25530-6","volume":"12","author":"N Faraji","year":"2022","unstructured":"Faraji, N. et al. ApInAPDB: a database of apoptosis-inducing anticancer peptides. Sci. Rep. 12, 21341 (2022).","journal-title":"Sci. Rep."},{"key":"2107_CR287","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2014.05.002","volume":"351","author":"D Wu","year":"2014","unstructured":"Wu, D. et al. Peptide-based cancer therapy: Opportunity and challenge. Cancer Lett. 351, 13\u201322 (2014).","journal-title":"Cancer Lett."},{"key":"2107_CR288","doi-asserted-by":"publisher","first-page":"109484","DOI":"10.1016\/j.abb.2022.109484","volume":"733","author":"M Kordi","year":"2023","unstructured":"Kordi, M. et al. Antimicrobial peptides with anticancer activity: Today status, trends and their computational design. Arch. Biochem. Biophys. 733, 109484 (2023).","journal-title":"Arch. Biochem. Biophys."},{"key":"2107_CR289","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.05.010","volume":"402","author":"I Rady","year":"2017","unstructured":"Rady, I., Siddiqui, I. A., Rady, M. & Mukhtar, H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 402, 16\u201331 (2017).","journal-title":"Cancer Lett."},{"key":"2107_CR290","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1021\/acs.jmedchem.5b02025","volume":"59","author":"BE Haug","year":"2016","unstructured":"Haug, B. E. et al. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. J. Med. Chem. 59, 2918\u20132927 (2016).","journal-title":"J. Med. Chem."},{"key":"2107_CR291","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00262-014-1540-0","volume":"63","author":"KA Camilio","year":"2014","unstructured":"Camilio, K. A. et al. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol. Immunother. 63, 601\u2013613 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"2107_CR292","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.peptides.2008.01.015","volume":"29","author":"K-r Wang","year":"2008","unstructured":"Wang, K.-r et al. Antitumor effects, cell selectivity and structure\u2013activity relationship of a novel antimicrobial peptide polybia-MPI. Peptides 29, 963\u2013968 (2008).","journal-title":"Peptides"},{"key":"2107_CR293","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.peptides.2005.04.026","volume":"26","author":"BM Souza","year":"2005","unstructured":"Souza, B. M. et al. Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp Polybia paulista. Peptides 26, 2157\u20132164 (2005).","journal-title":"Peptides"},{"key":"2107_CR294","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2008.12.027","volume":"278","author":"K-r Wang","year":"2009","unstructured":"Wang, K.-r et al. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. Cancer Lett. 278, 65\u201372 (2009).","journal-title":"Cancer Lett."},{"key":"2107_CR295","first-page":"647","volume":"17","author":"SH Kim","year":"2007","unstructured":"Kim, S. H. et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep. 17, 647\u2013651 (2007).","journal-title":"Oncol. Rep."},{"key":"2107_CR296","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1021\/jm800079s","volume":"51","author":"P Jones","year":"2008","unstructured":"Jones, P. et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem. 51, 2350\u20132353 (2008).","journal-title":"J. Med. Chem."},{"key":"2107_CR297","first-page":"125","volume":"36","author":"MY Ahn","year":"2010","unstructured":"Ahn, M. Y. et al. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. Int. J. Oncol. 36, 125\u2013131 (2010).","journal-title":"Int. J. Oncol."},{"key":"2107_CR298","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202300256","volume":"19","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Advances in biosynthesis of peptide drugs: Technology and industrialization. Biotechnol. J. 19, e2300256 (2024).","journal-title":"Biotechnol. J."},{"key":"2107_CR299","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"RB Merrifield","year":"1963","unstructured":"Merrifield, R. B. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J. Am. Chem. Soc. 85, 2149\u20132154 (1963).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR300","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1021\/acs.chemrev.2c00132","volume":"122","author":"A Sharma","year":"2022","unstructured":"Sharma, A., Kumar, A., de la Torre, B. G. & Albericio, F. Liquid-Phase Peptide Synthesis (LPPS): A Third Wave for the Preparation of Peptides. Chem. Rev. 122, 13516\u201313546 (2022).","journal-title":"Chem. Rev."},{"key":"2107_CR301","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1039\/C5NP00025D","volume":"32","author":"RS Al Toma","year":"2015","unstructured":"Al Toma, R. S., Brieke, C., Cryle, M. J. & S\u00fcssmuth, R. D. Structural aspects of phenylglycines, their biosynthesis and occurrence in peptide natural products. Nat. Prod. Rep. 32, 1207\u20131235 (2015).","journal-title":"Nat. Prod. Rep."},{"key":"2107_CR302","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/cbic.200500325","volume":"7","author":"F Lomb\u00f3","year":"2006","unstructured":"Lomb\u00f3, F. et al. Deciphering the biosynthesis pathway of the antitumor thiocoraline from a marine actinomycete and its expression in two streptomyces species. ChemBioChem 7, 366\u2013376 (2006).","journal-title":"ChemBioChem"},{"key":"2107_CR303","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/btpr.34","volume":"24","author":"AP Praseuth","year":"2008","unstructured":"Praseuth, A. P. et al. Complete sequence of biosynthetic gene cluster responsible for producing triostin A and evaluation of quinomycin-type antibiotics from Streptomyces triostinicus. Biotechnol. Prog. 24, 1226\u20131231 (2008).","journal-title":"Biotechnol. Prog."},{"key":"2107_CR304","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nchembio803","volume":"2","author":"K Watanabe","year":"2006","unstructured":"Watanabe, K. et al. Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli. Nat. Chem. Biol. 2, 423\u2013428 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"2107_CR305","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/bip.21489","volume":"93","author":"OE Zolova","year":"2010","unstructured":"Zolova, O. E., Mady, A. S. & Garneau-Tsodikova, S. Recent developments in bisintercalator natural products. Biopolymers 93, 777\u2013790 (2010).","journal-title":"Biopolymers"},{"key":"2107_CR306","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1399-3011.1990.tb00939.x","volume":"35","author":"GB Fields","year":"1990","unstructured":"Fields, G. B. & Noble, R. L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J. Pept. Protein Res. 35, 161\u2013214 (1990).","journal-title":"Int J. Pept. Protein Res."},{"key":"2107_CR307","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3762\/bjoc.10.118","volume":"10","author":"V M\u00e4de","year":"2014","unstructured":"M\u00e4de, V., Els-Heindl, S. & Beck-Sickinger, A. G. Automated solid-phase peptide synthesis to obtain therapeutic peptides. Beilstein J. Org. Chem. 10, 1197\u20131212 (2014).","journal-title":"Beilstein J. Org. Chem."},{"key":"2107_CR308","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00726-014-1776-1","volume":"46","author":"S Ramesh","year":"2014","unstructured":"Ramesh, S. et al. Microreactors for peptide synthesis: looking through the eyes of twenty first century !!! Amino Acids 46, 2091\u20132104 (2014).","journal-title":"Amino Acids"},{"key":"2107_CR309","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-62703-544-6_17","volume":"1047","author":"GS Vanier","year":"2013","unstructured":"Vanier, G. S. Microwave-assisted solid-phase peptide synthesis based on the Fmoc protecting group strategy (CEM). Methods Mol. Biol. 1047, 235\u2013249 (2013).","journal-title":"Methods Mol. Biol."},{"key":"2107_CR310","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13491","volume":"7","author":"S Fuse","year":"2016","unstructured":"Fuse, S., Mifune, Y., Nakamura, H. & Tanaka, H. Total synthesis of feglymycin based on a linear\/convergent hybrid approach using micro-flow amide bond formation. Nat. Commun. 7, 13491 (2016).","journal-title":"Nat. Commun."},{"key":"2107_CR311","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/cmdc.201800529","volume":"13","author":"R Zhou","year":"2018","unstructured":"Zhou, R. et al. Synthesis and biological evaluation of Reniochalistatins A-E and a Reniochalistatin E analogue. Chem. Med. Chem. 13, 2202\u20132207 (2018).","journal-title":"Chem. Med. Chem."},{"key":"2107_CR312","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1021\/np5006778","volume":"77","author":"KX Zhan","year":"2014","unstructured":"Zhan, K. X. et al. Reniochalistatins A-E, cyclic peptides from the marine sponge Reniochalina stalagmitis. J. Nat. Prod. 77, 2678\u20132684 (2014).","journal-title":"J. Nat. Prod."},{"key":"2107_CR313","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.cclet.2018.05.033","volume":"29","author":"H Luo","year":"2018","unstructured":"Luo, H. et al. Synthesis of cyclic peptide reniochalistatin E and conformational isomers. Chin. Chem. Lett. 29, 1143\u20131146 (2018).","journal-title":"Chin. Chem. Lett."},{"key":"2107_CR314","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.apsb.2021.03.040","volume":"11","author":"W Tian","year":"2021","unstructured":"Tian, W. et al. HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial\u2013mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K\/AKT and WNT\/\u03b2-catenin signaling activation. Acta Pharm. Sin. B. 11, 1592\u20131606 (2021).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR315","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.apsb.2019.10.005","volume":"9","author":"G Tuguzbaeva","year":"2019","unstructured":"Tuguzbaeva, G. et al. PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting \u03b1 v integrin\/FAK\/Src signaling in oral squamous cell carcinoma cells. Acta Pharm. Sin. B 9, 1163\u20131173 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"2107_CR316","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1111\/bph.14352","volume":"175","author":"S Yu","year":"2018","unstructured":"Yu, S. et al. PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition. Br. J. Pharm. 175, 3111\u20133130 (2018).","journal-title":"Br. J. Pharm."},{"key":"2107_CR317","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1016\/S0040-4020(01)90476-4","volume":"50","author":"I Lewis","year":"1994","unstructured":"Lewis, I. & Bruns, C. Synthesis of somatostatin analogues incorporating nucleo amino acids. Tetrahedron 50, 7485\u20137494 (1994).","journal-title":"Tetrahedron"},{"key":"2107_CR318","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/mmr.2017.6586","volume":"16","author":"X-X Wang","year":"2017","unstructured":"Wang, X.-X. et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet-induced obesity. Mol. Med. Report. 16, 109\u2013118 (2017).","journal-title":"Mol. Med. Report."},{"key":"2107_CR319","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/gast.2001.21619","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal, A. J. Octreotide and its effects on portal circulation. Gastroenterology 120, 303\u2013305 (2001).","journal-title":"Gastroenterology"},{"key":"2107_CR320","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177934","volume":"12","author":"G Remuzzi","year":"2017","unstructured":"Remuzzi, G. et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One 12, e0177934 (2017).","journal-title":"PLoS One"},{"key":"2107_CR321","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.2165\/00003495-200363220-00014","volume":"22","author":"SC Kate McKeage","year":"2003","unstructured":"Kate McKeage, S. C. & Antona, J. Wagstaff Octreotide long-acting release (LAR) a review of its use in the management of acromegaly. Drugs 22, 2473\u20132499 (2003).","journal-title":"Drugs"},{"key":"2107_CR322","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.anclin.2017.01.021","volume":"35","author":"RM Borna","year":"2017","unstructured":"Borna, R. M. et al. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks. Anesthesiol. Clin. 35, 327\u2013339 (2017).","journal-title":"Anesthesiol. Clin."},{"key":"2107_CR323","first-page":"161","volume":"5","author":"EM Wolin","year":"2012","unstructured":"Wolin, E. M. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest. Cancer Res. 5, 161\u2013168 (2012).","journal-title":"Gastrointest. Cancer Res."},{"key":"2107_CR324","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/med.21312","volume":"34","author":"N Micale","year":"2014","unstructured":"Micale, N. et al. Peptide\u2010Based Proteasome Inhibitors in Anticancer Drug Design. Med. Res. Rev. 34, 1001\u20131069 (2014).","journal-title":"Med. Res. Rev."},{"key":"2107_CR325","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak, P. & Robak, T. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs RD 19, 73\u201392 (2019).","journal-title":"Drugs RD"},{"key":"2107_CR326","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. Motixafortide: First Approval. Drugs 83, 1635\u20131643 (2023).","journal-title":"Drugs"},{"key":"2107_CR327","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1021\/jm200568c","volume":"55","author":"W-T Choi","year":"2011","unstructured":"Choi, W.-T. et al. Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4). J. Med. Chem. 55, 977\u2013994 (2011).","journal-title":"J. Med. Chem."},{"key":"2107_CR328","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan, Q., Zhang, H., Zheng, J. & Zhang, L. Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends Cancer 6, 605\u2013618 (2020).","journal-title":"Trends Cancer"},{"key":"2107_CR329","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura, P. et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol. 10, 168 (2019).","journal-title":"Front. Immunol."},{"key":"2107_CR330","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trecan.2019.11.004","volume":"6","author":"Q Tang","year":"2020","unstructured":"Tang, Q., Su, Z., Gu, W. & Rustgi, A. K. Mutant p53 on the Path to Metastasis. Trends Cancer 6, 62\u201373 (2020).","journal-title":"Trends Cancer"},{"key":"2107_CR331","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jmb.2010.03.005","volume":"398","author":"C Li","year":"2010","unstructured":"Li, C. et al. Systematic Mutational Analysis of Peptide Inhibition of the p53\u2013MDM2\/MDMX Interactions. J. Mol. Biol. 398, 200\u2013213 (2010).","journal-title":"J. Mol. Biol."},{"key":"2107_CR332","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1073\/pnas.0900947106","volume":"106","author":"M Pazgier","year":"2009","unstructured":"Pazgier, M. et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl Acad. Sci. USA 106, 4665\u20134670 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2107_CR333","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.drudis.2021.02.019","volume":"26","author":"V D\u2019Aloisio","year":"2021","unstructured":"D\u2019Aloisio, V., Dognini, P., Hutcheon, G. A. & Coxon, C. R. PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics. Drug Discov. Today 26, 1409\u20131419 (2021).","journal-title":"Drug Discov. Today"},{"key":"2107_CR334","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ph13030038","volume":"13","author":"U Hennrich","year":"2020","unstructured":"Hennrich, U. & Bene\u0161ov\u00e1, M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals 13, 38 (2020).","journal-title":"Pharmaceuticals"},{"key":"2107_CR335","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich, U. & Eder, M. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals 14, 713 (2021).","journal-title":"Pharmaceuticals"},{"key":"2107_CR336","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40291-023-00665-y","volume":"27","author":"Y-A Heo","year":"2023","unstructured":"Heo, Y.-A. Flotufolastat F 18: Diagnostic First Approval. Mol. Diagn. Ther. 27, 631\u2013636 (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"2107_CR337","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph, P. et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ. Res. 121, 677\u2013694 (2017).","journal-title":"Circ. Res."},{"key":"2107_CR338","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah, G. A., Fuster, V., Murray, C. J. L. & Roth, G. A. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J. Am. Coll. Cardiol. 82, 2350\u20132473 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2107_CR339","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","volume":"41","author":"U Landmesser","year":"2020","unstructured":"Landmesser, U. et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Eur. Heart J. 41, 3884\u20133899 (2020).","journal-title":"Eur. Heart J."},{"key":"2107_CR340","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/biomedicines11020579","volume":"11","author":"L Kraus","year":"2023","unstructured":"Kraus, L. & Beavens, B. The Current Therapeutic Role of Chromatin Remodeling for the Prognosis and Treatment of Heart Failure. Biomedicines 11, 579 (2023).","journal-title":"Biomedicines"},{"key":"2107_CR341","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1586\/14779072.2014.942285","volume":"12","author":"DJ Cao","year":"2014","unstructured":"Cao, D. J. Epigenetic regulation and heart failure. Expert Rev. Cardiovasc. Ther. 12, 1087\u20131098 (2014).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2107_CR342","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2014.02.008","volume":"173","author":"P Chaturvedi","year":"2014","unstructured":"Chaturvedi, P. & Tyagi, S. C. Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int. J. Cardiol. 173, 1\u201311 (2014).","journal-title":"Int. J. Cardiol."},{"key":"2107_CR343","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.isci.2021.103518","volume":"24","author":"W Xiao","year":"2021","unstructured":"Xiao, W. et al. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214-3p. iScience 24, 103518 (2021).","journal-title":"iScience"},{"key":"2107_CR344","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14934-5","volume":"11","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Full-length human GLP-1 receptor structure without orthosteric ligands. Nat. Commun. 11, 1272 (2020).","journal-title":"Nat. Commun."},{"key":"2107_CR345","doi-asserted-by":"publisher","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","volume":"14","author":"JY Wang","year":"2023","unstructured":"Wang, J. Y. et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol. (Lausanne) 14, 1085799 (2023).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"2107_CR346","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092\u20131100 (2005).","journal-title":"Diabetes Care"},{"key":"2107_CR347","doi-asserted-by":"publisher","first-page":"6820377","DOI":"10.1155\/2022\/6820377","volume":"2022","author":"D Xu","year":"2022","unstructured":"Xu, D. et al. Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovasc. Ther. 2022, 6820377 (2022).","journal-title":"Cardiovasc. Ther."},{"key":"2107_CR348","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","volume":"170","author":"WR Chen","year":"2015","unstructured":"Chen, W. R. et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am. Heart J. 170, 845\u2013854 (2015).","journal-title":"Am. Heart J."},{"key":"2107_CR349","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-015-0798-0","volume":"52","author":"WR Chen","year":"2016","unstructured":"Chen, W. R. et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine 52, 516\u2013526 (2016).","journal-title":"Endocrine"},{"key":"2107_CR350","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1177\/1060028016663218","volume":"50","author":"J Wroge","year":"2016","unstructured":"Wroge, J. & Williams, N. T. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Ann. Pharmacother. 50, 1041\u20131050 (2016).","journal-title":"Ann. Pharmacother."},{"key":"2107_CR351","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"RS Ames","year":"1999","unstructured":"Ames, R. S. et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401, 282\u2013286 (1999).","journal-title":"Nature"},{"key":"2107_CR352","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","volume":"359","author":"SA Douglas","year":"2002","unstructured":"Douglas, S. A. et al. Congestive heart failure and expression of myocardial urotensin II. Lancet 359, 1990\u20131997 (2002).","journal-title":"Lancet"},{"key":"2107_CR353","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00210-004-0991-9","volume":"370","author":"R Vergura","year":"2004","unstructured":"Vergura, R. et al. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn-Schmiedeberg\u2019s. Arch. Pharmacol. 370, 347\u2013352 (2004).","journal-title":"Arch. Pharmacol."},{"key":"2107_CR354","doi-asserted-by":"publisher","first-page":"118551","DOI":"10.1016\/j.lfs.2020.118551","volume":"262","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway. Life Sci. 262, 118551 (2020).","journal-title":"Life Sci."},{"key":"2107_CR355","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10067-018-3978-5","volume":"38","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model. Clin. Rheumatol. 38, 29\u201335 (2019).","journal-title":"Clin. Rheumatol."},{"key":"2107_CR356","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/107424840200700308","volume":"7","author":"U Elkayam","year":"2002","unstructured":"Elkayam, U. et al. Nesiritide: a new drug for the treatment of decompensated heart failure. J. Cardiovasc. Pharmacol. Ther. 7, 181\u2013194 (2002).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"2107_CR357","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1373\/clinchem.2019.308106","volume":"65","author":"JC Burnett Jr","year":"2019","unstructured":"Burnett, J. C. Jr Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ. Clin. Chem. 65, 1602\u20131603 (2019).","journal-title":"Clin. Chem."},{"key":"2107_CR358","doi-asserted-by":"publisher","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","volume":"227","author":"K Kuwahara","year":"2021","unstructured":"Kuwahara, K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharm. Ther. 227, 107863 (2021).","journal-title":"Pharm. Ther."},{"key":"2107_CR359","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","volume":"293","author":"JD Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein, J. D., Kowalski, M., Fox, M. & Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900\u20131905 (2005).","journal-title":"JAMA"},{"key":"2107_CR360","first-page":"3871","volume":"81","author":"PJ Hunt","year":"1996","unstructured":"Hunt, P. J. et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J. Clin. Endocrinol. Metab. 81, 3871\u20133876 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2107_CR361","first-page":"343","volume":"76","author":"CN Wijeyaratne","year":"1993","unstructured":"Wijeyaratne, C. N. & Moult, P. J. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J. Clin. Endocrinol. Metab. 76, 343\u2013346 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2107_CR362","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1517\/14656566.8.3.361","volume":"8","author":"SJ Shah","year":"2007","unstructured":"Shah, S. J. & Teerlink, J. R. Nesiritide: a reappraisal of efficacy and safety. Expert Opin. Pharmacother. 8, 361\u2013369 (2007).","journal-title":"Expert Opin. Pharmacother."},{"key":"2107_CR363","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1517\/14656566.5.4.901","volume":"5","author":"S Iyengar","year":"2004","unstructured":"Iyengar, S., Feldman, D. S., Trupp, R. & Abraham, W. T. Nesiritide for the treatment of congestive heart failure. Expert Opin. Pharmacother. 5, 901\u2013907 (2004).","journal-title":"Expert Opin. Pharmacother."},{"key":"2107_CR364","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","volume":"25","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui, H. et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur. J. Heart Fail. 25, 616\u2013631 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"2107_CR365","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00380-017-0952-0","volume":"32","author":"M Ogiso","year":"2017","unstructured":"Ogiso, M. et al. Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses. Heart Vessels 32, 916\u2013925 (2017).","journal-title":"Heart Vessels"},{"key":"2107_CR366","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jjcc.2014.12.020","volume":"66","author":"T Ozawa","year":"2015","unstructured":"Ozawa, T. et al. Effects of human atrial natriuretic peptide on myocardial performance and energetics in heart failure due to previous myocardial infarction. J. Cardiol. 66, 232\u2013238 (2015).","journal-title":"J. Cardiol."},{"key":"2107_CR367","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cardfail.2015.05.007","volume":"21","author":"Y Matsue","year":"2015","unstructured":"Matsue, Y. et al. Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. J. Card. Fail. 21, 859\u2013864 (2015).","journal-title":"J. Card. Fail."},{"key":"2107_CR368","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clinthera.2023.10.006","volume":"46","author":"M Inamoto","year":"2024","unstructured":"Inamoto, M. et al. Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure. Clin. Ther. 46, 12\u201319 (2024).","journal-title":"Clin. Ther."},{"key":"2107_CR369","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/hr.2014.70","volume":"37","author":"H Asanuma","year":"2014","unstructured":"Asanuma, H. et al. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens. Res. 37, 716\u2013723 (2014).","journal-title":"Hypertens. Res."},{"key":"2107_CR370","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey, R. M. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension 72, e53\u2013e90 (2018).","journal-title":"Hypertension"},{"key":"2107_CR371","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","volume":"50","author":"AS Desai","year":"2007","unstructured":"Desai, A. S. et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J. Am. Coll. Cardiol. 50, 1959\u20131966 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2107_CR372","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med 358, 1547\u20131559 (2008).","journal-title":"N. Engl. J. Med"},{"key":"2107_CR373","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.foodchem.2017.02.039","volume":"228","author":"SY Lee","year":"2017","unstructured":"Lee, S. Y. & Hur, S. J. Antihypertensive peptides from animal products, marine organisms, and plants. Food Chem. 228, 506\u2013517 (2017).","journal-title":"Food Chem."},{"key":"2107_CR374","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0162-3109(99)00118-6","volume":"44","author":"H Fujita","year":"1999","unstructured":"Fujita, H. & Yoshikawa, M. LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology 44, 123\u2013127 (1999).","journal-title":"Immunopharmacology"},{"key":"2107_CR375","doi-asserted-by":"publisher","first-page":"106204","DOI":"10.1016\/j.bioorg.2022.106204","volume":"129","author":"RL da Silva","year":"2022","unstructured":"da Silva, R. L. et al. Peptide inhibitors of angiotensin-I converting enzyme based on angiotensin (1-7) with selectivity for the C-terminal domain. Bioorg. Chem. 129, 106204 (2022).","journal-title":"Bioorg. Chem."},{"key":"2107_CR376","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.foodres.2017.06.065","volume":"100","author":"AC Neves","year":"2017","unstructured":"Neves, A. C. et al. Peptide identification in a salmon gelatin hydrolysate with antihypertensive, dipeptidyl peptidase IV inhibitory and antioxidant activities. Food Res Int 100, 112\u2013120 (2017).","journal-title":"Food Res Int"},{"key":"2107_CR377","doi-asserted-by":"publisher","first-page":"127196","DOI":"10.1016\/j.ijbiomac.2023.127196","volume":"254","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Identification of novel angiotensin converting enzyme (ACE) inhibitory peptides from Pacific saury: In vivo antihypertensive effect and transport route. Int. J. Biol. Macromol. 254, 127196 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"2107_CR378","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1021\/acsfoodscitech.3c00417","volume":"3","author":"L Sorokina","year":"2023","unstructured":"Sorokina, L. et al. Low Molecular Weight Peptide Fraction from Poultry Byproduct Hydrolysate Features Dual ACE-1 and DPP4 Inhibition. ACS Food Sci. Technol. 3, 2219\u20132228 (2023).","journal-title":"ACS Food Sci. Technol."},{"key":"2107_CR379","doi-asserted-by":"publisher","first-page":"11b","DOI":"10.1016\/S0002-9149(97)00572-9","volume":"80","author":"DR Phillips","year":"1997","unstructured":"Phillips, D. R. & Scarborough, R. M. Clinical pharmacology of eptifibatide. Am. J. Cardiol. 80, 11b\u201320b (1997).","journal-title":"Am. J. Cardiol."},{"key":"2107_CR380","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/toxins11100564","volume":"11","author":"T Mohamed Abd El-Aziz","year":"2019","unstructured":"Mohamed Abd El-Aziz, T., Garcia Soares, A. & Stockand, J. D. Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving. Toxins 11, 564 (2019).","journal-title":"Toxins"},{"key":"2107_CR381","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","volume":"12","author":"J Huang","year":"2019","unstructured":"Huang, J. et al. Platelet integrin \u03b1IIb\u03b23: signal transduction, regulation, and its therapeutic targeting. J. Hematol. Oncol. 12, 26 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2107_CR382","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00003088-200342080-00001","volume":"42","author":"IC Gilchrist","year":"2003","unstructured":"Gilchrist, I. C. Platelet glycoprotein IIb\/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin. Pharmacokinet. 42, 703\u2013720 (2003).","journal-title":"Clin. Pharmacokinet."},{"key":"2107_CR383","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2020.09.054","volume":"139","author":"F Fischer","year":"2021","unstructured":"Fischer, F. et al. Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am. J. Cardiol. 139, 15\u201321 (2021).","journal-title":"Am. J. Cardiol."},{"key":"2107_CR384","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.108.847996","volume":"2","author":"HS Gurm","year":"2009","unstructured":"Gurm, H. S. et al. A comparison of abciximab and small-molecule glycoprotein IIb\/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ. Cardiovasc. Interv. 2, 230\u2013236 (2009).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"2107_CR385","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0002-9343(02)01146-4","volume":"112","author":"CP Cannon","year":"2002","unstructured":"Cannon, C. P. Oral glycoprotein IIb\/IIIa inhibition-great idea, but it didn\u2019t work. Am. J. Med. 112, 673\u2013675 (2002).","journal-title":"Am. J. Med."},{"key":"2107_CR386","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9343(02)01106-3","volume":"112","author":"LK Newby","year":"2002","unstructured":"Newby, L. K. et al. The failure of orally administered glycoprotein IIb\/IIIa inhibitors to prevent recurrent cardiac events. Am. J. Med. 112, 647\u2013658 (2002).","journal-title":"Am. J. Med."},{"key":"2107_CR387","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-37107-6_1","volume":"190","author":"S Britsch","year":"2007","unstructured":"Britsch, S. The neuregulin-I\/ErbB signaling system in development and disease. Adv. Anat. Embryol. Cell Biol. 190, 1\u201365 (2007).","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"2107_CR388","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1042\/CS20200230","volume":"134","author":"A Geissler","year":"2020","unstructured":"Geissler, A., Ryzhov, S. & Sawyer, D. B. Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease. Clin. Sci. (Lond.) 134, 2623\u20132643 (2020).","journal-title":"Clin. Sci. (Lond.)"},{"key":"2107_CR389","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40256-023-00585-6","volume":"23","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects. Am. J. Cardiovasc. Drugs 23, 419\u2013428 (2023).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"2107_CR390","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/472032a","volume":"472","author":"MA Cooper","year":"2011","unstructured":"Cooper, M. A. & Shlaes, D. Fix the antibiotics pipeline. Nature 472, 32 (2011).","journal-title":"Nature"},{"key":"2107_CR391","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9010024","volume":"9","author":"CH Chen","year":"2020","unstructured":"Chen, C. H. & Lu, T. K. Development and Challenges of Antimicrobial Peptides for Therapeutic Applications. Antibiotics (Basel). 9, e24 (2020).","journal-title":"Antibiotics (Basel)."},{"key":"2107_CR392","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/med.21542","volume":"39","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era. Med. Res. Rev. 39, 831\u2013859 (2019).","journal-title":"Med. Res. Rev."},{"key":"2107_CR393","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"RE Hancock","year":"2006","unstructured":"Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551\u20131557 (2006).","journal-title":"Nat. Biotechnol."},{"key":"2107_CR394","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/07388551.2011.594423","volume":"32","author":"M Pasupuleti","year":"2012","unstructured":"Pasupuleti, M., Schmidtchen, A. & Malmsten, M. Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 32, 143\u2013171 (2012).","journal-title":"Crit. Rev. Biotechnol."},{"key":"2107_CR395","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.biochi.2010.02.023","volume":"92","author":"D Takahashi","year":"2010","unstructured":"Takahashi, D., Shukla, S. K., Prakash, O. & Zhang, G. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie 92, 1236\u20131241 (2010).","journal-title":"Biochimie"},{"key":"2107_CR396","doi-asserted-by":"publisher","first-page":"9804","DOI":"10.1021\/bi050272k","volume":"44","author":"E Kl\u00fcver","year":"2005","unstructured":"Kl\u00fcver, E. et al. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 44, 9804\u20139816 (2005).","journal-title":"Biochemistry"},{"key":"2107_CR397","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.bbamem.2006.04.006","volume":"1758","author":"DI Chan","year":"2006","unstructured":"Chan, D. I., Prenner, E. J. & Vogel, H. J. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim Biophys. Acta 1758, 1184\u20131202 (2006).","journal-title":"Biochim Biophys. Acta"},{"key":"2107_CR398","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","volume":"19","author":"N Mookherjee","year":"2020","unstructured":"Mookherjee, N., Anderson, M. A., Haagsman, H. P. & Davidson, D. J. Antimicrobial host defence peptides: functions and clinical potential. Nat. Rev. Drug Discov. 19, 311\u2013332 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR399","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3223","volume":"25","author":"NO Ismail","year":"2019","unstructured":"Ismail, N. O. et al. Antimicrobial function of short amidated peptide fragments from the tick-derived OsDef2 defensin. J. Pept. Sci. 25, e3223 (2019).","journal-title":"J. Pept. Sci."},{"key":"2107_CR400","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbamem.2018.08.001","volume":"1861","author":"LN Irazazabal","year":"2019","unstructured":"Irazazabal, L. N. et al. Fast and potent bactericidal membrane lytic activity of PaDBS1R1, a novel cationic antimicrobial peptide. Biochim Biophys. Acta Biomembr. 1861, 178\u2013190 (2019).","journal-title":"Biochim Biophys. Acta Biomembr."},{"key":"2107_CR401","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.4155\/fmc-2018-0460","volume":"10","author":"L Giovati","year":"2018","unstructured":"Giovati, L., Ciociola, T., Magliani, W. & Conti, S. Antimicrobial peptides with antiprotozoal activity: current state and future perspectives. Future Med. Chem. 10, 2569\u20132572 (2018).","journal-title":"Future Med. Chem."},{"key":"2107_CR402","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2174\/0929867326666190805151654","volume":"27","author":"DC Brice","year":"2020","unstructured":"Brice, D. C. & Diamond, G. Antiviral Activities of Human Host Defense Peptides. Curr. Med. Chem. 27, 1420\u20131443 (2020).","journal-title":"Curr. Med. Chem."},{"key":"2107_CR403","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fcimb.2020.00105","volume":"10","author":"M Fern\u00e1ndez de Ullivarri","year":"2020","unstructured":"Fern\u00e1ndez de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E. & Cotter, P. D. Antifungal Peptides as Therapeutic Agents. Front Cell Infect. Microbiol 10, 105 (2020).","journal-title":"Front Cell Infect. Microbiol"},{"key":"2107_CR404","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/ph6081055","volume":"6","author":"W Aoki","year":"2013","unstructured":"Aoki, W. & Ueda, M. Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. Pharmaceuticals 6, 1055\u20131081 (2013).","journal-title":"Pharmaceuticals"},{"key":"2107_CR405","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00109-006-0143-4","volume":"85","author":"M Zaiou","year":"2007","unstructured":"Zaiou, M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J. Mol. Med. (Berl.) 85, 317\u2013329 (2007).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"2107_CR406","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-pharmtox-010611-134535","volume":"52","author":"NY Yount","year":"2012","unstructured":"Yount, N. Y. & Yeaman, M. R. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev. Pharm. Toxicol. 52, 337\u2013360 (2012).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"2107_CR407","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12275-015-5076-6","volume":"53","author":"MS Baba","year":"2015","unstructured":"Baba, M. S. et al. In vivo antimalarial activity of the endophytic actinobacteria, Streptomyces SUK 10. J. Microbiol. 53, 847\u2013855 (2015).","journal-title":"J. Microbiol."},{"key":"2107_CR408","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/bip.20286","volume":"80","author":"O Toke","year":"2005","unstructured":"Toke, O. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers 80, 717\u2013735 (2005).","journal-title":"Biopolymers"},{"key":"2107_CR409","first-page":"48","volume":"8","author":"QY Zhang","year":"2021","unstructured":"Zhang, Q. Y. et al. Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil. Med. Res. 8, 48 (2021).","journal-title":"Mil. Med. Res."},{"key":"2107_CR410","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12275-017-6452-1","volume":"55","author":"HK Kang","year":"2017","unstructured":"Kang, H. K., Kim, C., Seo, C. H. & Park, Y. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J. Microbiol. 55, 1\u201312 (2017).","journal-title":"J. Microbiol."},{"key":"2107_CR411","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.3390\/ijms20225713","volume":"20","author":"T Ron\u010devi\u0107","year":"2019","unstructured":"Ron\u010devi\u0107, T., Puizina, J. & Tossi, A. Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era? Int. J. Mol. Sci. 20, 5713 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR412","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1389450024605445","volume":"3","author":"M Cudic","year":"2002","unstructured":"Cudic, M. & Otvos, L. Jr Intracellular targets of antibacterial peptides. Curr. Drug Targets 3, 101\u2013106 (2002).","journal-title":"Curr. Drug Targets"},{"key":"2107_CR413","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0005-2736(99)00198-4","volume":"1462","author":"RM Epand","year":"1999","unstructured":"Epand, R. M. & Vogel, H. J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys. Acta 1462, 11\u201328 (1999).","journal-title":"Biochim Biophys. Acta"},{"key":"2107_CR414","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2217\/fmb-2017-0034","volume":"12","author":"V Pader","year":"2017","unstructured":"Pader, V. & Edwards, A. M. Daptomycin: new insights into an antibiotic of last resort. Future Microbiol 12, 461\u2013464 (2017).","journal-title":"Future Microbiol"},{"key":"2107_CR415","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"M Heidary","year":"2018","unstructured":"Heidary, M. et al. Daptomycin. J. Antimicrob. Chemother. 73, 1\u201311 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"2107_CR416","doi-asserted-by":"publisher","first-page":"689","DOI":"10.23736\/S0375-9393.18.13393-1","volume":"85","author":"C Tascini","year":"2019","unstructured":"Tascini, C. et al. Statins during daptomycin therapy: to give or not to give? Minerva Anestesiol. 85, 689\u2013690 (2019).","journal-title":"Minerva Anestesiol."},{"key":"2107_CR417","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","volume":"24","author":"SD Taylor","year":"2016","unstructured":"Taylor, S. D. & Palmer, M. The action mechanism of daptomycin. Bioorg. Med Chem. 24, 6253\u20136268 (2016).","journal-title":"Bioorg. Med Chem."},{"key":"2107_CR418","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1093\/jac\/dkx299","volume":"72","author":"P Daley","year":"2017","unstructured":"Daley, P. et al. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. J. Antimicrob. Chemother. 72, 3462\u20133470 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"2107_CR419","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40360-017-0123-z","volume":"18","author":"G Chandorkar","year":"2017","unstructured":"Chandorkar, G. et al. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers. BMC Pharm. Toxicol. 18, 24 (2017).","journal-title":"BMC Pharm. Toxicol."},{"key":"2107_CR420","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/jac\/dkx318","volume":"72","author":"K Cannon","year":"2017","unstructured":"Cannon, K. et al. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection. J. Antimicrob. Chemother. 72, 3453\u20133461 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"2107_CR421","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","volume":"16","author":"S Ramdeen","year":"2015","unstructured":"Ramdeen, S. & Boucher, H. W. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin. Pharmacother. 16, 2073\u20132081 (2015).","journal-title":"Expert Opin. Pharmacother."},{"key":"2107_CR422","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","volume":"77","author":"KP Garnock-Jones","year":"2017","unstructured":"Garnock-Jones, K. P. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs 77, 75\u201383 (2017).","journal-title":"Drugs"},{"key":"2107_CR423","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey, G. R. et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N. Engl. J. Med 370, 2180\u20132190 (2014).","journal-title":"N. Engl. J. Med"},{"key":"2107_CR424","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey, G. R. et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin. Infect. Dis. 60, 254\u2013262 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"2107_CR425","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1128\/AAC.02932-14","volume":"58","author":"G Lin","year":"2014","unstructured":"Lin, G., Pankuch, G., Appelbaum, P. C. & Kosowska-Shick, K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob. Agents Chemother. 58, 6251\u20136254 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2107_CR426","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed, Y. Y. Rezafungin: First Approval. Drugs 83, 833\u2013840 (2023).","journal-title":"Drugs"},{"key":"2107_CR427","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fmb-2020-0217","volume":"16","author":"YY Ham","year":"2021","unstructured":"Ham, Y. Y., Lewis, J. S. 2nd & Thompson, G. R. 3rd Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 16, 27\u201336 (2021).","journal-title":"Future Microbiol."},{"key":"2107_CR428","doi-asserted-by":"publisher","first-page":"e01556","DOI":"10.1128\/AAC.01556-19","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak, A. J., Zhao, M. & Andes, D. R. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrob. Agents Chemother. 63, e01556\u201301519 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2107_CR429","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/SLA.0000000000005508","volume":"277","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. Efficacy and Safety of PL-5 (Peceleganan) Spray for Wound Infections: A Phase IIb Randomized Clinical Trial. Ann. Surg. 277, 43\u201349 (2023).","journal-title":"Ann. Surg."},{"key":"2107_CR430","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3762\/bjoc.12.226","volume":"12","author":"DJ Atkinson","year":"2016","unstructured":"Atkinson, D. J., Naysmith, B. J., Furkert, D. P. & Brimble, M. A. Enduracididine, a rare amino acid component of peptide antibiotics: Natural products and synthesis. Beilstein J. Org. Chem. 12, 2325\u20132342 (2016).","journal-title":"Beilstein J. Org. Chem."},{"key":"2107_CR431","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrd2004","volume":"5","author":"E Breukink","year":"2006","unstructured":"Breukink, E. & de Kruijff, B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5, 321\u2013332 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR432","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","volume":"608","author":"R Shukla","year":"2022","unstructured":"Shukla, R. et al. Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 608, 390\u2013396 (2022).","journal-title":"Nature"},{"key":"2107_CR433","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.1039\/C7SC03241B","volume":"8","author":"A Parmar","year":"2017","unstructured":"Parmar, A. et al. Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding. Chem. Sci. 8, 8183\u20138192 (2017).","journal-title":"Chem. Sci."},{"key":"2107_CR434","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1016\/j.bbamem.2015.04.014","volume":"1848","author":"D M\u00fcnch","year":"2015","unstructured":"M\u00fcnch, D. & Sahl, H. G. Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides. Biochim Biophys. Acta 1848, 3062\u20133071 (2015).","journal-title":"Biochim Biophys. Acta"},{"key":"2107_CR435","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkv301","volume":"71","author":"PM Beringer","year":"2016","unstructured":"Beringer, P. M. et al. Rhesus \u03b8-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 71, 181\u2013188 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"2107_CR436","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1753425913514784","volume":"21","author":"KP Tai","year":"2015","unstructured":"Tai, K. P. et al. Microbicidal effects of \u03b1- and \u03b8-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Innate Immun. 21, 17\u201329 (2015).","journal-title":"Innate Immun."},{"key":"2107_CR437","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1128\/AAC.49.8.3208-3216.2005","volume":"49","author":"B Deslouches","year":"2005","unstructured":"Deslouches, B. et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother. 49, 3208\u20133216 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2107_CR438","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antibiotics13010071","volume":"13","author":"VC Scoffone","year":"2024","unstructured":"Scoffone, V. C. et al. New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis. Antibiotics (Basel) 13, 71 (2024).","journal-title":"Antibiotics (Basel)"},{"key":"2107_CR439","doi-asserted-by":"publisher","first-page":"547.e541","DOI":"10.1016\/j.cmi.2017.08.029","volume":"24","author":"C Chen","year":"2018","unstructured":"Chen, C., Deslouches, B., Montelaro, R. C. & Di, Y. P. Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia. Clin. Microbiol Infect. 24, 547.e541\u2013547.e548 (2018).","journal-title":"Clin. Microbiol Infect."},{"key":"2107_CR440","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4274\/tjps.galenos.2020.43078","volume":"19","author":"L Elsalem","year":"2022","unstructured":"Elsalem, L., Khasawneh, A. & Al Sheboul, S. WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial. Turk. J. Pharm. Sci. 19, 110\u2013116 (2022).","journal-title":"Turk. J. Pharm. Sci."},{"key":"2107_CR441","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-micro-020518-115759","volume":"73","author":"TS Fung","year":"2019","unstructured":"Fung, T. S. & Liu, D. X. Human Coronavirus: Host-Pathogen Interaction. Annu. Rev. Microbiol. 73, 529\u2013557 (2019).","journal-title":"Annu. Rev. Microbiol."},{"key":"2107_CR442","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"2107_CR443","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.7150\/ijms.47836","volume":"17","author":"Y-J Han","year":"2020","unstructured":"Han, Y.-J. et al. Advances and challenges in the prevention and treatment of COVID-19. Int. J. Med. Sci. 17, 1803\u20131810 (2020).","journal-title":"Int. J. Med. Sci."},{"key":"2107_CR444","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12929-022-00847-6","volume":"29","author":"K Nepali","year":"2022","unstructured":"Nepali, K. et al. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. J. Biomed. Sci. 29, 65 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2107_CR445","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu, L., Su, S., Yang, H. & Jiang, S. Antivirals with common targets against highly pathogenic viruses. Cell 184, 1604\u20131620 (2021).","journal-title":"Cell"},{"key":"2107_CR446","doi-asserted-by":"publisher","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","volume":"5","author":"S Xia","year":"2019","unstructured":"Xia, S. et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5, eaav4580 (2019).","journal-title":"Sci. Adv."},{"key":"2107_CR447","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1006\/viro.2000.0757","volume":"279","author":"TM Gallagher","year":"2001","unstructured":"Gallagher, T. M. & Buchmeier, M. J. Coronavirus Spike Proteins in Viral Entry and Pathogenesis. Virology 279, 371\u2013374 (2001).","journal-title":"Virology"},{"key":"2107_CR448","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"1367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 1367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"2107_CR449","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"2107_CR450","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.virusres.2014.10.007","volume":"194","author":"S Xia","year":"2014","unstructured":"Xia, S. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res 194, 200\u2013210 (2014).","journal-title":"Virus Res"},{"key":"2107_CR451","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3, 237\u2013261 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"2107_CR452","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Liu, Q. & Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 92, 418\u2013423 (2020).","journal-title":"J. Med. Virol."},{"key":"2107_CR453","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"C Gil","year":"2020","unstructured":"Gil, C. et al. COVID-19: Drug Targets and Potential Treatments. J. Med. Chem. 63, 12359\u201312386 (2020).","journal-title":"J. Med. Chem."},{"key":"2107_CR454","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb, Y. N. Nirmatrelvir Plus Ritonavir: First Approval. Drugs 82, 585\u2013591 (2022).","journal-title":"Drugs"},{"key":"2107_CR455","doi-asserted-by":"publisher","first-page":"236","DOI":"10.37201\/req\/002.2022","volume":"35","author":"J Reina","year":"2022","unstructured":"Reina, J. & Iglesias, C. Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination. Rev. Esp. Quimioter. 35, 236\u2013240 (2022).","journal-title":"Rev. Esp. Quimioter."},{"key":"2107_CR456","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cpt.3025","volume":"115","author":"K Wan","year":"2023","unstructured":"Wan, K. et al. Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation. Clin. Pharmacol. Ther. 115, 42\u201351 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2107_CR457","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","volume":"399","author":"J Heskin","year":"2022","unstructured":"Heskin, J. et al. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. Lancet 399, 21\u201322 (2022).","journal-title":"Lancet"},{"key":"2107_CR458","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 13, 689\u2013693 (2022).","journal-title":"Protein Cell"},{"key":"2107_CR459","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR460","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini, C. et al. Recommendations for the Management of Drug\u2013Drug Interactions Between the COVID\u201019 Antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications. Clin. Pharmacol. Ther. 112, 1191\u20131200 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2107_CR461","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343\u2013355 (2020).","journal-title":"Cell Res."},{"key":"2107_CR462","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","volume":"12","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm. Sin. B. 12, 1652\u20131661 (2022).","journal-title":"Acta Pharm. Sin. B."},{"key":"2107_CR463","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/v14030549","volume":"14","author":"Q Lan","year":"2022","unstructured":"Lan, Q. et al. A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. Viruses 14, 549 (2022).","journal-title":"Viruses"},{"key":"2107_CR464","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/v14030597","volume":"14","author":"L Xing","year":"2022","unstructured":"Xing, L. et al. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. Viruses 14, 597 (2022).","journal-title":"Viruses"},{"key":"2107_CR465","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbrc.2004.04.141","volume":"319","author":"J Zhu","year":"2004","unstructured":"Zhu, J. et al. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319, 283\u2013288 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2107_CR466","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1128\/JVI.02433-13","volume":"87","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus. J. Virol. 87, 13134\u201313140 (2013).","journal-title":"J. Virol."},{"key":"2107_CR467","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/22221751.2020.1770631","volume":"9","author":"H Sun","year":"2020","unstructured":"Sun, H. et al. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerg. Microbes Infect. 9, 1238\u20131241 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"2107_CR468","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s11427-023-2410-5","volume":"66","author":"L Wu","year":"2023","unstructured":"Wu, L. et al. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Sci. China Life Sci. 66, 2201\u20132213 (2023).","journal-title":"Sci. China Life Sci."},{"key":"2107_CR469","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/22221751.2021.1937329","volume":"10","author":"D Yu","year":"2021","unstructured":"Yu, D. et al. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg. Microbes Infect. 10, 1227\u20131240 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"2107_CR470","doi-asserted-by":"publisher","first-page":"101418","DOI":"10.1016\/j.xcrm.2024.101418","volume":"5","author":"W Bi","year":"2024","unstructured":"Bi, W. et al. An enhanced broad-spectrum peptide inhibits Omicron variants in vivo. Cell Rep. Med. 5, 101418 (2024).","journal-title":"Cell Rep. Med."},{"key":"2107_CR471","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/17474124.2.2.185","volume":"2","author":"P Cal\u00e8s","year":"2008","unstructured":"Cal\u00e8s, P. Vapreotide acetate for the treatment of esophageal variceal bleeding. Expert Rev. Gastroenterol. Hepatol. 2, 185\u2013192 (2008).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"2107_CR472","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1517\/14656560903207019","volume":"10","author":"BE Fortune","year":"2009","unstructured":"Fortune, B. E., Jackson, J., Leonard, J. & Trotter, J. F. Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding. Expert Opin. Pharmacother. 10, 2337\u20132342 (2009).","journal-title":"Expert Opin. Pharmacother."},{"key":"2107_CR473","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM200101043440104","volume":"344","author":"P Cal\u00e8s","year":"2001","unstructured":"Cal\u00e8s, P. et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N. Engl. J. Med. 344, 23\u201328 (2001).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR474","first-page":"385","volume":"12","author":"SB Cho","year":"2006","unstructured":"Cho, S. B. et al. Comparison of terlipressin and octreotide with variceal ligation for controlling acute esophageal variceal bleeding-a randomized prospective study. Korean J. Hepatol. 12, 385\u2013393 (2006).","journal-title":"Korean J. Hepatol."},{"key":"2107_CR475","first-page":"e42367","volume":"15","author":"SR Thangaraj","year":"2023","unstructured":"Thangaraj, S. R., Srinivasan, M., Arzoun, H. & Thomas, S. S. A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug. Cureus 15, e42367 (2023).","journal-title":"Cureus"},{"key":"2107_CR476","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","volume":"1","author":"GJ Holtmann","year":"2016","unstructured":"Holtmann, G. J., Ford, A. C. & Talley, N. J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 1, 133\u2013146 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2107_CR477","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(20)31548-8","volume":"396","author":"AC Ford","year":"2020","unstructured":"Ford, A. C., Sperber, A. D., Corsetti, M. & Camilleri, M. Functional gastrointestinal disorders 2 irritable bowel syndrome. Lancet 396, 1675\u20131688 (2020).","journal-title":"Lancet"},{"key":"2107_CR478","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","volume":"86","author":"AP Bryant","year":"2010","unstructured":"Bryant, A. P. et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 86, 760\u2013765 (2010).","journal-title":"Life Sci."},{"key":"2107_CR479","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2146\/ajhp130575","volume":"71","author":"BL Love","year":"2014","unstructured":"Love, B. L., Johnson, A. & Smith, L. S. Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome. Am. J. Health Syst. Pharm. 71, 1081\u20131091 (2014).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2107_CR480","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/DDDT.S32252","volume":"7","author":"GM Pitari","year":"2013","unstructured":"Pitari, G. M. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des. Devel. Ther. 7, 351\u2013360 (2013).","journal-title":"Drug Des. Devel. Ther."},{"key":"2107_CR481","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s10620-013-2684-z","volume":"58","author":"K Shailubhai","year":"2013","unstructured":"Shailubhai, K. et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Digestive Dis. Sci. 58, 2580\u20132586 (2013).","journal-title":"Digestive Dis. Sci."},{"key":"2107_CR482","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00280-020-04040-0","volume":"85","author":"BJ Mayo","year":"2020","unstructured":"Mayo, B. J. et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer Chemother. Pharmacol. 85, 793\u2013803 (2020).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2107_CR483","first-page":"131","volume":"10","author":"S Farr","year":"2014","unstructured":"Farr, S., Chess-Williams, R. & McDermott, C. Gemcitabine enhances release of atp but not acetylcholine or pge(2) from bladder urothelial cells. Asia Pac. J. Clin. Oncol. 10, 131\u2013131 (2014).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"2107_CR484","first-page":"134","volume":"10","author":"B Mayo","year":"2014","unstructured":"Mayo, B. et al. The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Asia Pac. J. Clin. Oncol. 10, 134\u2013134 (2014).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"2107_CR485","doi-asserted-by":"crossref","unstructured":"Karthaus, M. et al. Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 35, 10101\u201310101.","DOI":"10.1200\/JCO.2017.35.15_suppl.10101"},{"key":"2107_CR486","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz, M. & Silvestre, S. Alzheimer\u2019s disease: Recent treatment strategies. Eur. J. Pharmacol. 887, 173554 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"2107_CR487","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.conb.2020.02.003","volume":"61","author":"DM Walsh","year":"2020","unstructured":"Walsh, D. M. & Selkoe, D. J. Amyloid \u03b2-protein and beyond: the path forward in Alzheimer\u2019s disease. Curr. Opin. Neurobiol. 61, 116\u2013124 (2020).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2107_CR488","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuroscience.2020.04.019","volume":"438","author":"H Chidambaram","year":"2020","unstructured":"Chidambaram, H. & Chinnathambi, S. G-Protein Coupled Receptors and Tau-different Roles in Alzheimer\u2019s Disease. Neuroscience 438, 198\u2013214 (2020).","journal-title":"Neuroscience"},{"key":"2107_CR489","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen, Z. R., Huang, J. B., Yang, S. L. & Hong, F. F. Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules 27, 1816 (2022).","journal-title":"Molecules"},{"key":"2107_CR490","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.neuropharm.2010.04.005","volume":"59","author":"DJ Bonda","year":"2010","unstructured":"Bonda, D. J. et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59, 290\u2013294 (2010).","journal-title":"Neuropharmacology"},{"key":"2107_CR491","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","volume":"431","author":"TJ Huat","year":"2019","unstructured":"Huat, T. J. et al. Metal Toxicity Links to Alzheimer\u2019s Disease and Neuroinflammation. J. Mol. Biol. 431, 1843\u20131868 (2019).","journal-title":"J. Mol. Biol."},{"key":"2107_CR492","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-2001-3111","volume":"3","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 3, 75\u201380 (2001).","journal-title":"J. Alzheimers Dis."},{"key":"2107_CR493","first-page":"43","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb, M., Tao, W. & Chen, N. Alzheimer\u2019s Disease Puzzle: Delving into Pathogenesis Hypotheses. Aging Dis. 15, 43\u201373 (2024).","journal-title":"Aging Dis."},{"key":"2107_CR494","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert, M. et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron 3, 519\u2013526 (1989).","journal-title":"Neuron"},{"key":"2107_CR495","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-022-00526-y","volume":"17","author":"AH Brody","year":"2022","unstructured":"Brody, A. H. et al. Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy. Mol. Neurodegener. 17, 32 (2022).","journal-title":"Mol. Neurodegener."},{"key":"2107_CR496","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/JAD-2008-13404","volume":"13","author":"J Miklossy","year":"2008","unstructured":"Miklossy, J. Chronic inflammation and amyloidogenesis in Alzheimer\u2019s disease - role of Spirochetes. J. Alzheimers Dis. 13, 381\u2013391 (2008).","journal-title":"J. Alzheimers Dis."},{"key":"2107_CR497","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fnins.2019.00129","volume":"13","author":"M Fahnestock","year":"2019","unstructured":"Fahnestock, M. & Shekari, A. ProNGF and Neurodegeneration in Alzheimer\u2019s Disease. Front. Neurosci. 13, 129 (2019).","journal-title":"Front. Neurosci."},{"key":"2107_CR498","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2107_CR499","doi-asserted-by":"publisher","first-page":"11596","DOI":"10.3390\/ijms241411596","volume":"24","author":"S Ichimata","year":"2023","unstructured":"Ichimata, S. et al. Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer\u2019s Disease Associated with Down Syndrome. Int. J. Mol. Sci. 24, 11596 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR500","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar, T., Al Balushi, K. & Khan, S. A. Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease. Mol. Biol. Rep. 48, 5629\u20135645 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"2107_CR501","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cmdc.201500216","volume":"10","author":"AK Ghosh","year":"2015","unstructured":"Ghosh, A. K. & Tang, J. Prospects of \u03b2-Secretase Inhibitors for the Treatment of Alzheimer\u2019s Disease. ChemMedChem 10, 1463\u20131466 (2015).","journal-title":"ChemMedChem"},{"key":"2107_CR502","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1021\/jm0101803","volume":"44","author":"AK Ghosh","year":"2001","unstructured":"Ghosh, A. K. et al. Structure-based design: Potent inhibitors of human brain memapsin 2 (\u03b2-secretase). J. Med. Chem. 44, 2865\u20132868 (2001).","journal-title":"J. Med. Chem."},{"key":"2107_CR503","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3233\/JAD-150834","volume":"50","author":"S Eketj\u00e4ll","year":"2016","unstructured":"Eketj\u00e4ll, S. et al. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J. Alzheimers Dis. 50, 1109\u20131123 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"2107_CR504","doi-asserted-by":"publisher","first-page":"116229","DOI":"10.1016\/j.trac.2021.116229","volume":"137","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Screening of specific binding peptides using phage-display techniques and their biosensing applications. TrAC, Trends Anal. Chem. 137, 116229 (2021).","journal-title":"TrAC, Trends Anal. Chem."},{"key":"2107_CR505","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1021\/ja0619861","volume":"128","author":"BP Orner","year":"2006","unstructured":"Orner, B. P., Liu, L., Murphy, R. M. & Kiessling, L. L. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc. 128, 11882\u201311889 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR506","doi-asserted-by":"publisher","first-page":"13095","DOI":"10.1002\/anie.201504973","volume":"54","author":"E Andreetto","year":"2015","unstructured":"Andreetto, E. et al. A Hot-Segment-Based Approach for the Design of Cross-Amyloid Interaction Surface Mimics as Inhibitors of Amyloid Self-Assembly. Angew. Chem. Int Ed. Engl. 54, 13095\u201313100 (2015).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2107_CR507","doi-asserted-by":"publisher","first-page":"14503","DOI":"10.1002\/anie.201802979","volume":"57","author":"A Spanopoulou","year":"2018","unstructured":"Spanopoulou, A. et al. Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements. Angew. Chem. Int Ed. Engl. 57, 14503\u201314508 (2018).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2107_CR508","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.3390\/ijms241713110","volume":"24","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Advances in Alzheimer\u2019s Disease-Associated A\u03b2 Therapy Based on Peptide. Int. J. Mol. Sci. 24, 13110 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR509","doi-asserted-by":"publisher","first-page":"160696","DOI":"10.1098\/rsos.160696","volume":"4","author":"C Xue","year":"2017","unstructured":"Xue, C., Lin, T. Y., Chang, D. & Guo, Z. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R. Soc. Open Sci. 4, 160696 (2017).","journal-title":"R. Soc. Open Sci."},{"key":"2107_CR510","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","volume":"69","author":"S Wegmann","year":"2021","unstructured":"Wegmann, S., Biernat, J. & Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimer\u2019s disease. Curr. Opin. Neurobiol. 69, 131\u2013138 (2021).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2107_CR511","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease. Int. J. Biol. Sci. 17, 2181\u20132192 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2107_CR512","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon, E. E. et al. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat. Rev. Neurol. 19, 715\u2013736 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"2107_CR513","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41392-021-00669-2","volume":"6","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduct. Target Ther. 6, 269 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2107_CR514","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157\u2013172 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"2107_CR515","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/cells11121885","volume":"11","author":"Y Rajesh","year":"2022","unstructured":"Rajesh, Y. & Kanneganti, T. D. Innate Immune Cell Death in Neuroinflammation and Alzheimer\u2019s Disease. Cells 11, 1885 (2022).","journal-title":"Cells"},{"key":"2107_CR516","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13098-023-01082-1","volume":"15","author":"M Alrouji","year":"2023","unstructured":"Alrouji, M. et al. The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer\u2019s diseases. Diabetol. Metab. Syndr. 15, 101 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"2107_CR517","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"2107_CR518","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","volume":"42","author":"HI Roessler","year":"2021","unstructured":"Roessler, H. I., Knoers, N., van Haelst, M. M. & van Haaften, G. Drug Repurposing for Rare Diseases. Trends Pharmacol. Sci. 42, 255\u2013267 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"2107_CR519","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/bib\/bbr021","volume":"12","author":"D Sardana","year":"2011","unstructured":"Sardana, D. et al. Drug repositioning for orphan diseases. Brief. Bioinform. 12, 346\u2013356 (2011).","journal-title":"Brief. Bioinform."},{"key":"2107_CR520","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1127-0","volume":"14","author":"JE Posey","year":"2019","unstructured":"Posey, J. E. Genome sequencing and implications for rare disorders. Orphanet J. Rare Dis. 14, 153 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"2107_CR521","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/adc.2006.104455","volume":"93","author":"P Guillem","year":"2008","unstructured":"Guillem, P. et al. Rare diseases in disabled children: an epidemiological survey. Arch. Dis. Child. 93, 115\u2013118 (2008).","journal-title":"Arch. Dis. Child."},{"key":"2107_CR522","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"LN Jeffrey","year":"2010","unstructured":"Jeffrey, L. N. et al. Rett syndrome: Revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944\u2013950 (2010).","journal-title":"Ann. Neurol."},{"key":"2107_CR523","doi-asserted-by":"publisher","first-page":"12488","DOI":"10.3390\/ijms241512488","volume":"24","author":"D Valenti","year":"2023","unstructured":"Valenti, D. & Vacca, R. A. Brain Mitochondrial Bioenergetics in Genetic Neurodevelopmental Disorders: Focus on Down, Rett and Fragile X Syndromes. Int. J. Mol. Sci. 24, 12488 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR524","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul, J. L. et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat. Med. 29, 1468\u20131475 (2023).","journal-title":"Nat. Med."},{"key":"2107_CR525","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","volume":"278","author":"MJ Bickerdike","year":"2009","unstructured":"Bickerdike, M. J. et al. NNZ-2566: A Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J. Neurol. Sci. 278, 85\u201390 (2009).","journal-title":"J. Neurol. Sci."},{"key":"2107_CR526","first-page":"243","volume":"17","author":"D Al Shaer","year":"2024","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F. & de la Torre, B. G. 2023 FDA TIDES (Peptides and Oligonucleotides). Harvest. Pharm. 17, 243 (2024).","journal-title":"Harvest. Pharm."},{"key":"2107_CR527","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon, D. & Bril, V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs 82, 865\u2013887 (2022).","journal-title":"Drugs"},{"key":"2107_CR528","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 14, 1023\u20131036 (2015).","journal-title":"Lancet Neurol."},{"key":"2107_CR529","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","volume":"120","author":"MJ Krisinger","year":"2012","unstructured":"Krisinger, M. J. et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120, 1717\u20131725 (2012).","journal-title":"Blood"},{"key":"2107_CR530","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","volume":"5","author":"JH Foley","year":"2016","unstructured":"Foley, J. H. et al. Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine 5, 175\u2013182 (2016).","journal-title":"EBioMedicine"},{"key":"2107_CR531","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bpg.2016.02.011","volume":"30","author":"L Pironi","year":"2016","unstructured":"Pironi, L. Definitions of intestinal failure and the short bowel syndrome. Best. Pract. Res. Clin. Gastroenterol. 30, 173\u2013185 (2016).","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"2107_CR532","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.dld.2019.11.013","volume":"52","author":"S Massironi","year":"2020","unstructured":"Massironi, S. et al. Understanding short bowel syndrome: Current status and future perspectives. Dig. Liver Dis. 52, 253\u2013261 (2020).","journal-title":"Dig. Liver Dis."},{"key":"2107_CR533","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/nu13030786","volume":"13","author":"A Diamanti","year":"2021","unstructured":"Diamanti, A. et al. Etiology and Management of Pediatric Intestinal Failure: Focus on the Non-Digestive Causes. Nutrients 13, 786 (2021).","journal-title":"Nutrients"},{"key":"2107_CR534","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gtc.2017.10.004","volume":"47","author":"PB Jeppesen","year":"2018","unstructured":"Jeppesen, P. B. & Fuglsang, K. A. Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. Gastroenterol. Clin. North Am. 47, 61\u201375 (2018).","journal-title":"Gastroenterol. Clin. North Am."},{"key":"2107_CR535","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1136\/gut.2006.091108","volume":"55","author":"J Nightingale","year":"2006","unstructured":"Nightingale, J. Guidelines for management of patients with a short bowel. Gut 55, iv1\u2013iv12 (2006).","journal-title":"Gut"},{"key":"2107_CR536","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molmet.2017.01.005","volume":"6","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport. Mol. Metab. 6, 245\u2013255 (2017).","journal-title":"Mol. Metab."},{"key":"2107_CR537","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40265-017-0703-7","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim, E. S. & Keam, S. J. Teduglutide: A Review in Short Bowel Syndrome. Drugs 77, 345\u2013352 (2017).","journal-title":"Drugs"},{"key":"2107_CR538","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1053\/j.gastro.2012.09.007","volume":"143","author":"PB Jeppesen","year":"2012","unstructured":"Jeppesen, P. B. et al. Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure. Gastroenterology 143, 1473\u20131481 (2012).","journal-title":"Gastroenterology"},{"key":"2107_CR539","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00383-020-04797-8","volume":"37","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. Long-term outcomes of various pediatric short bowel syndrome in China. Pediatr. Surg. Int. 37, 495\u2013502 (2021).","journal-title":"Pediatr. Surg. Int."},{"key":"2107_CR540","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/21678707.2013.814536","volume":"7","author":"PB Jeppesen","year":"2013","unstructured":"Jeppesen, P. B. The non-surgical treatment of adult patients with short bowel syndrome. Expert Opin. Orphan Drugs 7, 527\u2013538 (2013).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"2107_CR541","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/gut.2004.061440","volume":"54","author":"PB Jeppesen","year":"2005","unstructured":"Jeppesen, P. B. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54, 1224\u20131231 (2005).","journal-title":"Gut"},{"key":"2107_CR542","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","volume":"76","author":"HA Blair","year":"2016","unstructured":"Blair, H. A. Etelcalcetide: First Global Approval. Drugs 76, 1787\u20131792 (2016).","journal-title":"Drugs"},{"key":"2107_CR543","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26640-x","volume":"12","author":"N Hadidi","year":"2022","unstructured":"Hadidi, N. & Pazuki, G. Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS. Sci. Rep. 12, 22042 (2022).","journal-title":"Sci. Rep."},{"key":"2107_CR544","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/0897190017725984","volume":"31","author":"C Bell","year":"2017","unstructured":"Bell, C. et al. Development of Glatopa\u00ae (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. J. Pharm. Pract. 31, 481\u2013488 (2017).","journal-title":"J. Pharm. Pract."},{"key":"2107_CR545","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.mehy.2010.09.015","volume":"76","author":"B Ben-Zeev","year":"2011","unstructured":"Ben-Zeev, B., Aharoni, R., Nissenkorn, A. & Arnon, R. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. Med. Hypotheses 76, 190\u2013193 (2011).","journal-title":"Med. Hypotheses"},{"key":"2107_CR546","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen, P. et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N. Engl. J. Med. 384, 1028\u20131037 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR547","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17417-9","volume":"11","author":"M Jiang","year":"2020","unstructured":"Jiang, M. et al. Identification of osteogenic progenitor cell-targeted peptides that augment bone formation. Nat. Commun. 11, 4278 (2020).","journal-title":"Nat. Commun."},{"key":"2107_CR548","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung, M. R. et al. Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N. Engl. J. Med. 370, 412\u2013420 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR549","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR550","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant, H. K. et al. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass. J. Bone Miner. Res. 32, 181\u2013187 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"2107_CR551","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi, D. et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J. Clin. Pharmacol. 54, 168\u2013178 (2014).","journal-title":"J. Clin. Pharmacol."},{"key":"2107_CR552","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/ijms17111885","volume":"17","author":"S Pigossi","year":"2016","unstructured":"Pigossi, S. et al. Role of Osteogenic Growth Peptide (OGP) and OGP(10\u201314) in Bone Regeneration: A Review. Int. J. Mol. Sci. 17, 1885 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR553","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397, 1496\u20131504 (2021).","journal-title":"Lancet"},{"key":"2107_CR554","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo, A. F. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev. Pharm. Toxicol. 55, 533\u2013552 (2015).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"2107_CR555","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40259-017-0250-5","volume":"31","author":"H Yuan","year":"2017","unstructured":"Yuan, H., Lauritsen, C. G., Kaiser, E. A. & Silberstein, S. D. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. Biodrugs 31, 487\u2013501 (2017).","journal-title":"Biodrugs"},{"key":"2107_CR556","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1124\/jpet.110.165993","volume":"334","author":"KY Chan","year":"2010","unstructured":"Chan, K. Y. et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J. Pharm. Exp. Ther. 334, 746\u2013752 (2010).","journal-title":"J. Pharm. Exp. Ther."},{"key":"2107_CR557","doi-asserted-by":"publisher","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries, T., Villal\u00f3n, C. M. & MaassenVanDenBrink, A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharm. Ther. 211, 107528 (2020).","journal-title":"Pharm. Ther."},{"key":"2107_CR558","first-page":"635","volume":"44","author":"L Lionetto","year":"2019","unstructured":"Lionetto, L. et al. Calcitonin gene-related peptide (CGRP) receptor antagonist. Treat. migraine 44, 635 (2019).","journal-title":"Treat. migraine"},{"key":"2107_CR559","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus, R. et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34, 114\u2013125 (2014).","journal-title":"Cephalalgia"},{"key":"2107_CR560","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop, R. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394, 737\u2013745 (2019).","journal-title":"Lancet"},{"key":"2107_CR561","doi-asserted-by":"publisher","first-page":"e13707","DOI":"10.1111\/cts.13707","volume":"17","author":"R Boinpally","year":"2024","unstructured":"Boinpally, R., Shebley, M. & Trugman, J. M. Atogepant: Mechanism of action, clinical and translational science. Clin. Transl. Sci. 17, e13707 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"2107_CR562","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani, J. et al. Atogepant for the Preventive Treatment of Migraine. N. Engl. J. Med 385, 695\u2013706 (2021).","journal-title":"N. Engl. J. Med"},{"key":"2107_CR563","doi-asserted-by":"publisher","first-page":"10644","DOI":"10.1021\/jm3013147","volume":"55","author":"G Luo","year":"2012","unstructured":"Luo, G. et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J. Med. Chem. 55, 10644\u201310651 (2012).","journal-title":"J. Med. Chem."},{"key":"2107_CR564","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","volume":"11","author":"KS Pan","year":"2020","unstructured":"Pan, K. S., Siow, A., Hay, D. L. & Walker, C. S. Antagonism of CGRP Signaling by Rimegepant at Two Receptors. Front. Pharmacol. 11, 1240 (2020).","journal-title":"Front. Pharmacol."},{"key":"2107_CR565","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01425-9","volume":"23","author":"S Hage La Cour","year":"2022","unstructured":"Hage La Cour, S. et al. Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor. J. Headache Pain. 23, 59 (2022).","journal-title":"J. Headache Pain."},{"key":"2107_CR566","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston, K. et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J. Headache Pain. 23, 10 (2022).","journal-title":"J. Headache Pain."},{"key":"2107_CR567","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton, R. B. et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 22, 209\u2013217 (2023).","journal-title":"Lancet Neurol."},{"key":"2107_CR568","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-777X.77299","volume":"3","author":"AS Clem","year":"2011","unstructured":"Clem, A. S. Fundamentals of vaccine immunology. J. Glob. Infect. Dis. 3, 73 (2011).","journal-title":"J. Glob. Infect. Dis."},{"key":"2107_CR569","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s41193-016-0200-5","volume":"22","author":"G Casey","year":"2016","unstructured":"Casey, G. Vaccines-how and why they work. Nurs. N.Z. 22, 20 (2016).","journal-title":"Nurs. N.Z."},{"key":"2107_CR570","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/v13081637","volume":"13","author":"BA Stanfield","year":"2021","unstructured":"Stanfield, B. A., Kousoulas, K. G., Fernandez, A. & Gershburg, E. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses 13, 1637 (2021).","journal-title":"Viruses"},{"key":"2107_CR571","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines8030373","volume":"8","author":"M Skwarczynski","year":"2020","unstructured":"Skwarczynski, M. et al. Progress in the development of subunit vaccines against malaria. Vaccines 8, 373 (2020).","journal-title":"Vaccines"},{"key":"2107_CR572","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.survophthal.2021.04.001","volume":"67","author":"JY Cheng","year":"2022","unstructured":"Cheng, J. Y. & Margo, C. E. Ocular adverse events following vaccination: overview and update. Surv. Ophthalmol. 67, 293\u2013306 (2022).","journal-title":"Surv. Ophthalmol."},{"key":"2107_CR573","doi-asserted-by":"publisher","first-page":"1232910","DOI":"10.1126\/science.1232910","volume":"340","author":"WC Koff","year":"2013","unstructured":"Koff, W. C. et al. Accelerating Next-Generation Vaccine Development for Global Disease Prevention. Science 340, 1232910 (2013).","journal-title":"Science"},{"key":"2107_CR574","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.vaccine.2018.11.045","volume":"37","author":"T Nakayama","year":"2019","unstructured":"Nakayama, T. Causal relationship between immunological responses and adverse reactions following vaccination. Vaccine 37, 366\u2013371 (2019).","journal-title":"Vaccine"},{"key":"2107_CR575","doi-asserted-by":"publisher","first-page":"113928","DOI":"10.1016\/j.addr.2021.113928","volume":"177","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Advancedoral vaccine delivery strategies for improving the immunity. Adv. Drug Del. Rev. 177, 113928 (2021).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR576","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","volume":"120","author":"RJ Malonis","year":"2019","unstructured":"Malonis, R. J., Lai, J. R. & Vergnolle, O. Peptide-based vaccines: current progress and future challenges. Chem. Rev. 120, 3210\u20133229 (2019).","journal-title":"Chem. Rev."},{"key":"2107_CR577","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4161\/hv.27332","volume":"10","author":"F Azmi","year":"2014","unstructured":"Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M. & Toth, I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum. Vaccin. Immunother. 10, 778\u2013796 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2107_CR578","doi-asserted-by":"publisher","first-page":"2007576","DOI":"10.1002\/adma.202007576","volume":"33","author":"D Lee","year":"2021","unstructured":"Lee, D. et al. Harnessing innate immunity using biomaterials for cancer immunotherapy. Adv. Mater. 33, 2007576 (2021).","journal-title":"Adv. Mater."},{"key":"2107_CR579","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cells9122673","volume":"9","author":"C Bellini","year":"2020","unstructured":"Bellini, C. & Horvati, K. Recent advances in the development of protein-and peptide-based subunit vaccines against tuberculosis. Cells 9, 2673 (2020).","journal-title":"Cells"},{"key":"2107_CR580","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2174\/156802612802652402","volume":"12","author":"T-Y Liu","year":"2012","unstructured":"Liu, T.-Y., Hussein, M. W., Toth, I. & Skwarczynski, M. Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines. Curr. Top. Med. Chem. 12, 1581\u20131592 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"2107_CR581","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cmdc.201200487","volume":"8","author":"PM Moyle","year":"2013","unstructured":"Moyle, P. M. & Toth, I. Modern Subunit Vaccines: Development, Components, and Research Opportunities. ChemMedChem 8, 360\u2013376 (2013).","journal-title":"ChemMedChem"},{"key":"2107_CR582","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","volume":"6","author":"AW Purcell","year":"2007","unstructured":"Purcell, A. W., McCluskey, J. & Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404\u2013414 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR583","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/C5SC03892H","volume":"7","author":"M Skwarczynski","year":"2016","unstructured":"Skwarczynski, M. & Toth, I. Peptide-based synthetic vaccines. Chem. Sci. 7, 842\u2013854 (2016).","journal-title":"Chem. Sci."},{"key":"2107_CR584","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"2107_CR585","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480\u2013489 (2011).","journal-title":"Nature"},{"key":"2107_CR586","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","volume":"196","author":"Q Song","year":"2018","unstructured":"Song, Q., Zhang, C.-d & Wu, X.-h Therapeutic cancer vaccines: From initial findings to prospects. Immunol. Lett. 196, 11\u201321 (2018).","journal-title":"Immunol. Lett."},{"key":"2107_CR587","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine. Clin. Cancer Res. 17, 3520\u20133526 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2107_CR588","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40824-023-00369-8","volume":"27","author":"M Xiao","year":"2023","unstructured":"Xiao, M. et al. Emerging biomaterials for tumor immunotherapy. Biomater. Res. 27, 1\u201352 (2023).","journal-title":"Biomater. Res."},{"key":"2107_CR589","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1073\/pnas.92.17.8078","volume":"92","author":"B Mukherji","year":"1995","unstructured":"Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. 92, 8078\u20138082 (1995).","journal-title":"Proc. Natl Acad. Sci."},{"key":"2107_CR590","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/biomedicines10020468","volume":"10","author":"PV Belousov","year":"2022","unstructured":"Belousov, P. V. The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges. Biomedicines 10, 468 (2022).","journal-title":"Biomedicines"},{"key":"2107_CR591","first-page":"A106","volume":"9","author":"D Langan","year":"2021","unstructured":"Langan, D. et al. 97 High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies. J. Immunother. Cancer 9, A106\u2013A106 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2107_CR592","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 5, 67\u201373 (2019).","journal-title":"JAMA Oncol."},{"key":"2107_CR593","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"2107_CR594","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","volume":"5","author":"A Chabeda","year":"2018","unstructured":"Chabeda, A. et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 5, 46\u201358 (2018).","journal-title":"Papillomavirus Res."},{"key":"2107_CR595","doi-asserted-by":"publisher","first-page":"544579","DOI":"10.3389\/fonc.2020.544579","volume":"10","author":"R Zhang","year":"2021","unstructured":"Zhang, R., Dong, L. & Yu, J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front. Oncol. 10, 544579 (2021).","journal-title":"Front. Oncol."},{"key":"2107_CR596","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.ctrv.2021.102309","volume":"101","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka, M. et al. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat. Rev. 101, 102309 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"2107_CR597","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3390\/ijms22052625","volume":"22","author":"SE Rebuzzi","year":"2021","unstructured":"Rebuzzi, S. E. et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 22, 2625 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR598","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2107_CR599","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/2326-6066.CIR-16-0280","volume":"5","author":"SA Malaker","year":"2017","unstructured":"Malaker, S. A. et al. Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. Cancer Immunol. Res. 5, 376\u2013384 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2107_CR600","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000262","volume":"8","author":"VH Engelhard","year":"2020","unstructured":"Engelhard, V. H. et al. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. J. Immunother. Cancer 8, e00026 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2107_CR601","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2018","unstructured":"Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer Neoantigens. Annu. Rev. Immunol. 37, 173\u2013200 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"2107_CR602","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10989-019-09918-z","volume":"26","author":"E Raoufi","year":"2020","unstructured":"Raoufi, E. et al. Epitope Prediction by Novel Immunoinformatics Approach: A State-of-the-art Review. Int. J. Pept. Res. Ther. 26, 1155\u20131163 (2020).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"2107_CR603","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834 (2020).","journal-title":"Cell"},{"key":"2107_CR604","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-2876-4","volume":"20","author":"RO Schenck","year":"2019","unstructured":"Schenck, R. O. et al. NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline. BMC Bioinforma. 20, 264 (2019).","journal-title":"BMC Bioinforma."},{"key":"2107_CR605","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"2107_CR606","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.1103822","volume":"189","author":"SM Jensen","year":"2012","unstructured":"Jensen, S. M. et al. Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence. J. Immunol. 189, 767\u2013776 (2012).","journal-title":"J. Immunol."},{"key":"2107_CR607","doi-asserted-by":"publisher","first-page":"1271449","DOI":"10.3389\/fimmu.2023.1271449","volume":"14","author":"H Zelba","year":"2023","unstructured":"Zelba, H. et al. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer. Front. Immunol. 14, 1271449 (2023).","journal-title":"Front. Immunol."},{"key":"2107_CR608","doi-asserted-by":"publisher","first-page":"e15268","DOI":"10.1200\/JCO.2020.38.15_suppl.e15268","volume":"38","author":"JP Marquez-Manriquez","year":"2020","unstructured":"Marquez-Manriquez, J. P. et al. Multipeptide vaccine to prevent epithelial ovarian cancer relapse by microenvironment immunomodulation. J. Clin. Oncol. 38, e15268\u2013e15268 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2107_CR609","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00262-020-02729-y","volume":"70","author":"KL Lee","year":"2021","unstructured":"Lee, K. L., Schlom, J. & Hamilton, D. H. Combination therapies utilizing neoepitope-targeted vaccines. Cancer Immunol. Immunother. 70, 875\u2013885 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2107_CR610","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EME Verdegaal","year":"2016","unstructured":"Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during human melanoma\u2013T cell interactions. Nature 536, 91\u201395 (2016).","journal-title":"Nature"},{"key":"2107_CR611","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00755-7","volume":"19","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. J. Nanobiotechnol. 19, 1\u201316 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"2107_CR612","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"2107_CR613","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/vaccines11030649","volume":"11","author":"Y Li","year":"2023","unstructured":"Li, Y. & Chen, X. CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein. Vaccines 11, 649 (2023).","journal-title":"Vaccines"},{"key":"2107_CR614","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2018.02.006","volume":"275","author":"Z Beck","year":"2018","unstructured":"Beck, Z. et al. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J. Control. Release 275, 12\u201319 (2018).","journal-title":"J. Control. Release"},{"key":"2107_CR615","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","volume":"14","author":"E-J Ko","year":"2018","unstructured":"Ko, E.-J. & Kang, S.-M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum. Vaccin. Immunother. 14, 3041\u20133045 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2107_CR616","doi-asserted-by":"publisher","first-page":"40415","DOI":"10.1021\/acsami.1c12366","volume":"13","author":"L Zhu","year":"2021","unstructured":"Zhu, L. et al. Yeast Shells Encapsulating Adjuvant AS04 as an Antigen Delivery System for a Novel Vaccine against Toxoplasma Gondii. ACS Appl. Mater. Interfaces 13, 40415\u201340428 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2107_CR617","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.actbio.2023.02.034","volume":"161","author":"H Yan","year":"2023","unstructured":"Yan, H. et al. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. Acta Biomater. 161, 213\u2013225 (2023).","journal-title":"Acta Biomater."},{"key":"2107_CR618","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijbiomac.2020.02.297","volume":"152","author":"N Gupta","year":"2020","unstructured":"Gupta, N. et al. Receptor-ligand based molecular interaction to discover adjuvant for immune cell TLRs to develop next-generation vaccine. Int. J. Biol. Macromol. 152, 535\u2013545 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"2107_CR619","doi-asserted-by":"publisher","first-page":"fuab052","DOI":"10.1093\/femsre\/fuab052","volume":"46","author":"W Jaroszewicz","year":"2022","unstructured":"Jaroszewicz, W. et al. Phage display and other peptide display technologies. FEMS Microbiol. Rev. 46, fuab052 (2022).","journal-title":"FEMS Microbiol. Rev."},{"key":"2107_CR620","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13238-019-0639-7","volume":"10","author":"PE Saw","year":"2019","unstructured":"Saw, P. E. & Song, E.-W. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein cell 10, 787\u2013807 (2019).","journal-title":"Protein cell"},{"key":"2107_CR621","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","volume":"228","author":"GP Smith","year":"1985","unstructured":"Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315\u20131317 (1985).","journal-title":"Science"},{"key":"2107_CR622","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.3390\/ijms23158554","volume":"23","author":"K Zhang","year":"2022","unstructured":"Zhang, K., Tang, Y., Chen, Q. & Liu, Y. The screening of therapeutic peptides for anti-inflammation through phage display technology. Int. J. Mol. Sci. 23, 8554 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR623","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s43441-019-00059-5","volume":"54","author":"MS Zambrano-Mila","year":"2020","unstructured":"Zambrano-Mila, M. S., Blacio, K. E. S. & Vispo, N. S. Peptide phage display: Molecular principles and biomedical applications. Ther. Innov. Regul. Sci. 54, 308\u2013317 (2020).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2107_CR624","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/biom10050714","volume":"10","author":"MC Asar","year":"2020","unstructured":"Asar, M. C., Franco, A. & Soendergaard, M. Phage display selection, identification, and characterization of novel pancreatic cancer targeting peptides. Biomolecules 10, 714 (2020).","journal-title":"Biomolecules"},{"key":"2107_CR625","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/bab.2320","volume":"69","author":"B Bakhshinejad","year":"2022","unstructured":"Bakhshinejad, B. & Sadeghizadeh, M. Identification of a novel colon adenocarcinoma cell targeting peptide using phage display library biopanning. Biotechnol. Appl. Biochem. 69, 2753\u20132765 (2022).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"2107_CR626","doi-asserted-by":"publisher","first-page":"1231503","DOI":"10.3389\/fmicb.2023.1231503","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y., Yang, K.-d & Duan, H.-y Phage-based peptides for pancreatic cancer diagnosis and treatment: Alternative approach. Front. Microbiol. 14, 1231503 (2023).","journal-title":"Front. Microbiol."},{"key":"2107_CR627","doi-asserted-by":"publisher","first-page":"38053","DOI":"10.1021\/acsomega.2c05539","volume":"7","author":"SK Chan","year":"2022","unstructured":"Chan, S. K. et al. Isolation of a peptide that binds to Pseudomonas aeruginosa lytic bacteriophage. ACS omega 7, 38053\u201338060 (2022).","journal-title":"ACS omega"},{"key":"2107_CR628","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1021\/acsinfecdis.0c00206","volume":"6","author":"M Kelly","year":"2020","unstructured":"Kelly, M. et al. Peptide Probes of Colistin Resistance Discovered via Chemically Enhanced Phage Display. ACS Infect. Dis. 6, 2410\u20132418 (2020).","journal-title":"ACS Infect. Dis."},{"key":"2107_CR629","doi-asserted-by":"publisher","first-page":"146306","DOI":"10.1016\/j.brainres.2019.146306","volume":"1721","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Early detection of Alzheimer\u2019s disease by peptides from phage display screening. Brain Res 1721, 146306 (2019).","journal-title":"Brain Res"},{"key":"2107_CR630","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.7150\/thno.68636","volume":"12","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhang, X., Gao, H. & Qing, G. Phage display derived peptides for alzheimer\u2019s disease therapy and diagnosis. Theranostics 12, 2041 (2022).","journal-title":"Theranostics"},{"key":"2107_CR631","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41420-024-01822-w","volume":"10","author":"F Yu","year":"2024","unstructured":"Yu, F. et al. Generation of a new therapeutic d-peptide that induces the differentiation of acute myeloid leukemia cells through A TLR-2 signaling pathway. Cell Death Discov. 10, 51 (2024).","journal-title":"Cell Death Discov."},{"key":"2107_CR632","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nchembio.184","volume":"5","author":"C Heinis","year":"2009","unstructured":"Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502\u2013507 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"2107_CR633","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3390\/v15091903","volume":"15","author":"RK Fran\u00e7a","year":"2023","unstructured":"Fran\u00e7a, R. K. et al. Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy. Viruses 15, 1903 (2023).","journal-title":"Viruses"},{"key":"2107_CR634","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1021\/acschembio.2c00565","volume":"17","author":"JT Hampton","year":"2022","unstructured":"Hampton, J. T. et al. Novel regioselective approach to cyclize phage-displayed peptides in combination with epitope-directed selection to identify a potent neutralizing macrocyclic peptide for SARS-CoV-2. ACS Chem. Biol. 17, 2911\u20132922 (2022).","journal-title":"ACS Chem. Biol."},{"key":"2107_CR635","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39158-1","volume":"14","author":"KU Gaynor","year":"2023","unstructured":"Gaynor, K. U. et al. Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. Nat. Commun. 14, 3583 (2023).","journal-title":"Nat. Commun."},{"key":"2107_CR636","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1021\/jacs.3c09615","volume":"146","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. MYC-targeting inhibitors generated from a stereodiversified bicyclic peptide library. J. Am. Chem. Soc. 146, 1356\u20131363 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR637","doi-asserted-by":"publisher","first-page":"962124","DOI":"10.3389\/fmicb.2022.962124","volume":"13","author":"AS Andre","year":"2022","unstructured":"Andre, A. S., Moutinho, I., Dias, J. N. R. & Aires-da-Silva, F. In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front. Microbiol. 13, 962124 (2022).","journal-title":"Front. Microbiol."},{"key":"2107_CR638","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s40425-019-0705-y","volume":"7","author":"L Hao","year":"2019","unstructured":"Hao, L. et al. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. J. Immunother. Cancer 7, 270 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2107_CR639","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jconrel.2022.07.018","volume":"349","author":"T Hailing","year":"2022","unstructured":"Hailing, T., Yonghong, P., Yufeng, Z. & Haitao, T. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment. J. Control. Release 349, 592\u2013605 (2022).","journal-title":"J. Control. Release"},{"key":"2107_CR640","doi-asserted-by":"publisher","first-page":"114081","DOI":"10.1016\/j.bios.2022.114081","volume":"205","author":"R da Fonseca Alves","year":"2022","unstructured":"da Fonseca Alves, R. et al. A novel peptide-based electrochemical biosensor for breast cancer characterization over a poly 3-(3-aminophenyl) propionic acid matrix. Biosens. Bioelectron. 205, 114081 (2022).","journal-title":"Biosens. Bioelectron."},{"key":"2107_CR641","doi-asserted-by":"publisher","first-page":"111814","DOI":"10.1016\/j.ejmech.2019.111814","volume":"185","author":"H Kim","year":"2020","unstructured":"Kim, H., Jang, J. H., Kim, S. C. & Cho, J. H. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa. Eur. J. Med. Chem. 185, 111814 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR642","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0167-7799(02)00006-9","volume":"21","author":"SY Lee","year":"2003","unstructured":"Lee, S. Y., Choi, J. H. & Xu, Z. Microbial cell-surface display. Trends Biotechnol. 21, 45\u201352 (2003).","journal-title":"Trends Biotechnol."},{"key":"2107_CR643","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1438-4221(00)80004-1","volume":"290","author":"H L\u00e5ng","year":"2000","unstructured":"L\u00e5ng, H. Outer membrane proteins as surface display systems. Int. J. Med. Microbiol. 290, 579\u2013585 (2000).","journal-title":"Int. J. Med. Microbiol."},{"key":"2107_CR644","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijbiomac.2022.03.113","volume":"208","author":"SZB Mahdavi","year":"2022","unstructured":"Mahdavi, S. Z. B. et al. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. Int. J. Biol. Macromol. 208, 421\u2013442 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"2107_CR645","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1002\/cbic.202000203","volume":"21","author":"E Csibra","year":"2020","unstructured":"Csibra, E., Renders, M. & Pinheiro, V. B. Bacterial Cell Display as a Robust and Versatile Platform for Engineering Low\u2010Affinity Ligands and Enzymes. ChemBioChem 21, 2844\u20132853 (2020).","journal-title":"ChemBioChem"},{"key":"2107_CR646","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43720-8","volume":"13","author":"VB Cioffi","year":"2023","unstructured":"Cioffi, V. B. et al. SARS-CoV-2 Spike protein peptides displayed in the Pyrococcus furiosus RAD system preserve epitopes antigenicity, immunogenicity, and virus-neutralizing activity of antibodies. Sci. Rep. 13, 16821 (2023).","journal-title":"Sci. Rep."},{"key":"2107_CR647","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1126\/science.aat0576","volume":"359","author":"X-H Li","year":"2018","unstructured":"Li, X.-H., Chavali, P. L. & Babu, M. M. Capturing dynamic protein interactions. Science 359, 1105\u20131106 (2018).","journal-title":"Science"},{"key":"2107_CR648","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/mps6010001","volume":"6","author":"DW-S Koh","year":"2022","unstructured":"Koh, D. W.-S., Tay, J.-H. & Gan, S. K.-E. Engineering Ag43 Signal Peptides with Bacterial Display and Selection. Methods Protoc. 6, 1 (2022).","journal-title":"Methods Protoc."},{"key":"2107_CR649","first-page":"4358","volume":"39","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Advances in the application of yeast surface display technology. Chin. J. Biotechnol. 39, 4358\u20134375 (2023).","journal-title":"Chin. J. Biotechnol."},{"key":"2107_CR650","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-2748-7_8","volume":"1319","author":"GM Cherf","year":"2015","unstructured":"Cherf, G. M. & Cochran, J. R. Applications of yeast surface display for protein engineering. Methods Mol. Biol. 1319, 155\u2013175 (2015).","journal-title":"Methods Mol. Biol."},{"key":"2107_CR651","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/microorganisms11010125","volume":"11","author":"S Shibasaki","year":"2023","unstructured":"Shibasaki, S. & Ueda, M. Progress of Molecular Display Technology Using Saccharomyces cerevisiae to Achieve Sustainable Development Goals. Microorganisms 11, 125 (2023).","journal-title":"Microorganisms"},{"key":"2107_CR652","doi-asserted-by":"publisher","first-page":"1056804","DOI":"10.3389\/fbioe.2022.1056804","volume":"10","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Saccharomyces cerevisiae cell surface display technology: Strategies for improvement and applications. Front Bioeng. Biotechnol. 10, 1056804 (2022).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2107_CR653","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-020-01316-1","volume":"19","author":"H Lei","year":"2020","unstructured":"Lei, H. et al. Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice. Microb. Cell. Fact. 19, 1\u20139 (2020).","journal-title":"Microb. Cell. Fact."},{"key":"2107_CR654","doi-asserted-by":"publisher","first-page":"dmm049309","DOI":"10.1242\/dmm.049309","volume":"15","author":"AH Kachroo","year":"2022","unstructured":"Kachroo, A. H., Vandeloo, M., Greco, B. M. & Abdullah, M. Humanized yeast to model human biology, disease and evolution. Dis. Model. Mech. 15, dmm049309 (2022).","journal-title":"Dis. Model. Mech."},{"key":"2107_CR655","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/13543776.2020.1781816","volume":"30","author":"F Roohvand","year":"2020","unstructured":"Roohvand, F. et al. Biomedical applications of yeasts-a patent view, part two: era of humanized yeasts and expanded applications. Expert Opin. Ther. Pat. 30, 609\u2013631 (2020).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2107_CR656","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41423-021-00717-5","volume":"18","author":"R Liu","year":"2021","unstructured":"Liu, R., Jiang, W. & Mellins, E. D. Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA). Cell. Mol. Immunol. 18, 1847\u20131860 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"2107_CR657","doi-asserted-by":"publisher","first-page":"102913","DOI":"10.1016\/j.jbc.2023.102913","volume":"299","author":"BD Huisman","year":"2023","unstructured":"Huisman, B. D., Balivada, P. A. & Birnbaum, M. E. Yeast display platform with expression of linear peptide epitopes for high-throughput assessment of peptide-MHC-II binding. J. Biol. Chem. 299, 102913 (2023).","journal-title":"J. Biol. Chem."},{"key":"2107_CR658","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/biot.201500579","volume":"11","author":"JJ Priola","year":"2016","unstructured":"Priola, J. J. et al. High\u2010throughput screening and selection of mammalian cells for enhanced protein production. Biotechnol. J. 11, 853\u2013865 (2016).","journal-title":"Biotechnol. J."},{"key":"2107_CR659","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/bit.1064","volume":"73","author":"KW Liao","year":"2001","unstructured":"Liao, K. W., Chou, W. C., Lo, Y. C. & Roffler, S. R. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol. Bioeng. 73, 313\u2013323 (2001).","journal-title":"Biotechnol. Bioeng."},{"key":"2107_CR660","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ymeth.2013.06.010","volume":"65","author":"PM Bowers","year":"2014","unstructured":"Bowers, P. M. et al. Mammalian cell display for the discovery and optimization of antibody therapeutics. Methods 65, 44\u201356 (2014).","journal-title":"Methods"},{"key":"2107_CR661","doi-asserted-by":"publisher","first-page":"18436","DOI":"10.1074\/jbc.RA120.015053","volume":"295","author":"N Robertson","year":"2020","unstructured":"Robertson, N. et al. Development of a novel mammalian display system for selection of antibodies against membrane proteins. J. Biol. Chem. 295, 18436\u201318448 (2020).","journal-title":"J. Biol. Chem."},{"key":"2107_CR662","doi-asserted-by":"publisher","first-page":"1170081","DOI":"10.3389\/fbioe.2023.1170081","volume":"11","author":"O Huhtinen","year":"2023","unstructured":"Huhtinen, O., Salbo, R., Lamminm\u00e4ki, U. & Prince, S. Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform. Front Bioeng. Biotechnol. 11, 1170081 (2023).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2107_CR663","first-page":"59","volume":"185","author":"J Li","year":"2023","unstructured":"Li, J. et al. Cell-Free Display Techniques for Protein Evolution. Adv. Biochem. Eng. Biotechnol. 185, 59\u201390 (2023).","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"2107_CR664","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/antib9030028","volume":"9","author":"A Kunamneni","year":"2020","unstructured":"Kunamneni, A., Ogaugwu, C., Bradfute, S. & Durvasula, R. Ribosome display technology: applications in disease diagnosis and control. Antibodies 9, 28 (2020).","journal-title":"Antibodies"},{"key":"2107_CR665","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1021\/acssynbio.2c00563","volume":"12","author":"A Ohoka","year":"2023","unstructured":"Ohoka, A. & Sarkar, C. A. Facile Display of Homomultivalent Proteins for In Vitro Selections. ACS Synth. Biol. 12, 634\u2013638 (2023).","journal-title":"ACS Synth. Biol."},{"key":"2107_CR666","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.1021\/jacs.3c04833","volume":"145","author":"SE Iskandar","year":"2023","unstructured":"Iskandar, S. E. et al. Identification of Covalent Cyclic Peptide Inhibitors in mRNA Display. J. Am. Chem. Soc. 145, 15065\u201315070 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2107_CR667","doi-asserted-by":"publisher","first-page":"1067833","DOI":"10.3389\/fnins.2023.1067833","volume":"17","author":"R Maz\u00f3n-Cabrera","year":"2023","unstructured":"Maz\u00f3n-Cabrera, R. et al. Novel maternal autoantibodies in autism spectrum disorder: Implications for screening and diagnosis. Front. Neurosci. 17, 1067833 (2023).","journal-title":"Front. Neurosci."},{"key":"2107_CR668","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/protein\/gzt003","volume":"26","author":"S Patel","year":"2013","unstructured":"Patel, S., Mathonet, P., Jaulent, A. M. & Ullman, C. G. Selection of a high-affinity WW domain against the extracellular region of VEGF receptor isoform-2 from a combinatorial library using CIS display. Protein Eng. Des. Sel. 26, 307\u2013315 (2013).","journal-title":"Protein Eng. Des. Sel."},{"key":"2107_CR669","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2022040322","volume":"40","author":"R Thakur","year":"2023","unstructured":"Thakur, R., Suri, C. R., Kaur, I. P. & Rishi, P. Peptides as diagnostic, therapeutic, and theranostic tools: progress and future challenges. Crit. Rev. Ther. Drug Carr. Syst. 40, 49\u2013100 (2023).","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"2107_CR670","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.drudis.2022.103464","volume":"28","author":"K Sharma","year":"2023","unstructured":"Sharma, K., Sharma, K. K., Sharma, A. & Jain, R. Peptide-based drug discovery: Current status and recent advances. Drug Discov. Today 28, 103464 (2023).","journal-title":"Drug Discov. Today"},{"key":"2107_CR671","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1021\/acs.jcim.2c01485","volume":"63","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Deep Learning-Based Bioactive Therapeutic Peptide Generation and Screening. J. Chem. Inf. Model. 63, 835\u2013845 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"2107_CR672","doi-asserted-by":"publisher","first-page":"105740","DOI":"10.1016\/j.antiviral.2023.105740","volume":"220","author":"PP Parvatikar","year":"2023","unstructured":"Parvatikar, P. P. et al. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antivir. Res 220, 105740 (2023).","journal-title":"Antivir. Res"},{"key":"2107_CR673","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3390\/ijms24032026","volume":"24","author":"C Sarkar","year":"2023","unstructured":"Sarkar, C. et al. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int. J. Mol. Sci. 24, 2026 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR674","doi-asserted-by":"publisher","first-page":"134690","DOI":"10.1016\/j.foodchem.2022.134690","volume":"404","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Deep learning drives efficient discovery of novel antihypertensive peptides from soybean protein isolate. Food Chem. 404, 134690 (2023).","journal-title":"Food Chem."},{"key":"2107_CR675","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4155\/fmc-2021-0243","volume":"14","author":"SA Kumar","year":"2021","unstructured":"Kumar, S. A. et al. Machine learning and deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry. Future Med. Chem. 14, 245\u2013270 (2021).","journal-title":"Future Med. Chem."},{"key":"2107_CR676","doi-asserted-by":"publisher","first-page":"116262","DOI":"10.1016\/j.ejmech.2024.116262","volume":"268","author":"X Wu","year":"2024","unstructured":"Wu, X., Lin, H., Bai, R. & Duan, H. Deep learning for advancing peptide drug development: Tools and methods in structure prediction and design. Eur. J. Med. Chem. 268, 116262 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2107_CR677","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/17460441.2023.2250721","volume":"18","author":"A Cesaro","year":"2023","unstructured":"Cesaro, A. et al. Deep learning tools to accelerate antibiotic discovery. Expert Opin. Drug Dis. 18, 1245\u20131257 (2023).","journal-title":"Expert Opin. Drug Dis."},{"key":"2107_CR678","doi-asserted-by":"publisher","first-page":"bbad058","DOI":"10.1093\/bib\/bbad058","volume":"24","author":"Q Cao","year":"2023","unstructured":"Cao, Q. et al. Designing antimicrobial peptides using deep learning and molecular dynamic simulations. Brief. Bioinform. 24, bbad058 (2023).","journal-title":"Brief. Bioinform."},{"key":"2107_CR679","doi-asserted-by":"publisher","first-page":"1007635","DOI":"10.3389\/fgene.2022.1007635","volume":"13","author":"R Ge","year":"2022","unstructured":"Ge, R., Dong, C., Wang, J. & Wei, Y. Machine learning for peptide structure, function, and design. Front. Genet. 13, 1007635 (2022).","journal-title":"Front. Genet."},{"key":"2107_CR680","doi-asserted-by":"publisher","first-page":"2201988","DOI":"10.1002\/advs.202201988","volume":"9","author":"C Li","year":"2022","unstructured":"Li, C. et al. Machine Learning Guides Peptide Nucleic Acid Flow Synthesis and Sequence Design. Adv. Sci. 9, 2201988 (2022).","journal-title":"Adv. Sci."},{"key":"2107_CR681","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s42004-023-01029-7","volume":"6","author":"P Bryant","year":"2023","unstructured":"Bryant, P. & Elofsson, A. Peptide binder design with inverse folding and protein structure prediction. Comm. Chem. 6, 229 (2023).","journal-title":"Comm. Chem."},{"key":"2107_CR682","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.jafc.1c06110","volume":"70","author":"A Vidal-Limon","year":"2022","unstructured":"Vidal-Limon, A., Aguilar-Toal\u00e1, J. E. & Liceaga, A. M. Integration of Molecular Docking Analysis and Molecular Dynamics Simulations for Studying Food Proteins and Bioactive Peptides. J. Agric. Food Chem. 70, 934\u2013943 (2022).","journal-title":"J. Agric. Food Chem."},{"key":"2107_CR683","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","volume":"60","author":"H Guterres","year":"2020","unstructured":"Guterres, H. & Im, W. Improving Protein-Ligand Docking Results with High-Throughput Molecular Dynamics Simulations. J. Chem. Inf. Model. 60, 2189\u20132198 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"2107_CR684","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.csbj.2023.03.051","volume":"21","author":"B Wang","year":"2023","unstructured":"Wang, B., Razavi, S. & Gamazon, E. R. Towards mechanistic models of mutational effects: Deep learning on Alzheimer\u2019s A\u03b2 peptide. Comp. Struct. Biotechnol. J. 21, 2434\u20132445 (2023).","journal-title":"Comp. Struct. Biotechnol. J."},{"key":"2107_CR685","first-page":"411","volume":"11","author":"A Bolatchiev","year":"2022","unstructured":"Bolatchiev, A., Baturin, V., Shchetinin, E. & Bolatchieva, E. Novel Antimicrobial Peptides Designed Using a Recurrent Neural Network Reduce Mortality in Experimental Sepsis. Antibiotics. lElectroencephalography Clin. Neurophysiol. Suppl. 11, 411 (2022).","journal-title":"Antibiotics. lElectroencephalography Clin. Neurophysiol. Suppl."},{"key":"2107_CR686","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36994-z","volume":"14","author":"P Szymczak","year":"2023","unstructured":"Szymczak, P. et al. Discovering highly potent antimicrobial peptides with deep generative model HydrAMP. Nat. Commun. 14, 1453 (2023).","journal-title":"Nat. Commun."},{"key":"2107_CR687","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13321-019-0397-9","volume":"11","author":"O Prykhodko","year":"2019","unstructured":"Prykhodko, O. et al. A de novo molecular generation method using latent vector based generative adversarial network. J. Cheminform. 11, 74 (2019).","journal-title":"J. Cheminform."},{"key":"2107_CR688","doi-asserted-by":"publisher","first-page":"btad036","DOI":"10.1093\/bioinformatics\/btad036","volume":"39","author":"X Xie","year":"2023","unstructured":"Xie, X., Valiente, P. A. & Kim, P. M. HelixGAN a deep-learning methodology for conditional de novo design of \u03b1-helix structures. Bioinformatics 39, btad036 (2023).","journal-title":"Bioinformatics"},{"key":"2107_CR689","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-023-06953-1","volume":"626","author":"S V\u00e1zquez Torres","year":"2024","unstructured":"V\u00e1zquez Torres, S. et al. De novo design of high-affinity binders of bioactive helical peptides. Nature 626, 435\u2013442 (2024).","journal-title":"Nature"},{"key":"2107_CR690","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41312-8","volume":"14","author":"F Mihali\u010d","year":"2023","unstructured":"Mihali\u010d, F. et al. Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets. Nat. Commun. 14, 5636 (2023).","journal-title":"Nat. Commun."},{"key":"2107_CR691","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","volume":"605","author":"L Cao","year":"2022","unstructured":"Cao, L. et al. Design of protein-binding proteins from the target structure alone. Nature 605, 551\u2013560 (2022).","journal-title":"Nature"},{"key":"2107_CR692","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-021-00644-3","volume":"24","author":"S Kolluri","year":"2022","unstructured":"Kolluri, S. et al. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 24, 1\u201310 (2022).","journal-title":"AAPS J."},{"key":"2107_CR693","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.drudis.2021.01.008","volume":"26","author":"SR Khan","year":"2021","unstructured":"Khan, S. R., Al Rijjal, D., Piro, A. & Wheeler, M. B. Integration of AI and traditional medicine in drug discovery. Drug Discov. Today 26, 982\u2013992 (2021).","journal-title":"Drug Discov. Today"},{"key":"2107_CR694","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.2174\/1381612826666200515131245","volume":"26","author":"A Thakur","year":"2020","unstructured":"Thakur, A. et al. Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies. Curr. Pharm. Des. 26, 3569\u20133578 (2020).","journal-title":"Curr. Pharm. Des."},{"key":"2107_CR695","doi-asserted-by":"publisher","first-page":"20170387","DOI":"10.1098\/rsif.2017.0387","volume":"15","author":"T Ching","year":"2018","unstructured":"Ching, T. et al. Opportunities and obstacles for deep learning in biology and medicine. J. R. Soc. Interface 15, 20170387 (2018).","journal-title":"J. R. Soc. Interface"},{"key":"2107_CR696","doi-asserted-by":"publisher","first-page":"bbab569","DOI":"10.1093\/bib\/bbab569","volume":"23","author":"SR Stahlschmidt","year":"2022","unstructured":"Stahlschmidt, S. R., Ulfenborg, B. & Synnergren, J. Multimodal deep learning for biomedical data fusion: a review. Brief. Bioinform. 23, bbab569 (2022).","journal-title":"Brief. Bioinform."},{"key":"2107_CR697","doi-asserted-by":"publisher","first-page":"e210014","DOI":"10.1148\/ryai.2021210014","volume":"3","author":"S Candemir","year":"2021","unstructured":"Candemir, S., Nguyen, X. V., Folio, L. R. & Prevedello, L. M. Training Strategies for Radiology Deep Learning Models in Data-limited Scenarios. Radio. Artif. Intell. 3, e210014 (2021).","journal-title":"Radio. Artif. Intell."},{"key":"2107_CR698","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3578938","volume":"55","author":"G Menghani","year":"2023","unstructured":"Menghani, G. Efficient deep learning: A survey on making deep learning models smaller, faster, and better. ACM Comput. Surv. 55, 1\u201337 (2023).","journal-title":"ACM Comput. Surv."},{"key":"2107_CR699","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"S Mitragotri","year":"2014","unstructured":"Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655\u2013672 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2107_CR700","doi-asserted-by":"publisher","first-page":"024103","DOI":"10.1088\/1748-605X\/ac494c","volume":"17","author":"X Yuan","year":"2022","unstructured":"Yuan, X. et al. Smart delivery of poly-peptide composite for effective cancer therapy. Biomed. Mater. 17, 024103 (2022).","journal-title":"Biomed. Mater."},{"key":"2107_CR701","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biomaterials.2012.08.070","volume":"34","author":"CY Dombu","year":"2013","unstructured":"Dombu, C. Y. & Betbeder, D. Airway delivery of peptides and proteins using nanoparticles. Biomaterials 34, 516\u2013525 (2013).","journal-title":"Biomaterials"},{"key":"2107_CR702","doi-asserted-by":"publisher","first-page":"20170030","DOI":"10.1098\/rsfs.2017.0030","volume":"7","author":"KL Zapadka","year":"2017","unstructured":"Zapadka, K. L., Becher, F. J., Gomes dos Santos, A. L. & Jackson, S. E. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus 7, 20170030 (2017).","journal-title":"Interface Focus"},{"key":"2107_CR703","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12951-015-0136-y","volume":"13","author":"G Sharma","year":"2015","unstructured":"Sharma, G. et al. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J. Nanobiotechnol. 13, 74 (2015).","journal-title":"J. Nanobiotechnol."},{"key":"2107_CR704","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","volume":"321","author":"DS Collins","year":"2020","unstructured":"Collins, D. S., S\u00e1nchez-F\u00e9lix, M., Badkar, A. V. & Mrsny, R. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J. Control. Release 321, 475\u2013482 (2020).","journal-title":"J. Control. Release"},{"key":"2107_CR705","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/IJN.S283416","volume":"16","author":"C Li","year":"2021","unstructured":"Li, C. et al. Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment. Int. J. Nanomed. 16, 1261\u20131280 (2021).","journal-title":"Int. J. Nanomed."},{"key":"2107_CR706","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Y Su","year":"2021","unstructured":"Su, Y. et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 28, 1397\u20131418 (2021).","journal-title":"Drug Deliv."},{"key":"2107_CR707","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0169-409X(01)00203-4","volume":"53","author":"Y Qiu","year":"2001","unstructured":"Qiu, Y. & Park, K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Del. Rev. 53, 321\u2013339 (2001).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR708","doi-asserted-by":"publisher","first-page":"122401","DOI":"10.1016\/j.biomaterials.2023.122401","volume":"303","author":"MH Barlek","year":"2023","unstructured":"Barlek, M. H. et al. Systemic peptide amphiphile nanofiber delivery following subcutaneous injection. Biomaterials 303, 122401 (2023).","journal-title":"Biomaterials"},{"key":"2107_CR709","doi-asserted-by":"publisher","first-page":"1144963","DOI":"10.3389\/fbioe.2023.1144963","volume":"11","author":"M Du","year":"2023","unstructured":"Du, M. et al. Establishment of ultrasound-responsive SonoBacteriaBot for targeted drug delivery and controlled release. Front Bioeng. Biotechnol. 11, 1144963 (2023).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2107_CR710","doi-asserted-by":"publisher","first-page":"123266","DOI":"10.1016\/j.ijpharm.2023.123266","volume":"643","author":"X Yi","year":"2023","unstructured":"Yi, X. et al. Visually controlled pulsatile release of insulin from chitosan poly-acrylic acid nanobubbles triggered by focused ultrasound. Int. J. Pharm. 643, 123266 (2023).","journal-title":"Int. J. Pharm."},{"key":"2107_CR711","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.7150\/thno.61747","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. Oral delivery of protein and peptide drugs: From non-specific formulation approaches to intestinal cell targeting strategies. Theranostics 12, 1419 (2022).","journal-title":"Theranostics"},{"key":"2107_CR712","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1039\/C8FO01450G","volume":"9","author":"L Sams","year":"2018","unstructured":"Sams, L. et al. Characterization of pepsin from rabbit gastric extract, its action on \u03b2-casein and the effects of lipids on proteolysis. Food Funct. 9, 5975\u20135988 (2018).","journal-title":"Food Funct."},{"key":"2107_CR713","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1055\/s-0036-1588840","volume":"28","author":"CW Torn\u00f8e","year":"2017","unstructured":"Torn\u00f8e, C. W., Johansson, E. & Wahlund, P.-O. Divergent Protein Synthesis of Bowman\u2013Birk Protease Inhibitors, their Hydrodynamic Behavior and Co-crystallization with \u03b1-Chymotrypsin. Synlett 28, 1901\u20131906 (2017).","journal-title":"Synlett"},{"key":"2107_CR714","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2016.04.008","volume":"110-111","author":"H Wang","year":"2017","unstructured":"Wang, H., Feng, Z. & Xu, B. D-amino acid-containing supramolecular nanofibers for potential cancer therapeutics. Adv. Drug Del. Rev. 110-111, 102\u2013111 (2017).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR715","doi-asserted-by":"publisher","first-page":"102638","DOI":"10.1016\/j.cis.2022.102638","volume":"302","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Strategies for improving the safety and RNAi efficacy of noncovalent peptide\/siRNA nanocomplexes. Adv. Colloid Interface Sci. 302, 102638 (2022).","journal-title":"Adv. Colloid Interface Sci."},{"key":"2107_CR716","doi-asserted-by":"publisher","first-page":"116728","DOI":"10.1016\/j.bmc.2022.116728","volume":"61","author":"K Shinga","year":"2022","unstructured":"Shinga, K. et al. L17ER4: A cell-permeable attenuated cationic amphiphilic lytic peptide. Biorg. Med. Chem. 61, 116728 (2022).","journal-title":"Biorg. Med. Chem."},{"key":"2107_CR717","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1021\/acs.bioconjchem.0c00152","volume":"31","author":"SM Meier-Menches","year":"2020","unstructured":"Meier-Menches, S. M. & Casini, A. Design Strategies and Medicinal Applications of Metal-Peptidic Bioconjugates. Bioconjugate Chem. 31, 1279\u20131288 (2020).","journal-title":"Bioconjugate Chem."},{"key":"2107_CR718","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1039\/D1OB00411E","volume":"19","author":"HC Hayes","year":"2021","unstructured":"Hayes, H. C., Luk, L. Y. P. & Tsai, Y.-H. Approaches for peptide and protein cyclisation. Org. Biomol. Chem. 19, 3983\u20134001 (2021).","journal-title":"Org. Biomol. Chem."},{"key":"2107_CR719","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cbpa.2017.04.012","volume":"38","author":"MR Naylor","year":"2017","unstructured":"Naylor, M. R., Bockus, A. T., Blanco, M.-J. & Lokey, R. S. Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets. Curr. Opin. Chem. Biol. 38, 141\u2013147 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2107_CR720","doi-asserted-by":"publisher","first-page":"2181744","DOI":"10.1080\/10717544.2023.2181744","volume":"30","author":"J He","year":"2023","unstructured":"He, J. et al. Folic acid-modified reverse micelle-lipid nanocapsules overcome intestinal barriers and improve the oral delivery of peptides. Drug Deliv. 30, 2181744 (2023).","journal-title":"Drug Deliv."},{"key":"2107_CR721","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF01922409","volume":"52","author":"HF St\u00e4helin","year":"1996","unstructured":"St\u00e4helin, H. F. The history of cyclosporin A (Sandimmune\u00ae) revisited: Another point of view. Experientia 52, 5\u201313 (1996).","journal-title":"Experientia"},{"key":"2107_CR722","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1016\/j.cell.2022.07.019","volume":"185","author":"G Bhardwaj","year":"2022","unstructured":"Bhardwaj, G. et al. Accurate de novo design of membrane-traversing macrocycles. Cell 185, 3520\u20133532 (2022).","journal-title":"Cell"},{"key":"2107_CR723","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/acs.accounts.2c00108","volume":"55","author":"Y Zheng","year":"2022","unstructured":"Zheng, Y., Cong, Y., Schmidt, E. W. & Nair, S. K. Catalysts for the Enzymatic Lipidation of Peptides. Acc. Chem. Res. 55, 1313\u20131323 (2022).","journal-title":"Acc. Chem. Res."},{"key":"2107_CR724","doi-asserted-by":"publisher","first-page":"122238","DOI":"10.1016\/j.ijpharm.2022.122238","volume":"628","author":"S Berg","year":"2022","unstructured":"Berg, S. et al. Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers. Int. J. Pharm. 628, 122238 (2022).","journal-title":"Int. J. Pharm."},{"key":"2107_CR725","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.4155\/fmc-2020-0140","volume":"12","author":"A Falanga","year":"2020","unstructured":"Falanga, A. et al. The world of cell penetrating: the future of medical applications. Future Med. Chem. 12, 1431\u20131446 (2020).","journal-title":"Future Med. Chem."},{"key":"2107_CR726","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1080\/17425247.2022.2152791","volume":"19","author":"D Sanjanwala","year":"2022","unstructured":"Sanjanwala, D. et al. Polysaccharide-based hydrogels for drug delivery and wound management: a review. Expert Opin. Drug Deliv. 19, 1664\u20131695 (2022).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2107_CR727","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.2147\/DDDT.S217211","volume":"13","author":"M Doostmohammadi","year":"2019","unstructured":"Doostmohammadi, M. et al. Hydrogels For Peptide Hormones Delivery: Therapeutic And Tissue Engineering Applications. Drug Des. Devel. Ther. 13, 3405\u20133418 (2019).","journal-title":"Drug Des. Devel. Ther."},{"key":"2107_CR728","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11102-016-0785-3","volume":"20","author":"NR Biermasz","year":"2017","unstructured":"Biermasz, N. R. New medical therapies on the horizon: oral octreotide. Pituitary 20, 149\u2013153 (2017).","journal-title":"Pituitary"},{"key":"2107_CR729","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.drudis.2021.01.001","volume":"26","author":"SK Dubey","year":"2021","unstructured":"Dubey, S. K. et al. Oral peptide delivery: challenges and the way ahead. Drug Discov. Today 26, 931\u2013950 (2021).","journal-title":"Drug Discov. Today"},{"key":"2107_CR730","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. 10, 155 (2019).","journal-title":"Front. Endocrinol."},{"key":"2107_CR731","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acs.jmedchem.1c01599","volume":"64","author":"TJ Tucker","year":"2021","unstructured":"Tucker, T. J. et al. A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors. J. Med. Chem. 64, 16770\u201316800 (2021).","journal-title":"J. Med. Chem."},{"key":"2107_CR732","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41565-023-01565-2","volume":"19","author":"NJ Hunt","year":"2024","unstructured":"Hunt, N. J. et al. Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia. Nat. Nanotechnol. 19, 534\u2013544 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2107_CR733","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.drudis.2022.04.014","volume":"27","author":"E Kaffash","year":"2022","unstructured":"Kaffash, E., Shahbazi, M.-A., Hatami, H. & Nokhodchi, A. An insight into gastrointestinal macromolecule delivery using physical oral devices. Drug Discov. Today 27, 2309\u20132321 (2022).","journal-title":"Drug Discov. Today"},{"key":"2107_CR734","doi-asserted-by":"publisher","first-page":"109706","DOI":"10.1016\/j.cbi.2021.109706","volume":"351","author":"DK Chellappan","year":"2022","unstructured":"Chellappan, D. K. et al. Protein and peptide delivery to lungs by using advanced targeted drug delivery. Chem. -Biol. Interact. 351, 109706 (2022).","journal-title":"Chem. -Biol. Interact."},{"key":"2107_CR735","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1124\/jpet.123.001690","volume":"388","author":"A Sanchit","year":"2024","unstructured":"Sanchit, A. et al. Recent Advances in Delivery of Peptide and Protein Therapeutics to the Brain. J. Pharmacol. Exp. Ther. 388, 54 (2024).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2107_CR736","doi-asserted-by":"publisher","first-page":"115139","DOI":"10.1016\/j.addr.2023.115139","volume":"203","author":"T Zhang","year":"2023","unstructured":"Zhang, T., Luo, X., Xu, K. & Zhong, W. Peptide-containing nanoformulations: Skin barrier penetration and activity contribution. Adv. Drug Del. Rev. 203, 115139 (2023).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR737","doi-asserted-by":"publisher","first-page":"114441","DOI":"10.1016\/j.addr.2022.114441","volume":"188","author":"SA Attia","year":"2022","unstructured":"Attia, S. A. & MacKay, J. A. Protein and polypeptide mediated delivery to the eye. Adv. Drug Del. Rev. 188, 114441 (2022).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR738","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/ijms19061778","volume":"19","author":"J Montgomery","year":"2018","unstructured":"Montgomery, J. et al. Connexin 43-Based Therapeutics for Dermal Wound Healing. Int. J. Mol. Sci. 19, 1778 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2107_CR739","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","volume":"16","author":"SE Alavi","year":"2019","unstructured":"Alavi, S. E., Cabot, P. J. & Moyle, P. M. Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency. Mol. Pharm. 16, 2278\u20132295 (2019).","journal-title":"Mol. Pharm."},{"key":"2107_CR740","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1002\/ncp.10974","volume":"38","author":"L Wauters","year":"2023","unstructured":"Wauters, L. & Joly, F. Treatment of short bowel syndrome: Breaking the therapeutic ceiling? Nutr. Clin. Pract. 38, S76\u2013S87 (2023).","journal-title":"Nutr. Clin. Pract."},{"key":"2107_CR741","doi-asserted-by":"publisher","first-page":"114864","DOI":"10.1016\/j.addr.2023.114864","volume":"197","author":"X Fan","year":"2023","unstructured":"Fan, X. et al. Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies. Adv. Drug Del. Rev. 197, 114864 (2023).","journal-title":"Adv. Drug Del. Rev."},{"key":"2107_CR742","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(23)01291-6","volume":"402","author":"CM Apovian","year":"2023","unstructured":"Apovian, C. M. & McDonnell, M. E. CagriSema and the link between obesity and type 2 diabetes. Lancet 402, 671\u2013673 (2023).","journal-title":"Lancet"},{"key":"2107_CR743","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2020.1750595","volume":"29","author":"M Bassetti","year":"2020","unstructured":"Bassetti, M., Del Puente, F., Magnasco, L. & Giacobbe, D. R. Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin. Investig. Drugs 29, 495\u2013506 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2107_CR744","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.molmet.2023.101762","volume":"75","author":"W Guo","year":"2023","unstructured":"Guo, W. et al. Discovery of ecnoglutide-a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol. Metab. 75, 101762 (2023).","journal-title":"Mol. Metab."},{"key":"2107_CR745","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","volume":"109","author":"I Takacs","year":"2024","unstructured":"Takacs, I. et al. An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. J. Clin. Endocrinol. Metab. 109, 2199\u20132209 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2107_CR746","first-page":"15","volume":"6","author":"V G\u00fczelbur\u00e7","year":"2019","unstructured":"G\u00fczelbur\u00e7, V. Nokt\u00fcri: De\u011ferlendirme ve Tedavi. Kontinans ve N.\u00f6ro\u00fcroloji B\u00fclteni 6, 15\u201312 (2019).","journal-title":"Kontinans ve N.\u00f6ro\u00fcroloji B\u00fclteni"},{"key":"2107_CR747","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/jpen.1767","volume":"44","author":"MK Hvistendahl","year":"2020","unstructured":"Hvistendahl, M. K. et al. Effect of glepaglutide, a long\u2010acting glucagon\u2010like peptide\u20102 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial. J. Parenter. Enter. Nutr. 44, 1535\u20131544 (2020).","journal-title":"J. Parenter. Enter. Nutr."},{"key":"2107_CR748","doi-asserted-by":"publisher","first-page":"JC6","DOI":"10.7326\/J23-0110","volume":"177","author":"A Liakos","year":"2024","unstructured":"Liakos, A., Karagiannis, T. & Tsapas, A. In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk. Ann. Intern. Med. 177, JC6 (2024).","journal-title":"Ann. Intern. Med."},{"key":"2107_CR749","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-021-04750-3","volume":"22","author":"M Bettonville","year":"2021","unstructured":"Bettonville, M. et al. Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan GF 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II\/III study. BMC Musculoskelet. Disord. 22, 1\u201315 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"2107_CR750","doi-asserted-by":"publisher","first-page":"SUN-609","DOI":"10.1210\/jendso\/bvaa046.1004","volume":"4","author":"R Harisseh","year":"2020","unstructured":"Harisseh, R., Delale, T., Yeh, M. & Allas, S. SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome. J. Endocr. Soc. 4, SUN-609 (2020).","journal-title":"J. Endocr. Soc."},{"key":"2107_CR751","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00134-020-06109-z","volume":"46","author":"B Fran\u00e7ois","year":"2020","unstructured":"Fran\u00e7ois, B. et al. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. Intensive Care Med 46, 1425\u20131437 (2020).","journal-title":"Intensive Care Med"},{"key":"2107_CR752","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill, M. D. et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395, 878\u2013887 (2020).","journal-title":"Lancet"},{"key":"2107_CR753","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.diagmicrobio.2016.06.012","volume":"86","author":"RK Flamm","year":"2016","unstructured":"Flamm, R. K., Rhomberg, P. R., Farrell, D. J. & Jones, R. N. In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagn. Microbiol. Infect. Dis. 86, 66\u201369 (2016).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"2107_CR754","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2017.07.035","volume":"153","author":"M Camilleri","year":"2017","unstructured":"Camilleri, M. et al. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology 153, 1240\u20131250 (2017).","journal-title":"Gastroenterology"},{"key":"2107_CR755","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00264-018-4245-8","volume":"43","author":"Y Sun","year":"2019","unstructured":"Sun, Y., Leung, V. Y. & Cheung, K. M. Clinical trials of intervertebral disc regeneration: current status and future developments. Int. Orthop. 43, 1003\u20131010 (2019).","journal-title":"Int. Orthop."},{"key":"2107_CR756","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR757","first-page":"225","volume":"29","author":"L Qian-yu","year":"2020","unstructured":"Qian-yu, L., Ling-Qian, D. U., Tian, D. & Shao-hua, G. E. Effects of exenatide-4 on proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells. Shanghai J. Stomatol. 29, 225 (2020).","journal-title":"Shanghai J. Stomatol."},{"key":"2107_CR758","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2021-149219","volume":"138","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek, S. et al. A phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera. Blood 138, 1504 (2021).","journal-title":"Blood"},{"key":"2107_CR759","doi-asserted-by":"publisher","first-page":"e074216","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen, T. K., Hoenig, M. P., Nitsch, D. & Grams, M. E. Advances in the management of chronic kidney disease. BMJ 383, e074216 (2023).","journal-title":"BMJ"},{"key":"2107_CR760","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/ggi.13782","volume":"19","author":"H Nakagami","year":"2019","unstructured":"Nakagami, H. et al. Investigator\u2010initiated clinical study of a functional peptide, SR\u20100379, for limb ulcers of patients with Werner syndrome as a pilot study. Geriatr. Gerontol. Int. 19, 1118\u20131123 (2019).","journal-title":"Geriatr. Gerontol. Int."},{"key":"2107_CR761","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162\u2013173 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2107_CR762","doi-asserted-by":"publisher","first-page":"937142","DOI":"10.3389\/fmed.2022.937142","volume":"9","author":"Z Yu","year":"2022","unstructured":"Yu, Z. et al. New, potent, small molecule agonists of tyrosine kinase receptors attenuate dry eye disease. Front. Med. 9, 937142 (2022).","journal-title":"Front. Med."},{"key":"2107_CR763","doi-asserted-by":"publisher","first-page":"697586","DOI":"10.3389\/fmolb.2021.697586","volume":"8","author":"W Cabri","year":"2021","unstructured":"Cabri, W. et al. Therapeutic peptides targeting PPI in clinical development: Overview, mechanism of action and perspectives. Front. Mol. Biosci. 8, 697586 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"2107_CR764","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/v12101092","volume":"12","author":"RA Al-Horani","year":"2020","unstructured":"Al-Horani, R. A. & Kar, S. Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: A comprehensive review. Viruses 12, 1092 (2020).","journal-title":"Viruses"},{"key":"2107_CR765","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14656566.2016.1161027","volume":"17","author":"K Al Wadi","year":"2016","unstructured":"Al Wadi, K. & Ghatage, P. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer. Expert Opin. Pharmacother. 17, 853\u2013860 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"2107_CR766","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer, M. et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N. Engl. J. Med. 376, 1956\u20131964 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2107_CR767","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2217\/fon-2021-1634","volume":"18","author":"J Bourhis","year":"2022","unstructured":"Bourhis, J. et al. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 18, 1669\u20131678 (2022).","journal-title":"Future Oncol."},{"key":"2107_CR768","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coph.2019.02.007","volume":"47","author":"G Guidotti","year":"2019","unstructured":"Guidotti, G., Brambilla, L. & Rossi, D. Peptides in clinical development for the treatment of brain tumors. Curr. Opin. Pharmacol. 47, 102\u2013109 (2019).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2107_CR769","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MAO.0000000000002229","volume":"40","author":"H Staecker","year":"2019","unstructured":"Staecker, H. et al. Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness\u2014A double-blind, randomized, placebo-controlled phase 3 study. Otol. Neurotol. 40, 584 (2019).","journal-title":"Otol. Neurotol."},{"key":"2107_CR770","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1124\/dmd.111.040725","volume":"39","author":"Y Miyaji","year":"2011","unstructured":"Miyaji, Y. et al. Distribution of KAI-9803, a novel \u03b4-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab. Disposition. 39, 1946\u20131953 (2011).","journal-title":"Drug Metab. Disposition."},{"key":"2107_CR771","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/pme.12058","volume":"14","author":"MJ Cousins","year":"2013","unstructured":"Cousins, M. J. et al. The safety and efficacy of KAI-1678\u2014an inhibitor of epsilon protein kinase C (\u03b5PKC)\u2014versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain. Med 14, 533\u2013540 (2013).","journal-title":"Pain. Med"},{"key":"2107_CR772","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.7150\/thno.20678","volume":"7","author":"M Miampamba","year":"2017","unstructured":"Miampamba, M. et al. Sensitive in vivo visualization of breast cancer using ratiometric protease-activatable fluorescent imaging agent, AVB-620. Theranostics 7, 3369 (2017).","journal-title":"Theranostics"},{"key":"2107_CR773","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ajo.2016.10.012","volume":"174","author":"C Chiquet","year":"2017","unstructured":"Chiquet, C. et al. Postoperative ocular inflammation: a single subconjunctival injection of XG-102 compared to dexamethasone drops in a randomized trial. Am. J. Ophthalmol. 174, 76\u201384 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"2107_CR774","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/IJN.S110274","volume":"11","author":"R Coriat","year":"2016","unstructured":"Coriat, R. et al. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int. J. Nanomed. 11, 6207\u20136216 (2016).","journal-title":"Int. J. Nanomed."},{"key":"2107_CR775","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","volume":"27","author":"MN Saleh","year":"2021","unstructured":"Saleh, M. N. et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin. Cancer Res. 27, 5236\u20135247 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2107_CR776","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","volume":"66","author":"V Guerlavais","year":"2023","unstructured":"Guerlavais, V. et al. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized \u03b1-helical peptide in clinical development. J. Med. Chem. 66, 9401\u20139417 (2023).","journal-title":"J. Med. Chem."},{"key":"2107_CR777","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/bioe.2020.0012","volume":"2","author":"CC Young","year":"2020","unstructured":"Young, C. C., Vedadghavami, A. & Bajpayee, A. G. Bioelectricity for drug delivery: the promise of cationic therapeutics. Bioelectricity 2, 68\u201381 (2020).","journal-title":"Bioelectricity"},{"key":"2107_CR778","doi-asserted-by":"publisher","first-page":"148732","DOI":"10.1016\/j.cej.2024.148732","volume":"481","author":"T Sun","year":"2024","unstructured":"Sun, T. et al. Visible-light-driven photo-Fenton oxidation enhanced by Fe\/Bi-nanocrystal phase transformation as a universal way for various organic pollutants mineralization. Chem. Eng. J. 481, 148732 (2024).","journal-title":"Chem. Eng. J."},{"key":"2107_CR779","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/jid.2008.264","volume":"129","author":"LB Lopes","year":"2009","unstructured":"Lopes, L. B. et al. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-\u03b21-induced CTGF expression in keloid fibroblasts. J. Invest. Dermatol. 129, 590\u2013598 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"2107_CR780","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1111\/ene.16020","volume":"30","author":"DN Weemering","year":"2023","unstructured":"Weemering, D. N. et al. A randomized, double\u2010blind, placebo\u2010controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 30, 3722\u20133731 (2023).","journal-title":"Eur. J. Neurol."},{"key":"2107_CR781","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mds.27353","volume":"33","author":"T Zesiewicz","year":"2018","unstructured":"Zesiewicz, T. et al. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich\u2019s ataxia. Mov. Disord. 33, 1000\u20131005 (2018).","journal-title":"Mov. Disord."},{"key":"2107_CR782","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1097\/DSS.0000000000000276","volume":"41","author":"E Garcia-Murray","year":"2015","unstructured":"Garcia-Murray, E. et al. Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: results of a phase 1\/2, open-label, sequential dose-escalation study. Dermatol. Surg. 41, S47\u2013S55 (2015).","journal-title":"Dermatol. Surg."},{"key":"2107_CR783","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918\u2013928 (2009).","journal-title":"Lancet Neurol."},{"key":"2107_CR784","first-page":"5764","volume":"49","author":"JT Doss Jr","year":"2008","unstructured":"Doss, J. T. Jr et al. Topical Phosphorodiamidate Morpholino Oligomer Antisense Compounds Effectivly Delay Cornea Rejection in a Transplant Rat Model. Invest. Ophthalmol. Vis. Sci. 49, 5764\u20135764 (2008).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2107_CR785","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/jop.2011.0135","volume":"28","author":"A Hosseini","year":"2012","unstructured":"Hosseini, A. et al. Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J. Ocul. Pharmacol. Ther. 28, 194\u2013201 (2012).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2107_CR786","first-page":"101","volume":"8","author":"F Su","year":"2020","unstructured":"Su, F. et al. Bovine HDL and dual domain HDL-mimetic peptides inhibit tumor development in mice. J. Cancer Res. Ther. 8, 101 (2020).","journal-title":"J. Cancer Res. Ther."},{"key":"2107_CR787","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.coph.2019.03.014","volume":"47","author":"T Jauset","year":"2019","unstructured":"Jauset, T. & Beaulieu, M.-E. Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead. Curr. Opin. Pharmacol. 47, 133\u2013140 (2019).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2107_CR788","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1158\/1538-7445.AM2023-6129","volume":"83","author":"R Farhat","year":"2023","unstructured":"Farhat, R. et al. The proapoptotic peptide PEP-010 is efficient on several models of different tumor origins and it can be monitored by pharmacodynamic biomarker candidates in clinical practice. Cancer Res 83, 6129\u20136129 (2023).","journal-title":"Cancer Res"},{"key":"2107_CR789","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar, P. et al. ANG1005, a brain-penetrating peptide\u2013drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin. Cancer Res. 26, 2789\u20132799 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2107_CR790","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/annonc\/mdv091.1","volume":"26","author":"S Bates","year":"2015","unstructured":"Bates, S. et al. ANG-1005 in Patients with Brain Metastases from Breast Cancer: Correlative Imaging with 18F-FLT-PET\/CT. Ann. Oncol. 26, ii20 (2015).","journal-title":"Ann. Oncol."},{"key":"2107_CR791","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0959-8049(16)32642-9","volume":"69","author":"G Bennett","year":"2016","unstructured":"Bennett, G. et al. Development of BT1718, a Bicycle Drug Conjugate\u00ae(BDC) targeting MT1-MMP for treatment of solid tumours. Eur. J. Cancer 69, S21 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2107_CR792","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","volume":"19","author":"G Bennett","year":"2020","unstructured":"Bennett, G. et al. MMAE delivery using the bicycle toxin conjugate BT5528. Mol. Cancer Ther. 19, 1385\u20131394 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2107_CR793","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3390\/cancers14081877","volume":"14","author":"J-C Currie","year":"2022","unstructured":"Currie, J.-C. et al. The peptide-drug conjugate th1902: a new sortilin receptor-mediated cancer therapeutic against ovarian and endometrial cancers. Cancers (Basel) 14, 1877 (2022).","journal-title":"Cancers (Basel)"},{"key":"2107_CR794","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/1538-7445.AM2020-1061","volume":"80","author":"M Demeule","year":"2020","unstructured":"Demeule, M. et al. Increasing potency of anticancer drugs through sortilin receptor-mediated cancer therapy: a new targeted approach for the treatment of ovarian cancer. Cancer Res 80, 1061\u20131061 (2020).","journal-title":"Cancer Res"},{"key":"2107_CR795","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/cancers11060833","volume":"11","author":"D Mahalingam","year":"2019","unstructured":"Mahalingam, D. et al. A phase II, multicenter, single-arm study of mipsagargin (G-202) as a second-line therapy following sorafenib for adult patients with progressive advanced hepatocellular carcinoma. Cancers (Basel) 11, 833 (2019).","journal-title":"Cancers (Basel)"},{"key":"2107_CR796","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","volume":"19","author":"V Gregorc","year":"2018","unstructured":"Gregorc, V. et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 19, 799\u2013811 (2018).","journal-title":"Lancet Oncol."},{"key":"2107_CR797","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.3390\/cancers12123536","volume":"12","author":"WE Berdel","year":"2020","unstructured":"Berdel, W. E. et al. Animal safety, toxicology, and pharmacokinetic studies according to the ICH S9 guideline for a novel fusion protein tTF-NGR targeting procoagulatory activity into tumor vasculature: Are results predictive for humans? Cancers (Basel) 12, 3536 (2020).","journal-title":"Cancers (Basel)"},{"key":"2107_CR798","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2021.39.15_suppl.4110","volume":"39","author":"DM Halperin","year":"2021","unstructured":"Halperin, D. M. et al. The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results. J. Clin. Oncol. 39, 4110\u20134110 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2107_CR799","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jog.13980","volume":"45","author":"C Gr\u00fcndker","year":"2019","unstructured":"Gr\u00fcndker, C., Wokoun, U., Hellriegel, M. & Emons, G. Inhibition of aerobic glycolysis enhances the anti\u2010tumor efficacy of Zoptarelin Doxorubicin in triple\u2010negative breast cancer cells. J. Obstet. Gynaecol. Res. 45, 1334\u20131342 (2019).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"2107_CR800","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1200\/JCO.2023.41.16_suppl.5577","volume":"41","author":"J Gong","year":"2023","unstructured":"Gong, J. et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. J. Clin. Oncol. 41, 5577\u20135577 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2107_CR801","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1158\/1538-7445.AM2018-1936","volume":"78","author":"C Rice","year":"2018","unstructured":"Rice, C. et al. The central role of NFAT signalling in the mechanism of action of the TRPV6 oncochannel inhibitor and clinical candidate SOR-C13. Cancer Res. 78, 1936\u20131936 (2018).","journal-title":"Cancer Res."},{"key":"2107_CR802","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels, E. et al. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J. Nucl. Med. 64, 632\u2013638 (2023).","journal-title":"J. Nucl. Med."},{"key":"2107_CR803","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.122.264383","volume":"64","author":"EA Carlsen","year":"2023","unstructured":"Carlsen, E. A. et al. Prospective phase II trial of [68Ga] Ga-NODAGA-E [c (RGDyK)] 2 PET\/CT imaging of integrin \u03b1v\u03b23 for prognostication in patients with neuroendocrine neoplasms. J. Nucl. Med. 64, 252\u2013259 (2023).","journal-title":"J. Nucl. Med."},{"key":"2107_CR804","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2967\/jnumed.117.202903","volume":"59","author":"Y Menda","year":"2018","unstructured":"Menda, Y. et al. 90Y-DOTATOC dosimetry\u2013based personalized peptide receptor radionuclide therapy. J. Nucl. Med. 59, 1692\u20131698 (2018).","journal-title":"J. Nucl. Med."},{"key":"2107_CR805","doi-asserted-by":"publisher","first-page":"898764","DOI":"10.3389\/fonc.2022.898764","volume":"12","author":"L Xiao","year":"2022","unstructured":"Xiao, L. & Xin, J. Advances in Clinical Oncology Research on 99mTc-3PRGD2 SPECT Imaging. Front. Oncol. 12, 898764 (2022).","journal-title":"Front. Oncol."},{"key":"2107_CR806","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen, S. A. et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57, 872\u2013878 (2016).","journal-title":"J. Nucl. Med."},{"key":"2107_CR807","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2217\/imt-2022-0121","volume":"14","author":"S Gayle","year":"2022","unstructured":"Gayle, S. et al. Antigen-independent tumor targeting by CBX-12 (alphalex\u2122\u2013exatecan) induces long-term antitumor immunity. Immunotherapy 14, 1467\u20131480 (2022).","journal-title":"Immunotherapy"},{"key":"2107_CR808","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4155\/tde-2020-0126","volume":"12","author":"E Harris","year":"2021","unstructured":"Harris, E. Industry News October 2020. Ther. Deliv. 12, 111\u2013117 (2021).","journal-title":"Ther. Deliv."},{"key":"2107_CR809","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1538-7445.AM2020-2910","volume":"80","author":"C Marsolais","year":"2020","unstructured":"Marsolais, C. et al. A novel Sortilin-targeted docetaxel peptide conjugate (TH1902), for the treatment of Sortilin-positive (SORT1+) triple-negative breast cancer. Cancer Res 80, 2910\u20132910 (2020).","journal-title":"Cancer Res"},{"key":"2107_CR810","first-page":"131","volume":"298","author":"K Kilk","year":"2005","unstructured":"Kilk, K. & Langel, U. Cellular delivery of peptide nucleic acid by cell-penetrating peptides. Methods Mol. Biol. 298, 131\u2013141 (2005).","journal-title":"Methods Mol. Biol."},{"key":"2107_CR811","doi-asserted-by":"publisher","first-page":"050901","DOI":"10.1117\/1.JBO.28.5.050901","volume":"28","author":"P Bou-Samra","year":"2023","unstructured":"Bou-Samra, P. et al. Intraoperative molecular imaging: 3rd biennial clinical trials update. J. Biomed. Opt. 28, 050901\u2013050901 (2023).","journal-title":"J. Biomed. Opt."},{"key":"2107_CR812","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ygyno.2020.11.013","volume":"160","author":"A Chelariu-Raicu","year":"2021","unstructured":"Chelariu-Raicu, A. et al. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Gynecol. Oncol. 160, 418\u2013426 (2021).","journal-title":"Gynecol. Oncol."},{"key":"2107_CR813","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1200\/jco.2008.26.15_suppl.4533","volume":"26","author":"M Jin","year":"2008","unstructured":"Jin, M. et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1\/CDDP (SP) versus 5-FU\/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J. Clin. Oncol. 26, 4533\u20134533 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2107_CR814","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.clgc.2017.06.002","volume":"15","author":"SY Steven","year":"2017","unstructured":"Steven, S. Y. et al. A phase II trial of AEZS-108 in castration-and taxane-resistant prostate cancer. Clin. Genitourin. Cancer 15, 742\u2013749 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"2107_CR815","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3389\/fimmu.2019.01657","volume":"10","author":"M Kolahdouzan","year":"2019","unstructured":"Kolahdouzan, M., Futhey, N. C., Kieran, N. W. & Healy, L. M. Novel molecular leads for the prevention of damage and the promotion of repair in neuroimmunological disease. Front. Immunol. 10, 1657 (2019).","journal-title":"Front. Immunol."},{"key":"2107_CR816","doi-asserted-by":"publisher","first-page":"iii52","DOI":"10.1093\/neuonc\/nox036.187","volume":"19","author":"T Fujimaki","year":"2017","unstructured":"Fujimaki, T. et al. P07. 02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM). Neuro Oncol. 19, iii52 (2017).","journal-title":"Neuro Oncol."},{"key":"2107_CR817","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott, D. et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol. 24, 2694\u20132698 (2013).","journal-title":"Ann. Oncol."},{"key":"2107_CR818","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cancers15051458","volume":"15","author":"BL Manning-Geist","year":"2023","unstructured":"Manning-Geist, B. L. et al. Phase I study of a multivalent WT1 peptide vaccine (Galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission. Cancers (Basel) 15, 1458 (2023).","journal-title":"Cancers (Basel)"},{"key":"2107_CR819","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006755","volume":"11","author":"CL Lorentzen","year":"2023","unstructured":"Lorentzen, C. L. et al. Long-term follow-up of anti-PD-1 na\u00efve patients with metastatic melanoma treated with IDO\/PD-L1 targeting peptide vaccine and nivolumab. J. Immunother. Cancer 11, e006755 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2107_CR820","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1016\/j.annonc.2023.09.3080","volume":"34","author":"S Patel","year":"2023","unstructured":"Patel, S. et al. 353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2+ GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. Ann. Oncol. 34, S323 (2023).","journal-title":"Ann. Oncol."},{"key":"2107_CR821","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s00262-020-02619-3","volume":"69","author":"H Daiko","year":"2020","unstructured":"Daiko, H. et al. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunol. Immunother. 69, 2247\u20132257 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"2107_CR822","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1517\/14712598.7.3.397","volume":"7","author":"A Gilliam","year":"2007","unstructured":"Gilliam, A. & Watson, S. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin. Biol. Ther. 7, 397\u2013404 (2007).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2107_CR823","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/imt.14.22","volume":"6","author":"EJ Schneble","year":"2014","unstructured":"Schneble, E. J. et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy 6, 519\u2013531 (2014).","journal-title":"Immunotherapy"},{"key":"2107_CR824","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.4161\/hv.29836","volume":"10","author":"GT Wurz","year":"2014","unstructured":"Wurz, G. T., Kao, C.-J., Wolf, M. & DeGregorio, M. W. Tecemotide: an antigen-specific cancer immunotherapy. Hum. Vaccin. Immunother. 10, 3383\u20133393 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2107_CR825","doi-asserted-by":"publisher","first-page":"vii60","DOI":"10.1093\/annonc\/mdy374.040","volume":"29","author":"M Murahashi","year":"2018","unstructured":"Murahashi, M. et al. Investigator initiated clinical trial of cancer vaccine OCV-C01 in advanced and recurrent biliary tract cancer. Ann. Oncol. 29, vii60 (2018).","journal-title":"Ann. Oncol."},{"key":"2107_CR826","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/mus.26919","volume":"62","author":"AA Habib","year":"2020","unstructured":"Habib, A. A., Ahmadi Jazi, G. & Mozaffar, T. Update on immune\u2010mediated therapies for myasthenia gravis. Muscle Nerve 62, 579\u2013592 (2020).","journal-title":"Muscle Nerve"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02107-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:02:54Z","timestamp":1741114974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02107-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":826,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02107-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}